[go: up one dir, main page]

TWI223001B - Fusion proteins of mycobacterium tuberculosis antigens and their uses - Google Patents

Fusion proteins of mycobacterium tuberculosis antigens and their uses Download PDF

Info

Publication number
TWI223001B
TWI223001B TW088105532A TW88105532A TWI223001B TW I223001 B TWI223001 B TW I223001B TW 088105532 A TW088105532 A TW 088105532A TW 88105532 A TW88105532 A TW 88105532A TW I223001 B TWI223001 B TW I223001B
Authority
TW
Taiwan
Prior art keywords
ala
gly
ser
val
leu
Prior art date
Application number
TW088105532A
Other languages
English (en)
Inventor
Mark Alderson
Antonio Campos-Neto
Yasir A W Skeiky
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Application granted granted Critical
Publication of TWI223001B publication Critical patent/TWI223001B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Description

1223001 坎、發明說明: 1 · Jii 本發明是有關含有至少二個結核分枝桿菌抗原的融合蛋 白質。特f之’其係有關含有二個個別的結核分枝桿菌抗 原之雙融合蛋白質,含有三個結核分枝桿菌抗原之叁融合 蛋白質’含有四個結核分枝桿菌抗原之肆融合蛋白質,及 含有五個結核分枝桿菌抗原之伍融合蛋白質,及其用於診 斷、治療及預防結核病感染之用法。
2·直A 結核病是由結核分桿菌感染所引起的慢性感染疾病。其 疋發展中國家的主要疾病,以及已發展地區漸增之問題, 母年有約8百萬的新增病例及3百萬的死亡病例。雖然感染 中有相田&時期是無症狀的,但疾病最常見之表徵是肺 P之心丨生感木,迻成發燒及非產出性咳漱。若未予以治療 會造成嚴重的併發症及致死。 “、、、口核病可利用長期的抗生素療法予以控制,然而^ 療法並不足以預防疾病之散佈。受感染個體可能無症艰 但具傳染性達-段時間。此外,雖然療程之順從性很嚴苛 :病糊于為仍難追蹤。某些病人無法完成療程,其以 成典效治療及柷藥性的發展。 為了控制結核病夕典彳女 士、, 早期診斷是最重要的=的免疫接種及疾病確實^ 性免疫力之最有效方、去。二活菌免疫接種是誘綱 BCG H丄此目的之最常用分枝桿菌是 疋刀κ無毒力株。然而,bcg之安全性及
O:\57\57961 -920605.DOC 1223001 效力疋肀論來源,且在某些國家中,如美洲,並不以此作 用物對一般大眾進行免疫接種。 結核病的診斷通常利用皮膚試驗來達成,其中涉及與結 核菌素PPD(蛋白負 '純化之衍生物)之皮内曝露。抗原特異 的T細胞反應,可在注射後造成注射部位48_72小時的可偵 測足硬結生成,其表示係曝於分枝桿菌抗原之下。然而, 敏感性及特異性在此試驗下有其問題存在,且接受BCG免 疫接種之個體與受感染個體是無法區別的。 雖然巨噬細胞已示出可作用如結核分枝桿菌免疫力之主 要效應物,τ細胞是此免疫力的主要謗導者。τ細胞在保護 性拮抗結核分枝桿菌感染中之必要角色,可由結核分枝桿 菌在後天免疫缺失症候群病人之高發生率予以說明,此乃 因為與人類免疫缺失病毒(HIV)感染有關之CD4+T細胞耗 盡之故。與分枝桿菌具反應性之CD4+T細胞已示出是γ _干 擾素(IFN- 之強力產製者,其接著已示出可啟動老鼠巨 噬細胞之抗-分枝桿菌作用。雖然IFN_ r在人體之角色較不 清楚’但研究已顯示出1,25-二羥基-維生素D3,不論單獨 的或組合以IFN- 7或腫瘤壞死因子-r,均可活化人類巨噬 細胞以抑制結核分枝桿菌之感染。再者已知,IFN_ 7可利 激人類巨嗟細胞製作1,25-二經基-維生素D3。類似地,已 示出間白素-12 (IL-12)在刺激對結核分枝桿菌感染抗性上 扮决一角色。關於結核分枝桿菌感染免疫學之總覽,見Chan and Kaufmann, 1 9945 Tuberculosis: Pathogenesis, Protection and Control,Bloom (ed·),ASM Press,Washington,DC。
O:\57\57961-920605.DOC 因此’關於改進之疫苗刀祖 、、 、 士〜核病診斬,預防及治療之 改進方法仍有需求。 ’、 占 本發明是有關結核分枝桿菌抗原之融合蛋白質。特言之 /、係有關含有—個以上結核分枝桿菌抗原之融合多肽,編 =多肽之聚核#酸,利用此多肽及聚核《於結核分枝 才干囷診斷,治療及預防上之用法。 本發明有部份是依據本發明者之發現,即含有二至五個 結核分枝桿菌編碼序列之聚料酸可產生保有其個別組份 免疫原性及抗原性之重组體融合蛋白質。此中所述之融合 蛋白質可謗生T細胞及B細胞反應,此可由了細胞增殖,細 胞動素產製及抗體之產製予以僧測。再者,融合蛋白質可 充作免疫原,配合佐劑於活體内誘生對結核分枝桿菌之細 胞調介的及體液的免疫力。另外,利用融合構體可製備融 合蛋白質,並配合佐劑應用於疫苗調和物中,以在動物體 内生成長期的保護作用,拮抗結核病之發展。融合蛋白質 疋較其個別蛋白質組份之混合物為更有效率之免疫原。 在本發明之特異具體實例中,本發明經分離或純化之結 核分枝桿菌多肽可調和成醫藥組合物,以供投予至個體中 以預防及/或治療結核分枝桿菌之感染。經由佐劑之納入, 也可加強融合蛋白質之免疫原性。 本發明另-方面’使用經分離或純化之聚核甞酸,於試 管内產生重組體融合多肽抗原。另外,聚核苷酸可直接投 予至個體,呈DNA疫苗型式造成個體抗原之表現,接下來
O:\57\5796U920605.DOC 1223001 則誘生抗-結核分枝桿菌免疫反應。 本發明目的之一也包括使用多肽於試管内分析中,以偵 測拮抗結核分枝桿菌之體液抗體或細胞調介之免疫力,而 診斷感染或追蹤疫病發展。另外,多肽可充作活體内之診 斷劑,於皮内皮膚試驗型式中。另外,多肽也可充作免疫 原,以在非人類之動物中產生抗·結核分枝桿菌抗體。抗體 可於活體内及試管内用於偵測標的抗原。 4.附圖說明 圖1A及1B:叁融合蛋白質Ral2-TbH9-Ra35(命名為 Mtb32A)之核苷酸序列(SEQ ID ΝΟ:1)及胺基酸序列(SEQ ID N〇:2)。 圖2:參融合蛋白質Erdl4-DPV-MTI(命名為Mtb39A)之核 苷酸序列(SEQIDNO:3)及胺基酸序列(SEQIDNO:4)。 圖3A-3D:叁融合蛋白質TbRa3-38kD-Tb38-l之核苷酸序 列(SEQIDN〇:5)及胺基酸序列(SEQIDNO:6)。 圖4A-4D:雙融合蛋白質TbH9-Tb38-l之核苷酸序列(SEQ ID NO:7)及胺基酸序列(SEQ ID NO:8)。 圖 5A-5J:肆融合蛋白質 TbRa3-38kD-Tb38-l-DPEP(命名 為TbF-2)之核苷酸序列(SEQ ID NO:9)及胺基酸序列(SEQ ID N〇:10)。 圖 6A 及 6B:伍融合蛋白質 Erdl4-DPV-MTI-MSL-MTCC2 (命名為Mtb88f)之核苷酸序列(SEQ ID N〇:ll)及胺基酸序 列(SEQ ID N〇:12)。 圖7A-7B:肆融合蛋白質Erdl4-DPV_MTI-MSL-(命名為
O:\57\57961-920605.DOC 1223001
Mtb46f)之核苷酸序列(SEQ ID NO:13)及胺基酸序列(SEQ ID N〇:14)。 圖8A及8B:肆融合蛋白質DPV-MTI-MSL-MTCC2(命名為 Mtb71f)之核苷酸序列(SEQ ID ΝΟ··15)及胺基酸序列(SEQ ID Ν〇:16)。 圖9Α及9Β:叁融合蛋白質DPV-MTI-MSL(命名為Mtb31f) 之核苷酸序列(SEQ ID NO:17)及胺基酸序列(SEQ ID NO: 1 8)。PET聚連接子及SEQ ID NO] 5之2143至2168位置 之xho I限制位置之胜肽轉錄物=SEQ ID NO:40。 圖10A及10B:叁融合蛋白質TbH9-DPV-MTI(命名為 Mtb61f)之核:y:酸序列(SEQ ID NO:19)及胺基酸序列(SEQ IDNO:20)。SEQIDNO:17之901至918位置之胜肽轉錄物 = SEQ ID N〇:41。 圖11A及11B:叁融合蛋白質Erdl4-DPV-MTI(命名為 Mtb36f)之核苷酸序列(SEQ ID NO:21)及胺基酸序列(SEQ ID NO:22)。 圖12A及12B:雙融合蛋白質TbH9-Ra35(命名為Mtb59f)之 核苷酸序列(SEQ ID NO:23)及胺基酸序列(SEQ ID NO:24)。 圖13A及13B:雙融合蛋白質Ral2-DPPD(命名為Mtb24)之 核苷酸序列(SEQ ID N〇:25)及胺基酸序列(譯讀架1=SEQ ID NO:26)。譯讀架2之胜肽=SEQ ID NOS丨7-3 1 ;譯讀架3 之胜肽=SEQ ID NOS:3 2-37。 圖14A-14F··六個PPD +個體,當以二個融合蛋白質及其個 別組份刺激時之T細胞增殖反應。 O:\57\57961-920605.DOC -10- 1223001 圖15A-15F:六個PPD +個體,當以二個融合蛋白質及其個 別組份刺激時之IFN- 7產製情形。 圖1 6 A-1 6F:老鼠以融合蛋白質或其個別組份及佐劑免疫 接種後之T細胞增殖。 圖17:老鼠以融合蛋白質或其個別組份及佐劑免疫接種 後之IFN- τ之產製。 圖1 8 :老鼠以融合蛋白質或其個別組份及佐劑免疫接種 後之IL-4之產製。 圖19A-19F:老鼠以融合蛋白質或其個別組份及佐劑免疫 接種後之血清抗體濃度。 圖20A-20C:結核分枝桿菌經氣霧劑挑戰後,天竺鼠之存 活。融合蛋白質,Mtb32A及Mtb39A,調合在佐劑 SBASlc(20A),SBAS2(20B)或 SBAS7(20C)中,並充作免疫 原在挑戰以細菌前注入天竺鼠内。B C G為陽性對照組。 圖21八及218:由融合蛋白質1^119-1^3 8-1在1^119-特異的 T細胞中刺激增殖及IFN- r之產製。 圖22A及22B:由融合蛋白質TbH9-Tb38-l在Tb38-1-特異 的T細胞中刺激增殖及IFN- τ之產製。 圖23A及23B:T細胞中刺激增殖及IFN- τ之產製,其於事 先已示出經由融合蛋白質TbH9-Tb3 8-l可對TbH9及Tb3 8-1 抗原均有反應。 5.詳細說明 本發明是有關可用於治療及預防結核病之抗原,編碼此 抗原之聚核苷酸,及其用法。本發明抗原為結核分枝桿菌 O:\57\57961-920605.DOC -11 - 1223001 及其變型之融合多肽。較特異的,本發明的抗原包括至少 二種結核分枝桿菌之多肽,其可稠合成較大之融合多肽分 子。本發明的抗原可進一步含有其他組份,經設計可加強 抗原之免疫原性或改進抗原之其他方面;如經由添加組胺 酸殘基段於抗原一端而分離出這些抗原。 5 · 1結核分枝桿菌特異抗原 本發明之抗原示例於圖1A至13B,包括這些抗原同質的 及變形。這些抗原可予以修飾,如下述般加入連接子肽序 列。這些連接子肽可嵌入一個以上多肽之間,其構成圖 1A-13B所示的各融合蛋白質。本發明的其他抗原為圖 1A-13B所示之抗原,其已連接至結核分枝桿菌之已知抗原 上,如先前所述之 38kD(SEQ ID NO:3 8)抗原(Andersen and Hansen, 1989, Infect. Immun. 57:2481-2488 ; Genbank Accession N〇.M30046) ° 5.2免疫原性分析 此中所述之抗原,及其免疫原部份具有誘生免疫原反應 4能力。較特異的,抗原在由結核分枝桿菌一免疫個體所 行生之T細胞,NK細胞,B細胞及/或巨噬細胞中,具有誘 導增殖作用及/或細胞動素產製(即干擾素_ r及/或干擾素 -12《產製能力。用於評估對抗原之免疫原反應之細胞 型式,其選擇依欲求之反應而定。例如,利用含有B細胞及 /或巨噬細胞之製劑,可最容易地評估間白素_12之產製。 結核分枝桿菌一免疫個體是被視為可抗阻結核病發展之個 體,因為可對結核分枝桿菌展開有效的τ細胞反應(即實質 O:\57\57961-920605.DOC -12- 1223001 上典疾病症狀)。此個體可依據對結核病蛋白質(ppD)有強 烈陽性(即大於約1〇毫米直徑之硬結)之皮内皮膚試驗反 應,及典結核病任何徵兆或症狀為基礎而鑑知。由結核分 枝桿菌一免疫個體衍生之T細胞,NK細胞,B細胞及巨噬細 胞1可利用精藝者熟知之方法製備。例如,可在勿需進一步 分出組份細胞下製備PBMCs(即周邊血液單核細胞)。 PBMCs通苇利用密度離心,經由,,FIC〇LL,,(winthr〇p Laboratories,NY)製成。用於此中所述分析法中之τ細胞也 可直接純化自PBMCs。另外,也可應用可反應性拮抗分枝 才干菌蛋白質之加豐的T細胞株,或與個別的分枝桿菌蛋白質 具反應性之T細胞純系。此τ細胞純系之產生,如自結核分 枝桿菌一免疫個體中取得PBMCS,再與分枝桿菌蛋白質共 口養4週如此可只擴大與分枝桿菌蛋白質特異的丁細 這些細胞再選殖及以 胞,生成僅由此細胞組成之細胞株 個別蛋白質測試,利用一般精藝者已知之方法,以更精確 地定義個別的T細胞特異性。—般而言,在利用由結核分枝 桿菌一免疫個體衍生之丁細胞,Νκ細胞,B細胞及/或巨噬 細胞的進行之增殖及/或細胞動素產製分析中(即,干擾素_ r及/或間白素-12產製)呈現陽性之抗原可視為具免疫原 性。此種分析法可利用τ述之代表性步驟進行。此抗原之 免疫原部份可利用類似分析法鐘定,且可存在於此中所述 之多肽之内。 多肽(如免疫原性抗原,或其部份或其他變型)誘導細胞 增殖作用之能力,可由細胞(如τ細胞及/或败細胞)與多肤
〇:\57\57961 -920605.DOC -13 - 1223001 接觸,並偵測細胞之增殖而評估。一般而言,足供評估之 多肽量約105細胞’範圍由約1〇毫微克/毫升至約1⑽微克/ 毫升,且較好是約10微克/毫升。多肽與細胞培育通常在37 C下進行約6天。與多肽培育後,分析細胞之增殖反應,可 利用知藝者已知之方法坪估’例如細胞曝於經放射標記之 胸嘗下’再須測標幟納入細胞DNA中之情形。一般而言, 多肽可造成較背景增殖3倍以上者(背景值為在無多肽下培 養細胞所觀察到之增殖)被視為可謗生增殖作用。 | 多肽刺激干擾素-r及/或間白素-12於細胞中產製之能 力,可由細胞與多肽接觸,再偵測由細胞產生之干擾素_ 或間白素-12水平而評估。一般而言,足以評估約1 〇5細胞 之多肽含量範圍由約10毫微克/毫升至約1⑽微克/毫升,且 較好是約1 0微克/毫升。多肽可固化在固相載體上,但未必 如此,如珠粒或可生物降解之微球,如美國專利案 Νο·4,897,268及5,075,109中所述。多肽與細胞之培育通常 為3 7 C下歷6天左右。與多肽培育後,細胞進行干擾素_ γ φ 及/或間白素-12之分析(或其一個以上之亞單位),其可以精 藝者已知之方法評估,如酵素-鍵結之免疫吸附分析 (ELISA),或於IL-12 Ρ70亞單位例子中,可採用偵測τ細胞 增殖之生物分析法。一般而言,將可使每毫升培養物上清 液產生至少50微之克(含有每毫升1〇5丁細胞)之多肽視 為可刺激干擾素產製者。而可使每1〇5巨噬細胞或B細胞 產製至少10微微克/毫升IL-12P70亞單位,及/或至少1〇〇微 微克/ ¾升IL-12 P40亞單位(或每3xl〇5 pbmc),可視為可刺 O:\57\57961-920605.DOC -14 - 1223001 激IL-12之產製。 一般而言,免疫原抗原為,可在由至少約25%結核分枝 桿菌-免疫個體所衍生之T細胞,NK細胞,B細胞及/或巨嗟 細胞中刺激增殖作用及/或細胞動素產製者(即,干擾素_ τ 及/或間白素-12之產製)。在這些免疫原抗原間,具有絕經 治療特性之多肽,可依據在上述分析中之反應幅度及依據 可觀察到反應之個體百分率為準而予以區別。此外,具絕 、、二…療特性之抗原,在非結核分枝桿菌一免疫之2 $ %以上 個所衍生之細胞中’於試管内不會刺激增殖作用及/或細_ 胞動素之產製,由是消除非結核分枝桿菌一反應性細胞特 兴之反應。可在由結核分枝桿菌一免疫個體來之τ細胞, NK細胞,B細胞及/或巨噬細胞製劑上誘生高比例反應之抗 原(在來自其他個體之細胞製劑中具低的反應發生率)具有 絕經之治療特性。 具極佳治療特性之抗原當呈疫苗型式投予時,也可依據 其在實驗動物中減弱結核分枝桿菌感染之嚴重性之能力而春 鑑知:可用於實驗動物之適合的疫苗製劑詳述於下。效力 之決定可以抗原提供至少約50%細菌數且之減少及/或至少 約4〇%死亡率減少之能力為準,此乃在實驗性感染後進 行。週合的實驗動物包括老鼠,天竺鼠及靈長類。 5.3盡碼序列之分· 本發明也伽可編碼結核分枝桿菌融合多肽之核酸分 下又第,、&貝例《特殊具體實例中,構築^個結核 分枝桿菌融合編碼序列。依據本發明,編碼融合蛋白質胺
O:\57\5796I-920605.DOC -15 - 序幻的任何核苷酸序列,均可用來產生重組體分子, 其指令編碼序列之表現。 #1了 k殖全長的編碼序列或其同源變形以產生融合聚核 11由核甘酸序列任何部份或此中所揭示之互補物中所 汉计 < 緃私圮的DNA探針,均可在由結核分枝桿菌各種菌 斤氣成之基團體或CDNA庫中篩選,以鐘定各個別組份之 扁馬序列。編碼序列之分離也可以聚合酶連鎖反應(PCR) 來進仃,利用以此中揭示之編碼序列為準設計的二個簡併 的暴核答酸引子匯集來進行。 本發明也是有關與SE,QID NOS:1,3,5,7,9, n,13, 15, 17,19,21,23及25之核苷酸序列互補的經分離或純化的聚 核苷酸,及可與此互補序列選擇性雜交之聚核甞酸。在一 個較佳的具體實例中,係提出可與SEq ID N〇:1,3, 5, 7, 9, 11,13, 15, 17, 19, 21,23及25序列或其互補序列,在低迫切 度條件下雜X ’且編碼保有SEQ ID NO:2, 4, 6,8,10,12,14, 16,18,20,22,24及26融合蛋白質免疫原性之蛋白質之聚 核甘fe。經由貫例且不予以限制,供示範之低迫切度條件 如下(也見 Shilo and Weinberg,1981,Proc. Natl. Acad. Sci. USA 78:6789-6792):含有DNA之濾膜在40°C,含有35%甲醯 胺,5X SSC,50mM Tris-HCl (pH 7.5),5mM EDTA,0·1% PVP,0.1% Ficoll,1% BSA,及5 00微克/毫升經變性之鮭魚 精子DN A之溶液中預處理6小時。雜交在相同溶液中進行, 但有以下變化:便用 0.02% PVP,0_02% Ficoll,0.2% BSA, 及100微克/毫升鼓魚精子DNA,10%(w/v)硫酸葡聚糖,及 O:\57\57961-920605.DOC -16 - 5-2〇X丨06 cpm經32P_標記之探針。濾膜在雜交混合物中以4〇 C培育18-20小時,再以55 °C在含有2X SSC 25mM Tds-Hcl(PH 7.4)、5mM EDTA及 〇 1% SDS之溶液中洗滌 i 5 小時。洗液以新鮮溶液替換,再於6〇它下再丨·5小時。濾膜 吸乾,再曝光經放射自顯術。若必要時,濾膜在65_68。〇下 再洗第二次’並再與底片曝光。可使用的其他低迫切度條 件為技藝中熟知的,(如用於交叉種屬之雜交)。 在另一較佳具體實例中,也提出可與SEQ m N〇S:1,3, 5, 7’ 9, 11,13, 15, 17, 19, 21,23及25之編碼序列或其互補序 列在南迫切度條件下雜交,並編碼保有SEq ID N〇:2, 4, 6, 8’ 10,12,14,16,18, 20, 22, 24及26之融合蛋白質免疫原性
之蛋白質之聚核苷酸。經由實例且不予以限制,高迫切度 示範條件如下:含有DNA之濾膜在65°C下於由6X SSC 50mM Tris-HCl (pH 7.5),ImM EDTA,0.02% PVP,0.02%
Ficoll,〇·〇2% BSA,及500微克/毫升變性的鮭魚精子〇ΝΑ 組成之緩衝落液中預雜交8小時至一夜。濾膜在含有1 〇〇微 克/毫升經變性之鮭魚精子DNA及5-20xl06 cpm 32P-經標記 探針之預雜交混合物中,以65t:雜交48小時。濾膜之洗滌 在含有 2X SSC 0.01% pvp,001% Fic〇11 及 〇 〇1% bsa,之溶 液中以37°C進行1小時。此繼以在01X ssc中以5〇〇C洗45 刀4鱼’再行放射自顯術。其他可使用之高迫切度條件為技 藝中熟知的。 又在另一較佳具體實例中,提出可與SEq ID NO: 1,3, 5, 7, 9, 11,13, 15, 17, 19, 21,23及25編碼序列或其互補序列
〇A57\5796 l-920605.DOC -17- 在中度迫切度條件下雜交,並編碼保有SEq ID NO:2, 4, 6, 8 ’ 10’ 12,14,16,18,20,22,24及26之融合蛋白質免疫原性
之蛋白質之聚核苷酸。可供示範之中度迫切度條件如下:含 有DNA之滤膜在含有6XSSC,5XDenhan,s溶液,〇 5%SDS 及100微克/ ¾升變性的鮭魚精子DNA之溶液中以55它預處 理6小時。雜交在相同溶液及5-2〇 χ丨〇6 cpm經^^標記之探 針下進行。濾膜在雜交混合物中,以55t培育18-2〇小時, 再以含有IX SSC及0.1% SDS之溶液,於6〇t下洗滌二次, 各30矢4里。濾膜吸乾,再曝光行放射自顯術。可使用的其 他中度迫切條件為技藝中熟知的。濾膜之洗滌在37艺下於 含有2X SSC,0.1%SDS之溶液中進行丨小時。 5.4座編碼序列編雜^炙奸 依據本發明,編碼融合蛋白質,其片段或其功能同等物 《本發明的聚核苷酸,可用來產生重組體核酸分子,其可 扣令融合蛋白質’其片段或其功能同等物在適合宿主細胞 内之表現。由此聚㈣酸編碼之融合多肤產物,可由編碼 序列之分子操作予以改變。 由於遺傳密碼固有之簡併性,編碼實質上相同或功能上 相Γ胺基酸序列的其他職序列,均可用來實行本發明 二=:纽。此DNA序列包括可在低度,中度或高度 :刀::T’與此中揭示之編碼序列或其互補物雜交 者,如上示5 · 3所述。 斗《本發明可使用的經改變的料酸序列,包括 %•鉍殘基之刪除,加入或置換, ' k成可編碼相同或功能上
O:\57\57961-920605.DOC -18 - 1223001 相當足基因產物。基因產物本身可含有胺基酸殘基之刪 除,加入或置換,造成無聲改變因此產生功能上相當之抗 原性表位。此種保留性胺基酸之置換作用,可就所涉及殘 基在極性,電荷,溶解度,疏水性,親水性及/或親兩性本 質上相似性之基礎而製作。例如,負電荷之胺基酸包括天 冬胺酸及榖胺酸;正電荷之胺基酸包括賴胺酸,組胺酸及 精胺酸;具未荷電極性頭基且具相似疏水性值之胺基酸包 括下列:甘胺酸,天冬醯胺,榖胺醯胺,絲胺酸,蘇胺酸及 酪胺酸;而具非極性頭基之胺基酸包括:丙胺酸,纈胺酸, 異白胺酸,苯丙胺酸,脯胺酸,甲硫胺酸及色胺酸。 本發明之核甘序列可予以遺傳操作,以針對各種終端 用途改變融合蛋白質編碼序列,包括下列但不限於修飾基 因產物處理修飾及表現之改變。例如,可利用精藝者已知 之技術引入空變作用,如位置指令之空變作用,以嵌入新 的限制位置,改變糖基化型式,磷醯化作用等。 在本發明不同的具體實例中,融合蛋白質之編碼序列可 利用技藝中熟知之化學方法,全部地或部份地合成。如見 Caruthers et al·,1980, Nuc. Acids Res.Symp. Ser. 7:215-233 ; Crea and Horn,180, Nuc. Acids Res. 9(10):233 l:Matteucci and Caruthers, 1980? Tetrahedron Letter 21:719 ; and Chow and Kempe5 1981, Nuc. Acids Res. 9(12):28〇7_2817。另外,多肽本身可利用化學方法產生, 以全部或部份地合成胺基酸序列。例如,肽可以固相技術 合成,自樹脂中解離,並以製備式高性能液相層析純化。(見 O:\57\57961-920605.DOC -19- 1223001
Creighton, 1983, Proteins Structures And Molecular Principles, W.H. Freeman and Co.,Ν·Υ· pp· 50-60)。合成多 肽之組合物可由胺基酸分析或定序證實(如,Edman降解步 驟;見Creighton,1983,Proteins Structures and Molecular
Principles,W.H. Freeman and Co·,Ν·Υ,ρρ· 34_49) 〇 另外’融合蛋白質之編碼序列可於試管内或活體内空 變,以生成及/或破壞轉譯,啟動及/或終止序列,或在編碼 區生成變化及/或形成新的核酸内切限制酶位置,或破壞預 先存在者,以助進一步試管内之處理修飾。技藝中已知之 任何空變技術均可使用,包括下列但不限於此:化學空變作 用,試管内位置指令之空變作用(Hutchins〇n,C.,et al., 1978,J· Biol. Chem 253:655 1),TAB⑧連接子之使用 (Pharmacia)等。很重要的一點是,分子操作不可破壞融合 多肽之免疫原性。 此外,非典型的胺基酸或化學胺基酸類似物均可引入, 呈置換或加入方式引入序列之中。非典型的胺基酸包括下 列,但不限於此:一般胺基酸之D-異構物,α _胺基異丁酸, 4-胺基丁酸,Abu,2_胺基丁酸,r _Abu,ε _Ahx,卜胺基 己’ Aib,2-胺基異丁酸,3-胺基丙酸,鳥胺酸,正白胺 酉又,正纈胺鉍,羥基脯胺酸,肌胺酸,瓜胺酸,半胱胺酸, 第三丁基甘胺酸,第三丁基丙胺酸,苯甘胺酸,環己基丙 胺I,/3 _丙胺酸,氟胺基酸,經設計之胺基酸如甲基 月文基fe,甲基胺基酸,Να-甲基胺基酸,及一般的胺基 I類似物。再者,胺基酸可為D(右旋的)或L(左旋的)。
0:b7\57961-920605.DOC -20 - ,於融合蛋白質各抗原之編碼序
在一個特殊具體實例中, 列,在其胺基一或羧基末端 另外,也可鹿]Ϊ1日4·;击A 7 位交互作用’·及(3)缺乏疏水性或荷電殘基,其可能可呈與 多肽功能性表位交互作用。較佳之肽連接子序列含有GLy, Asn及Ser殘基。其他近乎中性之胺基酸,如Tbr及Aia也可 用於連接子序列中。可充作連接子之胺基酸序列包括揭於 下者:Maratea et al·,Gene 40:39-46,1985 ; Murphy et al., Proc. Natl. Acad. Sci· USA,83:8258-8262,1986 ; U.S 專利 案No·4,93 5,233’及美國專利案4,751,18o。連接子序列之 長度可由1至約5 0個胺基酸。當第一及第二多肽有非必需 N-末端胺基酸區域,其可用來分出功能區及預防位阻,則 此時肽序列是非必要的。例如,在融合蛋白質中之抗原可 經由具撓性之聚連接子而連接,如Gly-Cys-Gly或
Gly-Gly-Gly-Gly-Ser(SEQ ID NO:3 9),重覆 1 至 3 次(Bird,et al.? 1988, Science 242:423-426; Chaudhary et al.5 1990, Proc. Natl. Acad· Sci. U.S.A. 87:1066-1070) 〇 在一個具體實例中,此蛋白質由編碼蛋白質之核酸經重 O:\57\57961-920605.DOC -21 - 1223001 、且“現而屋生。此一融合蛋白質 列之適人的枋π & 、由、、扁碼欲求胺基酸序 」乏通口的核鉍序列,以精藝者已知 加据ΠΓ π ^ 土 〈万法’於正確讀譯 木構下互相連接而成,並以椅 、 ΛΚ , ^ 百匕知万法表現產物。另 ,Μ甘Α γ ^ I成,如使用肽合成 ^。其他义子之編碼序列,如 京或佐劑,也可加 土融合核菩酸中。 5 · 5靜合蛋电_!^之產製 為了產生本發明之結核分枝桿菌融合蛋白冑,指導合成 蛋白質或其功能同等物之核:y:酸序列被嵌入適合的表現載 體内,即含有可供所嵌入之編碼序列轉錄及轉譯所必要之 凡件之載體。以重組表現載體轉感或轉形之宿主細胞或細 胞株可應用於各種目的。此中包括融合蛋白質大規模的產 製,但亦可不限於此。 精藝者熟知之方法可用來構築表現載體,其中含有融合 的編碼序列及適合的轉錄/轉譯控制訊號。這些方法包括試 管内重組DNA技術’合成技術及活體内重組/遺傳重組。(如 見,述於 Sambrook et al.,1989 之技術,Molecular Cloning A Laboratory Manual,Cold Spring Harbor Laboratory,Ν·Υ· and Ausubel et al.5 1989, Current Protocols in Molecular
Biology, Greene Publishing Associates and Wiley Interscience,N.Y.)。可編碼多肽之RNA也可化學合成(Gait, ed·,1984,Oligonucleoide Synthesis,IRL Press,Oxford)。 5.5.1 .表現系統 可利用各樣的宿主一表現載體系統’來表現融合蛋白質 O:\57\57961-920605.DOC -22- 編碼序列。這些包括下列,但不限於此,微生物如細菌(如 E.coh,枯草桿菌)以含有編碼序列之重組體噬菌體〇^八’ 貝體DNA或黏接質體DNA表現載體所轉形;酵母(如釀酒酵 母,畢赤酵母)以含有編碼序列之重組酵母表現載體轉形; 昆蟲細胞學,以含有編碼序列之重組病毒表現載體(如桿病 毒)感染-植物細胞學,以重組病毒表現載體感染(如:花椰菜 花葉病母,CaMV,煙草花葉病毒,TMV)或以重组體質體 表現載體轉形(如Ti質體)其含有編碼序列;或哺乳動物細胞 學(如cos,CH0, BHK,293,3T3細胞)。這些系統的表現元· 件強度及特異性均可有變化。 依據所利用的朵主/載體系統,任何適合的轉錄及轉譯元 件’包括原構的及可誘導的啟動子,均可用於表現載體内。 例如,當於細菌系中選殖時,可使用可誘導之啟動子,如 嗟菌體入之昨,咖,_,邮(_如雜交啟動子;巨細 月已病母啟動子)等,當於昆蟲細胞系中選殖時,可使用啟動 子如桿病毒多肽角體啟動子;當於植物細胞系中選殖時,鲁 可使用由植物細胞基因體衍生之啟動子(如熱休克啟動 子’ RUBISCO小亞單位之啟動子;葉綠素α /沒結合蛋白質 《啟動子)或由植物病毒衍生之啟動子(如之MS RNA 啟動子,TMV又衣殼蛋白質啟動子);當於哺乳動物細胞系 中&殖時’可使用由哺乳動物細胞基因體衍生之啟動子(如 金屬硫新質啟動子)或由哺乳動物病毒衍生之啟動子(如腺 病毒晚期啟動子·’牛瘦苗病毒7.5K啟動子);當產生含有多 肽重套數之抗原編碼序列之細胞株時,可使用以π.,
O:\57\57961-920605.DOC >23 - 1223001 BPV-及EBV-為基礎之載體,並配合適合的可選擇標幟。 於結核分枝桿菌抗原表現時,以細菌系為較佳。於活體 内遞送時,可返傳操作如BCG之細菌,以在其細胞表面上 表現本發明之融合多肽。依據表現產物之用途,可有益地 選擇其他許多肽的細菌表現載體。例如,當欲產生大量融 合蛋白質以供醫樂組合物調和之用,以可指令高水平融合 蛋白貝產物表現之載體,且易純化者為較所欲求。適合的 載體包括下列’但不限於此:E coli表現載體pUR 278 (Ruther et al·,1983, EMBO J 2:1791),其中編碼序列可與 lacZ編碼區呈在架構中之型式連接至載體内,如此可產生 4 父虫白貝,pIN載體(Inouye and Inouye,1985,Nucleic Acids Res, 13.3101-3109 , Van Heeke and Schuster, 1989, J. Biol. Chem. 264:5503-5509)等。pGEX載體也可用來表現外 來的多肽,如與殼胱甘肽S_轉移酶(GST)呈融合蛋白質型 式 叙而έ,此融合蛋白質是可溶的,且可自溶解細胞 中客易地純化,其係利用吸附至殼胱甘肽一涼脂糖珠粒, 繼於無殼胱甘肽存在下溶離。設計pGEX載體以納有第Xa 因子蛋白酶解離位置,如此重點之經選殖的融合多肽可自 G S T部份中釋出。 5·5·21^質之純化 一旦重組蛋白質表現,其可以產物之物理或功能特性為 卞之刀析/去鐘定’包括產物之放射活性標記,繼以凝膠電 泳’放射免疫分析,ELIS A,生物分析法之分析。 一旦編碼之蛋白質被鑑知,其可以標準方法分離及純 O:\57\57961-920605.DOC -24- 1223001 化,包括層析(如高性能液相層析,離子交換,親和力及大 小分級管柱層析)’離心,差速溶解度,或利用其他純化蛋 白質之標準技術。所使用之確#條件,—料依以下因素 而定,如淨電荷,疏水性,親水性等,且對精藝者而言是 顧而易見的。功能特性可利用任何適合的分析法評估二 抗體結合,T細胞增殖作用之謗導,細胞動素產製之刺激: 祕2,IL_4及圓_7。於#行本發料,較好各融合蛋白 隸其他蛋白質有至少_純度。較好達鳩。於活體内投 藥時,較好蛋白質有95%以上之純度。 5.6^^^白質編碼庠列夕侍同 、本發明融合蛋白質編碼序列,可用來編碼蛋白質產物以 无作免疫原’用以誘生及/或加強對結核分枝桿菌之免疫反 應。此外,此編碼序列可與另—分子編碼序列連接,如細 胞動素或佐劑。此聚核甞酸可於活體内使用,充作DNA疫 苗(美國專利案編.5,589,466;5,679,647;5,703,055)。在 ^發明具ft實例中,聚料酸在其者中表現其編碼之蛋白 八直接身生免疫反應。聚核甞酸可注入自然個體中, 以引毛對其所編碼產物之免疫反應,或投予至受感染或免 疫個體中,以加強二次免疫反應。 、個軚佳具體貫例中,治療組合物含有融白蛋白質編 碼序列或其片段,其為表現載體的一部份。特別地,此一 二私知I 3有可操作鏈結至編碼區之啟動子,該啟動子是 I诱導的或原構的,且視所需是組織特異的。在另一具體 J中氷核知酸含有一段編碼序列,其鄰接區域係可促
O:\57\57961-920605.DOC 1223001 進在基因體中欲求部位之同質重組作用,因此提供編碼序 列之染色體内表現(Koller and Smithies,1989,Pn Natl
Acad. Sci. USA 86:8932-8935 ; Zijlstra et al.5 1989, Nature 342:435-438)。 核酸遞送至個體可直接的,在此例中個體直接與核酸或 “有核fe之載f豆曝路,或間接的,在此例中細胞先以核酸 於4 τ内轉形,再移植至個體内。此中有二個途徑是已知
的’分別是活體内或活體外基因轉移。 I 在特異具體實例中,核酸直接於活體内投予,其表現可 產生的編碼之融合蛋白質產物。此可由技藝中已知之許多 月太方法中任一方法完成,如將其構築成適合核酸表現載體 的崢彳77,並將之投予如此其可為細胞内的,如利用具缺 陷的或經減毒的反轉錄病毒或其他病毒載體(如見美國專 利案Ν〇·4,980,286)或採裸|DNA之直接注射,或使用微梪 子揎擊(如基因鎗;Biolistic,Dupont),或以脂質或細胞一 表面文體或轉感劑塗佈,包膠在脂質體,微粒或微膠囊(美奉 國專利業>^.5,407,609;5,8 53,763;5,814,3 44及 ’ 20’8 83) ’或將之連接至肽再投藥,此肽係已知可進入 核内者,或將之與配體連接投予,以接受受體一調介之胞 奴作用(如見 WU and Wu,1987, J.Biol.Chem· 262:4429-4432)
其可用來對率可特異表現受體之標的細胞型式。在另一具 體貫例中,可犯a 、A J心成核鉍一配體複合物,其中配體含有癒合 、而母肤其可以瓦解内囊胞,使核酸免於溶酶體降解作 用又在另一具體實例中,核酸可於活體内對準對攝入及
O:\57\5796i-920605.DOC -26- 1223001 母為基礎的遞送系其他目標有肝,中樞神經系,内皮細胞 及肌肉。腺病毒有可感染未分化細胞之優點。與腺體有關 之病毒(AAV)也被提出可用於活體内基因之轉移(waish et al·,1993, Proc. Soc. Exp· Biol· Med· 204:289-300)。 另一途徑涉及以電泳脈動,脂感作用,磷酸鈣調介之轉 感’或病毒感染等方法,將構體轉移至組織培養之細胞内。 通常,轉移方法包括將可選擇之標幟轉移至細胞。細胞再 置於筛選下以分離已被吸收之細胞,並表現所轉移之基 因。這些細胞再遞送至個體。 在此具體實例中,核酸引入細胞中,再於活體内投予所 生成之重組細胞。此引入可以技藝中已知之任何方法進 行,包括下列但不限於此··轉感,電泳脈動,微量注射,以 含有核酸序列之病毒或噬菌體載體感染,細胞融合,染色 體-凋介之基因轉移,微細胞_調介之基因轉移,球狀體融 合等。將外來基因引入細胞之方法技藝中之已知技術很多
Meth· Enzymol. Meth· Enzymol. 29:69-92)且可依 肽(如見 Loeffler and Behr,1993, 217:599-618 ; Cohen et al.? 1993, 217:618-644 ; Cline,1985, Pharmac. Ther. 據本發明使用。 本發明之聚核菩酸也可用於診斷結核病,以偵測病人與 結核分枝桿菌特異的聚核:y:酸序列。為完成此偵測可先自 疑似為細菌感染之病人中取得生物檢品,再行分離聚核答 一旦自生物檢品中分離出聚核菩酸,再令與—個以上 聚核誓酸互補的本發明經標記之聚核#酸與生物樣品中之
O:\57\57961-920605.DOC -28- ί223〇〇ι 一般精藝者已知 固相載體上行雜 聚核苷酸雜交,所利用之核酸雜交技術是 的。例如,此雜交可在溶液中進行,或在 交型式。 5 ·7遨合蛋...治療及預 純化或部份純化之融合蛋白質或其片段可調和成疫苗或 治療組合物。此組合物可含有佐劑以加強免疫反應。此外, 此蛋白質可進-步懸浮於油乳劑中,以於注射後可造成蛋
白質於活㈣之緩慢釋出。調和物中各組份之最適宜比例 可由精藝者熟知之技術決定。 各樣佐劑中的任一者均可用於本發明疫苗中,以加強免 疫反應。大多肽數的佐劑含有可保護抗原免於快速代謝之 物質,如氫氧化鋁或礦油,以及免疫反應非特異的刺激劑, 如脂質A,百日咳博德特瓦菌或結核分枝桿菌。適合的佐 劑是已商品化的,且包括如:Freund,s不完全佐劑及F^und,s 完合佐劑(Difco Lab〇m〇ries:^Merck Adjuvant 65 (Merck and C〇mpany,Inc·,Rahway,NJ)。其他適合的佐劑包括:铭_ 土’可生物降解的微球,單磷醯基脂質A,quil A,SBASlc, SBAS2 (Ling et al·,1997,Vaccine 15:1562-1567),SBAS7 and Al(〇H)3。 在本發明之疫苗中,較好佐劑可謗生包括Thl方面之免疫 反應。適合的佐劑系統包括如:單磷醯基脂質A,較好是3_ 去-0-乙醯基化單磷醯基脂質A(3D-MLP),加上鋁鹽之組 合。加強的系統包括單磷醯基脂質A及皂素衍生物之組 合’特別是3D-MLP&扈素(^21之組合,如W0 94/00153中 O:\57\57961-920605.DOC -29- 1223001 句示或車乂不致反應之組合物,其中Q S 2 1以固醇驟 令如W〇 96/"33739所揭示。先前的實驗已證明3D-MLP及 QS21在誘生體液及Thl型細胞免疫反應上,此組合有清楚 的協同作用。涉及QS21,3D_MLP及生育醇之特別強力的 佐劑調和物;於油水乳劑中,係述於WO 95/17210中,且是 一個較佳之調和物。 含有本發明抗原之調和物本身可投予至個體,咸呈藥學 或治療組合物型式。含有蛋白質之醫藥組合物可利用傳統 的混合,溶解,製粒,糖衣製作,磨光,乳化,包膠,截 陷或冷凍乾燥過程。醫藥組合物可利用一種以上的生理上 可接受的載劑,稀釋劑,賦形劑或有用於將多肽處理修飾 成可藥用之製劑之佐劑,以傳統方式調和。適合的調和物 依所選用之投藥路徑而定。 万;局#投樂時,蛋白質可調和成溶液劑,凝膠,油膏, 乳劑’懸液劑等,技藝中所熟知的。 全身性調和物包括經設計可供注射投予者,如皮下,靜 内肌肉,鞘内或腹膜内注射,以及經設計可供穿皮, 穿膜,口服或經肺投藥者。 方、/主射時,蛋白質可碉和於水性溶液中,較好是於生理 上可相容之緩衝溶液中,如Hanks,溶液,Ringer,vs液或生 良1水、、爰衝溶液。落液可含有調和劑,如助懸劑,穩定 及/或刀政劑。另外,蛋白質可呈粉末型式,以供適合的溶 躲如典菌無熱原的水,重組之用,再供使用。 於芽黏膜投藥時,適合欲穿透障壁之穿透劑可應用於調
O:\57\57961-920605.DOC -30- 1223001 和物中。此穿透劑通常是技藝中已知的。 於口服投藥時,組合物可由蛋白質混合以技藝中熟知之 木學上可接雙載劑而容易地調和。此載劑使蛋白質可調和 成錠劑,丸劑,衣錠,膠囊劑,液劑,凝膠,糖漿劑,於 漿劑,懸液劑等,可為欲治療之個體口服攝入。於口服固 體調和物,如散劑,膠囊劑及錠劑,適合的賦形劑包括充 填劑如糖類,如乳糖,蔗糖,甘露醇及山梨醇;纖維素劑 如玉米澱粉,小麥澱粉,米殿粉,馬铃薯殿粉,明膠,西 黃耆膠,甲基纖維素,羥丙基甲基纖維素,羧甲基纖維素 納,及/或聚乙烯吡咯啶酮(PVP);製粒劑;及黏合劑。若 欲求時,可加入崩散劑,如交聯的聚乙晞吡咯啶酮,脂, 或藻酸,或其鹽如藻酸鈉。 若欲求時,固體劑型可利用標準技術糖衣之或腸衣之。 關於液體製劑,如懸液劑,酏劑及溶液劑,適合的載劑, 賦形劑或稀釋劑包括水,甘醇,油,醇等。另外,也可加 入芳香劑,保藏劑,著色劑等。 供經頰投藥時’蛋白質可呈錠劑,著錠等,以傳統方式 調和。 供吸入投藥時,依據本發明使用之蛋白質,可呈氣霧齊 噴霧型式自加壓的包裝或噴霧器中,藉適合推進劑(如二裹 一氟甲k —氯氟甲燒’:氯四氟乙燒,二氧化碳或立仰 it合的氣fi)合宜地遞心於加签氣霧劑例子中,可由活严t 遞送計量之用量而決定其劑量單位。膠囊及如明膠之厘, 用於吸入器或吹入器時,可調和成含有蛋白質及適合散涂
O:\57\57961-920605.DOC -31 - 1223001 基劑,如乳糖或澱粉之粉末混合物。 蛋白質也可調和於直腸或陰道組合物中,如拴劑或滯留 性灌腸劑’如含有傳統的检劑基劑,如可可油脂气其他甘 油酉旨。 除了先前所述之調和物,蛋白質也可調和成貯置型製 劑。此長效調和物可採植入(如皮下或肌内)或肌内注射方 式投予。目此’蛋白質彳肖適合的聚合的或疏水性物質調 和(如呈在可接受油中之乳劑型式),或以離子系換樹脂調 和’或呈殆不溶之衍生物,如呈殆不溶的鹽。 另外’也可應用其他的藥用遞送系統。脂質體及乳劑是 遞送溶媒熟知之實例,其可用於遞送抗原。也可應用某些 有機溶劑,如二甲亞颯,’然而常有較大毒性之風險。融合 蛋白質也可包膠在微球内(美國專利案N〇s5,4〇7,6〇9: 冰3,763 ; 5,814,344及5,82(),883)。另外,蛋白質可利用相 績釋出學遞送’如未穿透性固相聚合物基皙,立中各有乂 療或免疫劑。各種持續釋出物f已發展,且為精㈣所: 知。持續㈣膠囊’依其化學本f,可釋出蛋白質逢數调 至1⑻天以上。依據試劑之化學本質及生物較性,也可應 用其他蛋白質穩定策略。 ^ 反應之融合蛋白質之有效劑 尤其是基於此中所揭示之詳 決定可在個體中謗生免疫 量’是在精藝者能力之内的, 文為準。 有效弹1量可由試管内分 ^ φ M 先仃估計。例如,可在動物 杈式中凋和劑量,以利用精、、 $知又技★•達成免疫反應
O:\57\5796I-920605.DOC •32- 基劑,如乳糖或殿粉之粉末混合物。 蛋白負也可调和^直腸或陰道組合物中,如拴 性灌腸劑’如含有傳統的栓劑基劑,如可可油脂或其他: 油酯。 除了先前所述之調和物,蛋白質也可調和成貯置型製 劑。此長效調和物可採植人(如皮下或肌内)或肌内注射方 式投予。因此,蛋白質可與適合的聚合的或疏水性物暂調 和(如呈在可接受油中之乳劑型式),或以離子系換樹脂調 和,或呈殆不溶之衍生物,如呈殆不溶的鹽。 另外也可應用其他的樂用遞送系統。脂質體及乳劑是 遞送溶媒熟知之實例,其可用於遞送抗原。也可應用某些 有機溶劑,如二甲賴’⑽常有較大毒性之風險。融: 蛋白質也可包膠在微球内(美國專利案Nos 5,407,609; 5/53,763 ; 5,814,344及5,82M83)。另和蛋白質可利用持 續釋出學遞送,如未穿透性固相聚合物基質,其中含有治 療或免疫劑。各種持續釋出物f已發展,且為精藝者所熟 知。持續釋出膠囊’依其化學本質,可釋出蛋自f逢數週 至100天以上。依據試劑之化學本質及生物穩定性,也可應 用其他蛋白質穩定策略。 “ g決定可在個體中誘生免疫反應之融合蛋白質之有效劑 量,是在精藝者能力之内的,尤其是基於此中所揭示之詳 文為準。 “有效劑量可由試管内分析法先行估計。例如,可在動物 模式中調和劑量’以利用精藝者熟知之技術達成免疫反應 °^57\57961-92〇6〇5.〇〇( -32- 1223001 之誘導。具一般技術者應 队佩動物貝枓,在人類有最注 《投藥。劑量及間隔可個別予以調整。例%,當充作疫苗 使用時’本發明的多肽及/或聚料酸可投予約i _ 3劑,持 續1-36週。較好’投予3劑,間隔約3_4㈣,之後定期給 予追加免疫接種。不同的策略可能適合個別的病人。適合 劑量是多肽或驅之量,其當如上述般投藥時可在經免疫 病人中生成足以保謾病人免於結核分枝桿菌感染歷至少 1-2年之免疫反應。一般而言,多肽之劑量為每公斤宿主體 重由約1微微克至約丨0 0毫克範圍劑量(或以此劑量D N A在 原位所產生的),通常由約10微微克至約i毫克,且較好由 約1〇〇微微克至約i微克。適合的劑量依病人體型大小而變 化,但通常由約0· 1毫升至約5毫升。 5 · 8融合蛋白質之診斷用法 本發明的融合多肽可用於試管内及活體内診斷結核病感 染之用。本發明多肽謗生細胞增殖或細胞動素產製之能 力,可以5.2上文的揭示之方法分析之。 在另一方面,本發明提出利用一種以上融合多肽,以皮 膚試驗活體内診斷結核病之方法。如此中所用的,皮膚試 驗是直接在病人上進行的任何分析法,其中在如上述皮内 注入一種以上多肽後,偵測延緩型過敏(DTH)反應(如腫 脹,紅腫或皮膚)。此注射可利用任何適合的裝置達成,其 係足以令多肽與病人的皮膚細胞接觸,如結核菌素注射器 或1毫升注射器。較好,反應在注射後至少約4 8小時時才偵 測,較好約48 —約72小時後。 Ο Λ --
O:\57\57961-920605.DOC DTH反應是一種細胞調升的免疫反應,其大多肽在先前 已曝於測試抗原(即所應用多肽之免疫原部份,或其變型) 之病人中發生。反應可採目視偵測,利用測徑尺。一般而 吕’將大於約0 · 5公分直徑,較好大於約1. 〇公分直徑之反鹿 稱為陽性反應,顯示結核病感染,其可或不同顯示是活動 期疾病。 本發明的融合多肽,當用於皮膚試驗中時,較好可調和 成含有多肽及生理上可接受載劑之醫藥組合物。此組合物 通常含有一個以上上述的多肽,劑量為在〇·丨毫升體殖中有 約1微克至約100微克,較好由約10微克至約50微克。較好, 應用於此醫樂組合物中之載劑有食鹽水溶液,並加上適合 的保藏劑,如酚及/或Tween80TM。 在另一方面,本發明提出利用多肽診斷結核病之方法。 在此方面,提出在生物檢品中偵測結核分枝桿菌感染之方 法’其中利用單獨的或組合之融合多肽。如此中所用,,, 生物樣品”是由病人取得的任何含有抗體之樣品。較好i樣 品是全血1痰,血清,血漿,噬液,腦脊髓液或尿液。較好, 樣品是得自病人或供血中心之血液,血清或血漿樣品。在 分析中使用多肽,如下述,以決定樣品中多肽之抗體存在 與否,並與預定截去值相比較。此抗體之存在顯示對分枝 桿菌抗原之敏化’此可顯示出結核病。 在應用不只一種融合多肽之具體實例中,所使用的多肽 較好是互補的(即一組份多肽傾向於偵測樣品中之感染,而 其中感染無法為另一組份多肽所偵測)。互補多肽通常利用 O:\57\57961-920605.DOC >34- 1223001 各多肽鑑定,其個別可評估由一系列已知感染有結核分枝 桿菌之病人取得之血清樣品。於以各多肽決定出何樣品呈 陽性係(如下述),可調和二種以上融合多肽之組人,並 偵測大多肽數受試樣品或所有的感染。在有結核病感染個 體之血清中’約25-30%對於任何單一蛋白質之抗體呈降 性。因此,互補的多肽可組合使用以改進一個診斷試驗之 敏感性。
有各樣精藝者已知之分析模式,可利用一種以上的多月太
以須測樣品中之抗體。如見Harlow and Lane,Antibodies A
Laboratory Manual. Cold Spring Harbor Laboratory, l988 .
其已列為本案參考。在一個較佳具體實例中,分析中使用 固化在固相載體上之多肽,以結合及移去樣品中之抗體。 已結合足抗體再利用偵測試劑偵測,其中係含有告知者基 團。適合的偵測試劑包括可與抗體丨多肽複合物結合之抗 體,及標記以告知者基團之自由態多肽(如於半、競爭性分 析中)。另外,也可利用競爭性分析,其中結合至多肤之抗 體標記以告知者基團,且在抗原與樣品培育後,可結合至 已固化杬原上。樣品組份抑制經標記抗體與多肽結合之程 度,可作為樣品與已固化多肽反應性之指示。 固相載體可為精藝者已知之任何固體物質,此中係可 附上抗原。例如,固相載體可以是在微較盤上之試驗 洞或硝化纖維膜或其他適合的膜。另外,載體可以是珠 或^,如破璃,纖維玻璃,乳膠或塑質材料如聚苯乙 或κ氯乙、希載體也可以是磁性粒子或光纖感應器,如
O:\57\57961-920605.DOC -35- 1223001 美國專利案No.5,359,68 1中所述的。 夕肽可利用精藝者已知之各樣技術結合至固相載體。在 本發明之環境下,所謂”結合的”指非共價結合如吸附作 用’及共價的黏附(其可為抗原及載體上功能基間之直接鏈 結’或可經由交又鏈結劑鏈結)。以經由吸附作用結合至微 滴足盤之孔洞,或至膜之結合為較佳。在此例中,為達成 吸附作用’可將多肽在適合的缓衝溶液中與固相載體接觸 一段適合時間。接觸時間隨溫度而變化,但通常介於約1 小時及1天之間。一般而言,將塑質微滴定盤孔洞(如聚苯 乙烯或聚氣乙烯)與由約丨〇毫微克至約1微克之多肽,且較 好約1 0 0晕微克接觸,足以結合適量之抗原。 多肽共價黏附至固相載體,通常可先將載體與雙官能試 别反應’其係可與載體及官能基反應,如輕基或胺基。例 如’多肽可結合至具有適合的聚合物外層之載體上,可使 用苯酿或以胺及多肽上之活性氫縮合載體上之醛基(如見
Pierce Immunotechnology Catalog and Handbook. 1991, at A12-A13)。 在某些具體貫例中,分析是酵素鏈結的免疫吸附分析法 (ELISA)。此分析之進行是先將已固化在固相載體上之融合 多肽抗原,通常此固相指微滴定盤之孔洞,與樣品接觸, 如此在樣品内之多肽抗體可結合至已固化之多肽上。再自 已固化之多肽中移去未結合樣品,再加入可結合至已固化 抗體-多肽複合物之偵測試劑。再以適合特異偵測試劑之方 法’決定仍結合至固相載體之偵測試劑含量。 O:\57\57961-9206O5.DOC -36- 1223001 較特異地,一旦多肽如上述固化在載體上,留在载體上 之a白貝、K置通常是被阻斷的。任何適合的阻斷劑, 如般釦本者热知之牛血清白蛋白或丁㈣⑶2〇τμ(84^
ChemicalC〇.,St.L〇uis,M〇)也可應用。已固化之多肽再與 樣品共培育’並令抗體與抗原結合。樣品以適合的稀釋劑 卿’、如磷酸鹽緩衝之食鹽水(PBS),再予以培育。一般^ 言’通合的接觸時間是足以偵測結核分枝桿菌感染樣品内 抗體存在之時間。較好’接觸時間是足以達到在已結合及 未^合抗體間平衡下的達成的至少95%結合水平之時間。· 精藝者應了解’達到平衡所必要的時間可藉由分析一段時 間後發生之結合水平而容易地決定。在室溫下約30分鐘之 培育時間通常已足夠。 $結合之樣品可由適合緩衝溶液,如含有〇ι% 20TM之PBS ’洗條固相載體而移去。再將摘測試劑加至固 相載體。適合的偵測試劑為可結合至經固化之抗體一多肽 複合物上4任何化合物’且其可以精藝者已知之各樣方法鲁 偵測。車乂好’偵測試劑含有共輛至告知者之結合劑(如蛋白 質A ’蛋白質G,外源凝集素,或自由態抗原)。較佳之告 知者基團包括酵素(如辣根過氧化酶),變質,辅因子,抑 制劑,染料’放射核種,螢光基團,化學發光基團,生物 素及膠態粒子,如膠態金及石西。結合劑與告知者基之共軛 作用可以和#者已知之標準方法達成。一般的結合劑也可 追加共軛至由許多肽商品化來源來之告知者基團上(如 Zymed Laboratories, San Francisco, CA. and Pierce,
O:\57\57961-920605.DOC -37- 1223001
Rockford. IL)。 偵測試劑再與已固化之抗體一多肽複合物培育一段充份 時間,以偵測已結合之抗體。適當的時間通常由廠商操作 指示決定,或分析一段時間後發生之結合水平而決定。未 結合 < 偵測試劑再移去,並利用告知者基團偵測已結合之 偵測試劑。用來偵測告知者基團之方法依告知者基團之本 質而疋。至於放射活性基團,液體閃爍計數或放射自顯術 方法通常是適合的。分光光度方法可用來偵測染料,化學馨 發光基及螢光基團。生物素可利用抗生物素蛋白偵測,其 並可偶合至不同的告知者基團上(通常是放射活性或螢光 基團或酵素)。酵素告知者基團通常由加入受質來偵測(通 常歷特異時間),繼以反應產物之分光光度或其他分析。 為了決疋樣品中抗-結核分枝桿菌抗體存在與否,由仍與 固相載體結合之告知者基團中測及之訊號,通常與相當於 預足4截去值之訊號比較。在一個較佳具體實例中,截去 值疋經固化抗原與未感染病人之樣品培育時所得之平均訊泰 唬值。一般而T,樣品所產生之訊號若為預定截去值三倍 偏差以上時,此樣品可視為結核病陽性。在另一較佳具體 貫例中,截去值利用接受者操作者曲線(Receiver 〇perat〇r Curve)來決定。此依 Sackeu 以 al·,1985,
Epidemiology: A Basic Science for Clinical Medicine, Little Brown and Co·,PP. 106-107之方法。簡言之,在此具體實 例中,截去值可由真陽性速率(即敏感性)及偽陽性速率 (100〇/〇-特兴性)成對作圖來;夬定,其相當於診斷試驗結果的 O:\57\5796I-920605.DOC '38- 1223001 ί個Γ能的截去值。在圖上最接近左上角之截去值(即包園 取大區域〈值)為最正確之截去值,因為以此方法決定出之 _去值之樣品訊號可視為陽性。另外,截去值 圖形移至左侧,以減小偽陽性率,或移至右侧以減小偽阶 性率。—般而言’以此方法決定之訊號若高於截去值時, 此樣品可視為結核病陽性。 在-個相關具體實财,分析係在快速流過式或長條气 驗模式中進行,其中抗原係固化在膜上,如硝化纖維素: 在流過式試驗中,當樣品通過膜時,樣品内之㈣可與i 固化之多肽結合。而當含有偵測試劑之溶液流過膜時,偵 測試劑(如蛋白質A _膠態金)可再與抗體一多肽複合物2 合。再如上進行已結合偵測試劑之偵測。在長條試驗模= 中’結合有多肽之膜端浸於樣品溶液中。樣品可沿著含偵 測試劑之區域移動,到達已固化多肽之區域。偵測試劑在 多肽處之濃縮表示樣品中存在有抗-結核分枝桿菌抗體。典 型而言,偵測試劑在此位置處之濃度可產生一種模式,^ 線形,此是可目視的。此型式之不存在表示一個陰性結果。 一般而言,選擇膜上已固化多肽之量,使得當生物樣品中 所含之抗體足以在ELISA上產生陽性訊號時,其可產生可 目視分別之型式。較好,固化在膜上之多肽含量由約5毫微 克至約1微克,且較好是由約50毫微克至約5〇〇毫微克。此 試驗通常以極少量(如一滴)病人血清或血液來進行。 本發明已加以描述,以下實例提出用以說明而非予以限 制0 O:\57\57961-920605.DOC -39- 1223001 6·實例:結核分枝椁萌杭原之融合蛋_白質保留個別組份之务 疫原性 6.1材料及方法 6.1.1融合蛋白質之構築 以PCR修飾結核分枝桿菌抗原之編碼序列,以助其融合 及接下來融合蛋白質之表現。DNA擴大作用之作行係利用 10微升10 X Pfu緩衝溶液,2微升1〇 mM dNTPs,各2微升的 PCR引子(10// Μ濃度),81·5微升水,1.5微升Pfu DNA聚合 · 酶(Stratagene,La Jolla,CA)及 1微升 DNA,於 70毫微克 /微 升(於TbRa3抗原)或50毫微克/微升(於38 kD及Tb38-1抗 原)。於TbRa3抗原上,94°C之變性進行2分鐘,繼以96°C 15 秒及7 2 °C 1分鐘4 0個循環,最佳是7 2 °C 4分鐘。於3 8 kD抗 原,在96°C下變性2分鐘,繼以96°C 30秒,68 °C 1 5秒及72 °C3分鐘的40個循環,最後是72°C4分鐘。於Tb38-1抗原, 在94°C下變性2分鐘,繼以96°C 15秒,68。(: 15秒及72°C 1.5 分鐘的10個循環,96°C 15秒,64°C 15秒及72°C 1·5秒的30個 _ 循環,及最後的72°C4分鐘。 在以核酸内切限制酶水解後,可生成欲求之不齊或乎齊 的末端’而與各融合多肽特異之聚核甞酸再連接至表現質 體。所生成之各質體含有各融合多肽個別抗原之編碼序 列。所使用之表現載體是PET-I2b及PT7 L2 IL1。 抗原Ral2’ TbH9及Ra35之編碼序列連接,以編碼融合蛋 白質(SEQ ID N0:^2_1A&1B)。抗原 £rd 14, dPV及 MTI另三個編碼序列連接以編碼第二個融合蛋白質(seq O:\57\5796i_920605.DOC -40- 1223001 10>^08:3及4)(圖2)。抗原1^1^3,3 81^0及1^3 8-1的三個編 碼序列連接以編碼融合蛋白質(SEQ ID NOS:5及6)(圖 3A-3D)。抗原TbH9及Tb38-1的二個編碼序列連接以編碼一 個融合蛋白質(SEQ ID NO:7及8)(圖4A-4D)。抗原TbRa3, 3 8kD ' Tb3 8-1及DPEP的四個編碼序列連接以編碼一個融合 蛋白質(SEQ ID NO:9 及 10)(圖 5A-5J)。抗原 Erdl4,DPV, MSL·及MTCC2的五個編碼序歹ij連接以編碼一個融合蛋白質 (SEQ ID ΝΟ:11 及 12)(圖 6A-6B)。抗原 Erdl4,DPV,MTI 及 MSL的四個編碼序列連接以編碼一個融合蛋白質(SEQ ID N〇:13及14)(圖7A-7B)。抗原DPV,MTI,MSL及MTCC2的四 個編碼序列連接以編碼一個融合蛋白質(SEQ ID NO:15及 16)(圖8A-8B)。抗原DPV,MTI及MSL的三個編碼序列連接 以編碼一個融合蛋白質(SEQIDNO:17及18)(圖9A_9B)。抗 原丁bH9,DPV及MTI三個編碼序列連接以編碼一個融合蛋 白質(SEQ ID NO:19 及 20)(圖 10A-10B)。抗原 Erdl4,DPV, 及MTI的三個編碼序列連接以編碼一個融合蛋白質(SEQ ID NO:21及22)(圖 11A-11B)。抗原 TbH9 及 Ra35的二個編碼 序列連接以編碼一個融合蛋白質(SEQ ID NO:23及24)(圖 12八及123)。抗原1^12及0??0的二個編碼序列連接以編碼 一個融合蛋白質(SEQ ID NO:25及 26)(圖 13A-13B)。 重組體蛋白質在E. coli中表現,其在胺基末端部份有六 個組胺酸殘基,此中利用pET質體載體(pET-17b)及T7 RNA 聚合酶表現系(Novagen,Madison,WI). E. coli strain BL21 (DE3) pLysE (Novagen)可用於高水平表現。重組體(His-Tag) O:\57\57961-920605.DOC -41 - 1223001 融合蛋白質自可溶的上清液或500毫升IPTG誘導之培養物 中之不落性包涵體中純化’此經由親和力層析利用單步馬〒 QIAexpress Ni-NTA 脂塘基質(QIAGEN,Chatswonh,CA) 於8M尿素存在下進行。簡言之,20毫升含有pET構體的 BL21隔夜飽和的培養物,加至500毫升2XYT培養基中,其 内含有5 0微克/耄升氨青黴素及3 4微克/毫升氯黴素,在3 7 °C下震盛培養。細菌培養物在OD560 0.3下以2 mM IPTG绣 導’並再培養3小時(〇D=l .3至1.9)。以離心回收來自5〇〇毫 升培養物之細胞,並再懸浮於20毫升結合緩衝溶液中1〇1M 磷酸鈉,pH 8.0 ; 10 mM Tris-HCl,pH 8·0),其中含有 2mM PMSF及20微克/耄升焭肽素加上一個完全的蛋白酶抑制劑 錠(BoehringerMannheim)每25毫升Ecoli計,再冷凍乾燥並 繼以快速音波震盪,之後在12k rpm下離心30分鐘使包涵體 成團塊。 包涵體於 1% CHAPS 於 10 mM Tris-HCl (pH 8.0)中洗二 次。此步驟大大地減低LPS污染之水平。包涵體最後溶解 於2〇毫升結合緩衝溶液中(含有8M尿素),或81^尿素直接加 至可洛的上清液内。有HB-Tag殘基的重組體融合蛋白質批 次結合至Ni-NTA脂塘樹脂上(5毫升樹脂/5〇〇毫升誘導作 用)係在室溫下震盪1小時,再將複合物通過管柱。流過液 通過相同管柱二次,且管柱L2各3〇毫升洗滌緩衝溶液洗三 次0.1M磷酸鈉及10mM Tris-HC1 (pH 6 3),其中也含有 尿素。已結合的蛋白質以30毫升15〇mM咪唑於洗滌緩衝溶 液中落離,再收集5毫升流份。將含有各重組融合蛋白質之
O:\57\57961-920605.DOC -42- 1223001 流份匯集,以10 mM Tris-HCl (pH 8·0)透析,結合一次以上 至Ni-NTA基質上,溶離並透析於1 〇 mM Tris-HCl (pH 7.8)。重組蛋白質之產率在每升已謗導之細菌培養中有 25-150毫克之變化,且純度在98%以上。利用Limulus分析 法(Bio Whittaker)分析重組蛋白質中内毒素之污染,且顯示 含量<10 E.U.I毫克。 6.1 ·2·T-細胞增殖分析 測試純化的融合多肽,其在周邊血液單核細胞(PBmc) 製劑中謗導T-細胞增殖之能力。已知為ppd皮膚試驗陽性 供者之PBMCs,及其T細胞可反映PPD而增殖者之PBMCs, 及來自結核分枝桿菌之粗製的可溶蛋白質,培養在rpmj 1640中,其中並添加有10%匯集的人類血清及5〇微克/毫升 健大霉素。經純化的多肽,以〇·5-10微克/毫升濃度加入重 覆二次。在96孔洞圓底盤中,以200微升體積培養6天後, 自各孔洞中移出50微升培養基,以決定IFN- 7水平,如下 文6.1.3段所述。盤中追加以ivci/孔洞之氚化的胸苷,歷 再1 8小時,回收,再以氣態閃燦計數決定氣之攝入。將所 造成之增殖作用較細胞單獨培養於培養基時所得的大三件 以上者’此指在二次實驗中均如此者,可視為陽性。 6.1.3.干擾素-τ分析 典菌地切出老鼠之脾,且單細胞懸液在紅血球溶解後製 備於完全的RPMI*。細胞以每孔洞1〇〇微升(2χι〇_5細胞) 堂佈在96孔洞之平底微滴定盤上。培養物以所指示之重組 體蛋白質刺激24小時,再分析上清液中之IFN-r。
O:\57\57961-9206O5.DOC •43 - 1223001 以二明治式ELIS分析上清液IFN_ ^之水平,利用取得自 PharMmgen之抗體對及步,驟。利用重組體老鼠細胞動素產 生標準曲線。ELIS A盤(Corning)塗佈以50微升/孔洞(丨微克/ 震升,於0.1 Μ碳酸氫鹽塗佈緩衝溶液pH 9 ·6)的細胞動素捕 獲 mAb(大鼠抗-老鼠 IFN- τ (PharMingen ; Cat.# 18181D)並 在室溫下培育4小時。震盪出盤内容物,以pBS-〇 〇5〇/。 Tween,1.0% BSA(200微升/孔洞)在4°C下阻斷一夜,再於 PBS-0.1G/〇 Tween 中洗 6X。再加入稀釋於 pbS-0.050/。
Tween,0.1%BSA之標準品(老鼠IFN_r )及上清液樣品,於 室溫下2小時。盤如上洗滌,再於室溫下與1 〇〇微升/孔洞二 次Ab共培育2小時(生物素大鼠α老鼠IFN- T (Cat # 18112D ; PharMingen)0.5 微克 / 毫升稀釋於 PBS-0.05%
Tween,0·1°/〇 BSA中)。洗滌後,盤與1〇〇微升/孔洞的鏈抗 生物素蛋白-HRP (Zymed)在1:2500稀釋於PBS-0.05% Tween,0.1% BSA在室溫下培育1小時。盤最後洗一次,再 以100微升/孔洞TMB受質展開(3,3,,5,5,-四甲基聯苯胺 Kirkegaard and Perry,Gaithersburg,MD),而在呈色後以 H2S〇4,5 0微升/孔洞,停止反應。在450毫微米波長下決定 吸光度(OD),利用570毫微克波長為參考波長,再以標準曲 線評估細胞動素之濃度。 6.2結果 6·2·1·叁融合蛋白質謗生的免疫反應 結核分枝桿菌抗原的三個編碼序列嵌入表現載體内,以 產製融合蛋白質。命名為Ral2,TbH9及Ra35之抗原產製成 O:\57\57961-920605.DOC -44- 1223001 一個重組體融合蛋白質(圖〗A&1B)。抗原Erdl4, DPV及 MTI產製成第二個融合蛋白質(圖2)。二種融合蛋白質以親 和力純化,以為試管内及活體内分析之用。 測試二種融合蛋白質刺激丁細胞反應之能力,此丁細胞來 自六個PPD+個體。當偵測T細胞增殖作用時,二種融合蛋 白$呈現如其個別組份般之相似反應型式(圖 14A-14F)。當偵測IFN_r產製時,可得相似的結果。(圖 15A-15F)。例如,個體D16〇可分別反應TbH9&MTi。個體 D1 60也可反應含有這些抗原之融合蛋白質(圖MR及 15B)。相反的,在D16〇並未觀察到對其他個別抗原的丁細 胞反應。另一個體,D2(H,其確實不與個別的Erdl4,Dpv 或MTI抗原反應,而對含有這些抗原的融合蛋白質也無反 應。應注意到,當對二種融合蛋白質三個別組份無特別強 的T細胞反應時,則融合蛋白質所刺激的反應相當於或高於 大多肽數例子中由個別抗原誘生之反應。 也在活體内測試Ral2-TbH9-Ra35叁融合蛋白質充作免 疫原之情況。在這些實驗中,融合蛋白質注入老鼠足墊以 兄疫接種各組二隻老鼠接受在不同佐劑調和物中之蛋白 質:SBASlc,SBAS2 (Ling et al·,1997,Vaccine 15:1562- 1567),SBAS7及AL(OH)3。以三週間隔二次皮下免疫接種 後,一週後犧性動物,且其排液之淋巴結回收以充作反應 細胞應用於T細胞增殖及細胞動素分析。 估不論使用何種佐劑於免疫接種中,當其充作個別抗原 時,仍可誘生出拮抗TbH9之強的T細胞增殖反應(圖16A)。 O:\57\57961-920605.DOC -45 - 1223001 而拮抗Ra35及Ral2則誘生較弱之反應(圖16B及16C)。當以 Ral2-TbH9-Ra35融合蛋白質充作免疫原時,可觀察到和拮 抗個別組份相似之反應。 當偵測細胞動素之產製時,佐劑SBASlc及SBAS2可產生 類似的IFN-τ (圖17)及IL-4反應(圖18)。然而,SBAS7及氫 氧化鋁之組合可產生最強的IFN- r反應,且對所有三種抗 原有最低水平之IL-4產製。關於活體内之體液抗體反應, 圖19A-19F顯示當與三種佐劑中任一者使用時,融合蛋白質 可謗生IgGl及IgG2a抗原-特異的反應。 另外,C57BL/6老鼠以二種表現構體之組合免疫接種, 其各自含有 Ral2-TbH9-Ra35 (Mtb32A)或 Erdl4-DPV-MTI (Mtd39A)編碼序列為DNA疫苗。經免疫的動物一旦繼以5 種細菌之氣霧劑挑戰後,可對結核病呈現顯著的保護作 用。依據這些結果,製備Mtb3 2A及Mtd3 9A編碼序列之融合 構體,且其編碼之產物在天竺鼠長期保護模式中進行測 試。在這些研究中,天竺鼠以單一重組融合蛋白質或 Mtb32A及Mtd39A蛋白質於含有佐劑之調和物中之混合物 免疫接種。圖20A-20C顯示,以融合蛋白質於SBASlc或 SBAS2免疫接種天竺鼠,一旦再施以挑戰時,可更佳地保 護拮抗結核病之發展,此與以二種抗原於相同佐劑調和物 混合物免疫接種動物比較而言。於SBAS2調和物之融合蛋 白質可在動物中生成最大的保護作用。因此,各種結核分 枝桿菌抗原之融合蛋白質可充作疫苗調和物中較個別組份 混合物更為有效之免疫原。 O:\57\57961-920605.DOC -46- 1223001 6·2·2·雙融合蛋白質謗生之免疫反應 以重組方法產生含有TbH9及Tb3 8-1抗原但無樞紐序列 之雙融合蛋白質。檢查TbH9-Tb3 8-l融合蛋白質謗導T細胞 增殖及IFN- r產製之能力。應用來自三位供者之pbmc: — 供者先前已示出可反應TbH9但Tb38-1則否(供者131); —者 可反應Tb3 8-1但非TbH9(供者184); —者反應二種抗原(供 者201)。這些研究結果證明,二種抗原在融合蛋白質中之 功能活性(圖21A及21B,22A及22B及23A及23B)。 6·2·3·二..種可與結核病病患血清反應之肆融合番白皙 以重組體方法產生含有TbRa3,38kD抗原Tb38-1及DPEP 之融合蛋白吳。以ELISA檢查此稱之為TbF-2之肆融合蛋白 質與雙結核分枝桿菌感染患者之血清之反應活性。這些研 究之結果(表1)證明所有四種抗原在融合蛋白質中獨立地 作用。 精藝者應了解,個別始A々5丄人IP i π、、_ ,、
含有活性表位之截斷型蛋白質。
W孫示之所有鹼基對大小均為相 。也應了解,針對核苷酸 似值’且僅供說明目的。
A5796I-920605.DOC -47- 1223001 此中所列之所有刊物均以全文列為參考之用。 表1 T B F - 2融合蛋白質與Τ B及正常血清之反應性 血清 ID 狀態 TbF OD450 狀態 TbF-2 OD450 狀態 ELISA反應性 38kD TbRa3 Tb38-1 DPEP B931-40 TB 0.57 + 0.321 + - + + B931-41 TB 0.601 + 0.396 + + + + 痛 B931-109 TB 0.494 + 0.404 + + + ++ - B931-132 TB 1.502 + 1.292 + + + + ++ 5004 TB 1.806 + 1.666 + ++ ++ + - 15004 TB 2.862 + 2.468 + + + + - 39004 TB 2.443 + 1.722 + + + + - 68004 TB 2.871 + 2.575 + + + + - 99004 TB 0.691 + 0.971 + 麵 ++ + - 107004 TB 0.875 + 0.732 + - ++ + - 92004 TB 1.632 + 1.394 + + ++ ++ - 97004 TB 1.491 + 1.979 + + ++ - + 118004 TB 3.182 + 3.045 + + ++ 一 - 173004 TB 3.644 + 3.578 + + + + - 175004 TB 3.332 + 2.916 + + + - - 274004 TB 3.696 + 3.716 + - + - + 276004 TB 3.243 + 2.56 + - + 晒 282004 TB 1.249 + 1.234 + + - 289004 TB 1.373 + 1.17 + • + • - 308004 TB 3.708 + 3.355 + 釋 • + • 314004 TB 1.663 + 1.399 + - - + - O:\57\57961-920605.DOC 48- 1223001 317004 TB 1.163 + 0.92 + + - 312004 TB 1.709 + 1.453 + - + - 380004 TB 0.238 - 0.461 + 嶋 ++ + 451004 TB 0.18 0.2 - 一 - ++ 478004 TB 0.188 0.469 + 灣 - • ++ 410004 TB 0.384 + 2.392 + ++ 擊 - + 411004 TB 0.306 + 0.874 + 一 + + 421004 TB 0.357 + 1.456 + + 一 + 528004 TB 0.047 - 0.196 一 一 晒 + A6-87 正常 0.094 0.063 峰 細 - - A6-88 正常 0.214 0.19 一 一 睡 A6-89 正常 0.248 嗎 0.125 睡 一 • A6-90 正常 0.179 0.206 - 一 崎 - A6-91 正常 0.135 議 0.151 一 寒 - A6-92 正常 0.064 轉 0.097 - - • - A6-93 正常 0.072 0.098 - 麵 細 - A6-94 正常 0.072 - 0.064 - - - A6-95 正常 0.125 0.159 - 一 - 細 A6-96 正常 0.121 • 0.12 一 麵 麵 • 截去值 0.284 0.266 O:\57\57961-920605.DOC 49-

Claims (1)

1223齡 —™IM^i()5532號申請案 中文申請專利範圍替換本(93年5月) 拾、申請專利範圍: h 一種經純化之多肽,其係由SEQ ID NO:2之胺基酸序列所 組成。 2·根據申請專利範圍第丨項之多肽,其係一種可溶性多肽。 3. 根據申請專利範圍第1項之多肽,其係以重組體DNA方法 所產製的。 4. 根據申請專利範圍第丨項之多肽,其係以化學合成方法所0 產製的。 5·根據申請專利範圍第丨項之多肽,其可謗生抗體反應。 6·根據申請專利範圍第丨項之多肽,其可謗生τ細胞反應。 7·根據申請專利範圍第1項之多肽,其係與一第二異質多肽 融合。 8· —種用於預防結核病之醫藥組合物,其包含有效劑量之根 據申請專利範圍第丨項之多肽。 9.-種广於預防結核病之醫藥組合物,其包含有效劑量之聚_ 核甘’此聚核嘗酸可編碼根據申請專利範圍第丄項之多 月太。 ^在個租中诱發抗 '结核分枝桿菌免疫反應之免疫 、醫藥、、'且合物’其係含有根據申請專利範圍第1項之多 兑對抗結核分枝桿菌之dna疫苗之醫藥組合物, …、3編碼根據申請專利範圍第i項之多肽之聚核甞 11. 12 酉父Ο 12 酉父Ο 13 Η. 15. 16. 17. 18. …種編碼_請專利㈣第1項之多肽之聚核芬酸。 .根據令請專利範圍第12嚷之聚核誓酸,其係由seqid N〇:1之序列所組成。 根據申請專利範圍第8至"項任一項之醫藥組合物,其 尚包括佐劑。 根據中請專利範圍帛14項之醫藥組合物,其中該佐劑包 括至少-種選自3D-MPL及QS21所組成之群之成分。 =請專利範圍第15項之醫藥組合物,其係滅 水(Oil-in-water)乳劑。 、/由 —種經純化之聚核甞酸,其係由SEQ⑴ 組成。 序列所 -種表現載體’其包括申請專利範圍第17項之聚枋# X甘酸。
O:\57\5796I-930506.DOC 口第0蒞1〇5532號專利申請案
十又補龙說明(92年6月) 序列表 <110>克里克索公司 <120>結核分枝桿菌抗原之融合蛋白質及其用途 <130> 014058-009010PC <140> WO PCT/US99/07717 <141> 1999-04-07 <150> US 09/056,556 <151> 1998-04-07 <150> US 09/223,040 <151> 1998-12-30 <160> 41 <170> Patentln Ver. 2.1 <210> 1 ' <211> 2287 <212> DNA <213 >人工序列 <220> <223>人工序列之說明:三-融合蛋白質 Ral2-TbH9-Ra35(命名為 Mtb32A) 、 <220> <221>修飾的_鹼基 <222> (30)— <223> n = g, a, c or t <220> <221>修飾的_鹼基 <222> (33) <223> n = g, a, c or t <220> <221〉 CDS <222> (42) . . (2231) <220> <221>修飾的_驗基 <222> (2270) <222> η = g, a, c or t <400> 1 tctagaaata attttgttta ctttaagaan ganatataca t atg cat cac cat cac 56 Met His His His His 1 5 cat cac acg gcc gcg tcc gat aac ttc cag ctg tcc cag ggt ggg cag 104 His His Thr Ala Ala Ser Asp Asn Phe Gin Leu Ser Gin Gly Gly Gin 10 15 20 1 1521223001 gga ttc gcc att ccg ate ggg cag geg atg geg ate geg ggc cag ate Gly Phe Ala lie Pro lie Gly Gin Ala Met Ala 工le Ala Gly Gin lie 25 30 35 ega teg ggt ggg ggg tea ccc acc gtt cat ate ggg cct acc gcc ttc Arg Ser Gly Gly Gly Ser Pro Thr Val His 工le Gly Pro Thr Ala Phe 40 45 50 etc ggc ttg ggt gtt gtc gac aac aac ggc aac ggc gca ega gtc caa Leu Gly Leu Gly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val Gin 55 60 65 ege gtg gtc ggg age get ccg geg gca agt etc ggc ate tee acc ggc Arg Val Val Gly Ser Ala Pro Ala Ala Ser Leu Gly lie Ser Thr Gly 70 75 80 85 gac gtg ate acc geg gtc gac ggc get ccg ate aac teg gcc acc geg Asp Val lie Thr Ala Val Asp Gly Ala Pro lie Asn Ser Ala Thr Ala 90 95 100 atg geg gac geg ett aac ggg cat cat ccc ggt gac gtc ate teg gtg Met Ala Asp Ala Leu Asn Gly His His Pro Gly Asp Val lie Ser Val 105 ' 110 115 acc tgg caa acc aag teg ggc ggc aeg cgt aca ggg aac gtg aca ttg Thr Trp Gin Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn Val Thr Leu 120 125 130 gcc gag gga ccc ccg gcc gaa ttc atg gtg gat ttc ggg geg tta cca Ala Glu Gly Pro Pro Ala Glu Phe Met Val Asp Phe Gly Ala Leu Pro 135 140 145 ccg gag ate aac tee geg agg atg tac gcc ggc ccg ggt teg gcc teg Pro Glu 工le Asn Ser Ala Arg Met Tyr Ala Gly Pro Gly Ser Ala Ser 150 155 160 165 ctg gtg gcc geg get cag atg tgg gac age gtg geg agt gac ctg ttt Leu Val Ala Ala Ala Gin Met Trp Asp Ser Val Ala Ser Asp Leu Phe 170 175 180 teg gcc geg teg geg ttt cag teg gtg gtc tgg ggt ctg aeg gtg ggg Ser Ala Ala Ser Ala Phe Gin Ser Val Val Trp Gly Leu Thr Val Gly 185 190 195 teg tgg ata ggt teg teg geg ggt ctg atg gtg geg geg gcc teg ccg Ser Trp 工le Gly Ser Ser Ala Gly Leu Met Val Ala Ala Ala Ser Pro 200 205 210 tat gtg geg tgg atg age gtc acc geg ggg cag gcc gag ctg acc gcc Tyr Val Ala Trp Met Ser Val Thr Ala Gly Gin Ala Glu Leu Thr Ala 215 220 225 gcc cag gtc egg gtt get geg geg gcc tac gag aeg geg tat ggg ctg Ala Gin Val Arg Val Ala Ala Ala Ala Tyr Glu Thr Ala Tyr Gly Leu 230 235 240 245 aeg gtg ccc ccg ccg gtg ate gcc gag aac cgt get gaa ctg atg att Thr Val Pro Pro Pro Val lie Ala Glu Asn Arg Ala Glu Leu Met lie 250 255 260 200 248 296 344 392 440 488 536 584 632 680 728 776 2 824 8721223001 ctg ata gcg acc aac etc ttg ggg caa aac acc ccg geg ate geg gtc Leu 工le Ala Thr Asn Leu Leu Gly Gin Asn Thr Pro Ala 工le Ala Val 265 270 275 aac gag gee gaa tac ggc gag atg tgg gee caa gac gee gee geg atg Asn Glu Ala Glu Tyr Gly Glu Met Trp Ala Gin Asp Ala Ala Ala Met 280 285 290 ttt ggc tac gee geg geg aeg geg aeg geg aeg geg aeg ttg ctg ccg Phe Gly Tyr Ala Ala Ala Thr Ala Thr Ala Thr Ala Thr Leu Leu Pro 295 300 305 ttc gag gag geg ccg gag atg acc age geg ggt ggg etc etc gag cag Phe Glu Glu Ala Pro Glu Met Thr Ser Ala Gly Gly Leu Leu Glu Gin 310 315 320 325 gee gee geg gtc gag gag gee tee gac acc gee geg geg aac cag ttg Ala Ala Ala Val Glu Glu Ala Ser Asp Thr Ala Ala Ala Asn Gin Leu 330 335 340 atg aac aat gtg ccc cag geg ctg caa cag ctg gee cag ccc aeg cag Met Asn Asn Val Pro Gin Ala Leu Gin Gin Leu Ala Gin Pro Thr Gin 345 " 350 355 ggc acc aeg cct tet tee aag ctg ggt ggc ctg tgg aag aeg gtc teg Gly Thr Thr Pro Ser Ser Lys Leu Gly Gly Leu Trp Lys Thr Val Ser 360 365 370 ccg cat egg teg ccg ate age aac atg gtg teg atg gee aac aac cac Pro His Arg Ser Pro 工le Ser Asn Met Val Ser Met Ala Asn Asn His 375 380 385 atg teg atg acc aac teg ggt gtg teg atg acc aac acc ttg age teg Met Ser Met Thr Asn Ser Gly Val Ser Met Thr Asn Thr Leu Ser Ser 390 395 400 405 atg ttg aag ggc ttt get ccg geg geg gee ege cag gee gtg caa acc Met Leu Lys Gly Phe Ala Pro Ala Ala Ala Arg Gin Ala Val Gin Thr 410 415 420 geg geg caa aac ggg gtc egg geg atg age teg ctg ggc age teg ctg Ala Ala Gin Asn Gly Val Arg Ala Met Ser Ser Leu Gly Ser Ser Leu 425 430 435 ggt tet teg ggt ctg ggc ggt ggg gtg gee gee aac ttg ggt egg geg Gly Ser Ser Gly Leu Gly Gly Gly Val Ala Ala Asn Leu Gly Arg Ala 440 445 450 gee teg gtc ggt teg ttg teg gtg ccg cag gee tgg gee geg gee aac Ala Ser Val Gly Ser Leu Ser Val Pro Gin Ala Trp Ala Ala Ala Asn 455 460 465 cag gca gtc acc ccg geg geg egg geg ctg ccg ctg acc age ctg acc Gin Ala Val Thr Pro Ala Ala Arg Ala Leu Pro Leu Thr Ser Leu Thr 470 475 480 485 age gee geg gaa aga ggg ccc ggg cag atg ctg ggc ggg ctg ccg gtg Ser Ala Ala Glu Arg Gly Pro Gly Gin Met Leu Gly Gly Leu Pro Val 490 495 500 920 968 1016 1064 1112 1160 1208 1256 1304 1352 1400 1448 1496 1544 3 1223001 ggg cag atg ggc gcc agg gcc ggt ggt ggg etc agt ggt gtg ctg cgt 1592 Gly Gin Met Gly Ala Arg Ala Gly Gly Gly Leu Ser Gly Val Leu Arg 505 510 515 gtt ccg ccg ega ccc tat gtg atg ccg cat tet ccg gca gcc ggc gat 1640 Val Pro Pro Arg Pro Tyr Val Met Pro His Ser Pro Ala Ala Gly Asp 520 525 530 ate gcc ccg ccg gcc ttg teg cag gac egg ttc gcc gac ttc ccc geg 1688 lie Ala Pro Pro Ala Leu Ser Gin Asp Arg Phe Ala Asp Phe Pro Ala 535 540 545 ctg ccc etc gac ccg tee geg atg gtc gcc caa gtg ggg cca cag gtg 1736 Leu Pro Leu Asp Pro Ser Ala Met Val Ala Gin Val Gly Pro Gin Val 550 555 560 565 gtc aac ate aac acc aaa ctg ggc tac aac aac gcc gtg ggc gcc ggg 1784 Val Asn lie Asn Thr Lys Leu Gly Tyr Asn Asn Ala Val Gly Ala Gly
570 575 580 acc ggc ate gtc ate gat ccc aac ggt gtc gtg ctg acc aac aac cac 1832 Thr Gly lie Val 工le Asp Pro Asn Gly Val Val Leu Thr Asn Asn His 585 " 590 595 gtg ate geg ggc gcc acc gac ate aat geg ttc age gtc ggc tee ggc 1880 Val 工le Ala Gly Ala Thr Asp 工le Asn Ala Phe Ser Val Gly Ser Gly 600 605 610 caa acc tac ggc gtc gat gtg gtc ggg tat gac ege acc cag gat gtc 1928 Gin Thr Tyr Gly Val Asp Val Val Gly Tyr Asp Arg Thr Gin Asp Val 615 620 625 geg gtg t:tg cag ctg ege ggt gcc ggt ggc ctg ccg teg geg geg ate 1976 Ala Val Leu Gin Leu Arg Gly Ala Gly Gly Leu Pro Ser Ala Ala lie 630 635 640 645 ggt ggc ggc gtc geg gtt ggt gag ccc gtc gtc geg atg ggc aac age 2024 Gly Gly Gly Val Ala Val Gly Glu Pro Val Val Ala Met Gly Asn Ser
650 655 660 ggt ggg cag ggc gga aeg ccc cgt geg gtg cct ggc agg gtg gtc geg 2072 Gly Gly Gin Gly Gly Thr Pro Arg Ala Val Pro Gly Arg Val Val Ala 665 670 675 etc ggc caa acc gtg cag geg teg gat teg ctg acc ggt gcc gaa gag 2120 Leu Gly Gin Thr Val Gin Ala Ser Asp Ser Leu Thr Gly Ala Glu Glu 680 685 690 aca ttg aac ggg ttg ate cag ttc gat gcc geg ate cag ccc ggt gat 2168 Thr Leu Asn Gly Leu lie Gin Phe Asp Ala Ala lie Gin Pro Gly Asp 695 700 705 teg ggc ggg ccc gtc gtc aac ggc eta gga cag gtg gtc ggt atg aac 2216 Ser Gly Gly Pro Val Val Asn Gly Leu Gly Gin Val Val Gly Met Asn 710 715 720 725 aeg gcc geg tee taggatatcc atcacactgg cggccgctcg agcagatccg 2268 Thr Ala Ala Ser gntgtaacaa agcccgaaa 2287 4 1223001 <210> 2 <211> 729 <212> PRT <213>人工序列 <223>人工序列之說明:三-融合蛋白質 Ral2-TbH9-Ra35(命名為 Mtb32A) <400〉 2 Met His His His His His His Thr Ala Ala Ser Asp Asn Phe Gin Leu 1 5 10 15 Ser Gin Gly Gly Gin Gly Phe Ala lie Pro lie Gly Gin Ala Met Ala 20 25 30 工le Ala Gly Gin lie Arg Ser Gly Gly Gly Ser Pro Thr Val His lie 35 40 45 Gly Pro Thr Ala Phe Leu Gly Leu Gly Val Val Asp Asn Asn Gly Asn 50 55 60 Gly Ala Arg Val Gin Arg Val Val Gly Ser Ala Pro Ala Ala Ser Leu 65 70 75 80 Gly lie Ser Thr Gly Asp Val lie Thr Ala Val Asp Gly Ala Pro lie 85 90 95 Asn Ser Ala Thr Ala Met Ala Asp Ala Leu Asn Gly His His Pro Gly 100 105 110 Asp Val 工le Ser Val Thr Trp Gin Thr Lys Ser Gly Gly Thr Arg Thr 115 120 125 Gly Asn Val Thr Leu Ala Glu Gly Pro Pro Ala Glu Phe Met Val Asp 130 135 140 Phe Gly Ala Leu Pro Pro Glu lie Asn Ser Ala Arg Met Tyr Ala Gly 145 150 155 160 Pro Gly Ser Ala Ser Leu Val Ala Ala Ala Gin Met Trp Asp Ser Val 165 170 175 Ala Ser Asp Leu Phe Ser Ala Ala Ser Ala Phe Gin Ser Val Val Trp 180 185 190 Gly Leu Thr Val Gly Ser Trp 工le Gly Ser Ser Ala Gly Leu Met Val 195 200 205 Ala Ala Ala Ser Pro Tyr Val Ala Trp Met Ser Val Thr Ala Gly Gin 210 215 220 Ala Glu Leu Thr Ala Ala Gin Val Arg Val Ala Ala Ala Ala Tyr Glu 225 230 235 240 Thr Ala Tyr Gly Leu Thr Val Pro Pro Pro Val 工le Ala Glu Asn Arg 245 250 255 Ala Glu Leu Met lie Leu 工le Ala Thr Asn Leu Leu Gly Gin Asn Thr 260 265 270 Pro Ala 工le Ala Val Asn Glu Ala Glu Tyr Gly Glu Met Trp Ala Gin 275 280 285
5 Asp Ala Ala Ala Met Phe Gly Tyr Ala Ala Ala Thr Ala Thr Ala Thr 290 295 300 Ala Thr Leu 305 Leu Pro Phe Glu Glu Ala Pro Glu Met Thr Ser Ala Gly 310 315 320 Gly Leu Leu Glu Gin Ala Ala Ala Val Glu Glu Ala Ser Asp Thr Ala 325 330 335 Ala Ala Asn Gin Leu Met Asn Asn Val Pro Gin Ala Leu Gin Gin Leu 340 345 350 Ala Gin Pro 355 Thr Gin Gly Thr Thr Pro Ser Ser Lys Leu Gly Gly Leu 360 365 Trp Lys Thr 370 Val Ser Pro His Arg Ser Pro lie Ser Asn Met Val Ser 375 380 Met Ala Asn Asn His Met Ser Met Thr Asn Ser Gly Val Ser Met Thr 385 390 395 400 Asn Thr Leu Ser Ser Met Leu Lys Gly Phe Ala Pro Ala Ala Ala Arg 405 410 415 Gin Ala Val Gin Thr Ala Ala Gin Asn Gly Val Arg Ala Met Ser Ser 420 425 430 Leu Gly Ser 435 Ser Leu Gly Ser Ser Gly Leu Gly Gly Gly Val Ala Ala 440 445 1223001 Asn Leu Gly Arg Ala Ala Ser Val Gly Ser Leu Ser Val Pro Gin Ala 450 455 460 Trp Ala Ala Ala Asn Gin Ala Val Thr Pro Ala Ala Arg Ala Leu Pro 465 470 475 480 Leu Thr Ser Leu Thr Ser Ala Ala Glu Arg Gly Pro Gly Gin Met Leu 485 490 495 Gly Gly Leu Pro Val Gly Gin Met Gly Ala Arg Ala Gly Gly Gly Leu 500 505 510 Ser Gly Val 515 Leu Arg Val Pro Pro Arg Pro Tyr Val Met Pro His Ser 520 525 Pro Ala Ala 530 Gly Asp 工le Ala Pro Pr〇 Ala Leu Ser Gin Asp Arg Phe 535 540 Ala Asp Phe 545 Pro Ala Leu Pro Leu Asp Pro Ser Ala Met Val Ala Gin 550 555 560 Val Gly Pro Gin Val Val Asn lie Asn Thr Lys Leu Gly Tyr Asn Asn 555 570 575 Ala Val Gly Ala Gly Thr Gly lie Val lie Asp Pro Asn Gly Vai Val 580 585 590 Leu Thr Asn Asn His Val 工le Ala Gly Ala Thr Asp lie Asn Ala Phe 595 600 605 6 1223001 Ser Val Gly Ser Gly Gin Thr Tyr Gly Val Asp Val Val Gly Tyr Asp 610 615 620 Arg Thr Gin Asp Val Ala Val Leu Gin Leu Arg Gly Ala Gly Gly Leu 625 630 635 640 Pro Ser Ala Ala He Gly Gly Gly Val Ala Val Gly Glu Pro Val Val 645 650 655 Ala Met Gly Asn Ser Gly Gly Gin Gly Gly Thr Pro Arg Ala Val Pro 660 665 670 Gly Arg Val Val Ala Leu Gly Gin Thr Val Gin Ala Ser Asp Ser Leu 675 680 685 Thr Gly Ala Glu Glu Thr Leu Asn Gly Leu lie Gin Phe Asp Ala Ala 690 695 700 lie Gin Pro Gly Asp Ser Gly Gly Pro Val Val Asn Gly Leu Gly Gin 705 710 715 720 Val Val Gly Met Asn Thr Ala Ala Ser 725 <210> 3 <211> 1081 <212> DNA <213>人工序列 <220> <223>人工序列之說明:三_融合蛋·白質 Erdl4 - DPV - ΜΉ (命名為 Mtb39A) <220> <221> CDS <222> (10) . . (1002) <400> 3 gatatacat atg cat cac cat cac cat cac atg gcc acc acc ctt ccc gtt Met His His His His His His Met Ala Thr Thr Leu Pro Val 15 10 cag cgc cac ccg egg tcc etc ttc ccc gag ttt tet gag ctg ttc geg Gin Arg His Pro Arg Ser Leu Phe Pro Glu Phe Ser Glu Leu Phe Ala 15 20 25 30 gcc ttc ccg tea ttc gcc gga etc egg ccc acc ttc gac acc egg ttg Ala Phe Pro Ser Phe Ala Gly Leu Arg Pro Thr Phe Asp Thr Arg Leu 35 40 45 atg egg ctg gaa gac gag atg aaa gag ggg cgc tac gag gta cgc geg Met Arg Leu Glu Asp Glu Met Lys Glu Gly Arg Tyr Glu Val Arg Ala 50 55 60 gag ctt ccc ggg gtc gac ccc gac aag gac gtc gac att atg gtc cgc Glu Leu Pro Gly Val Asp Pro Asp Lys Asp Val Asp 工le Met Val Arg 65 70 75 51 99 147 195 7 243 1223001 gat ggt cag ctg acc ate aag gee gag ege acc gag cag aag gac ttc 291 Asp Gly Gin Leu Thr 工le Lys Ala Glu Arg Thr Glu Gin Lys Asp Phe 80 85 90 gac ggt ege teg gaa ttc geg tac ggt tee ttc gtt ege aeg gtg teg 339 Asp Gly Arg Ser Glu Phe Ala Tyr Gly Ser Phe Val Arg Thr Val Ser 95 100 105 110 ctg ccg gta ggt get gac gag gac gac att aag gee acc tac gac aag 387 Leu Pro Val Gly Ala Asp Glu Asp Asp lie Lys Ala Thr Tyr Asp Lys 115 120 125 ggc att ett act gtg teg gtg geg gtt teg gaa ggg aag cca acc gaa 435 Gly 工le Leu Thr Val Ser Val Ala Val Ser Glu Gly Lys Pro Thr Glu 130 135 140 aag cac att cag ate egg tee acc aac aag ett gat ccc gtg gac geg 483 Lys His lie Gin 工le Arg Ser Thr Asn Lys Leu Asp Pro Val Asp Ala
145 150 155 gtc att aac acc acc tgc aat tac ggg cag gta gta get geg etc aac 531 Val 工le Asn Thr Thr Cys Asn Tyr Gly Gin Val Val Ala Ala Leu Asn 160 ' 165 170 geg aeg gat ccg ggg get gee gca cag ttc aac gee tea ccg gtg geg 579 Ala Thr Asp Pro Gly Ala Ala Ala Gin Phe Asn Ala Ser Pro Val Ala 175 180 185 190 cag tee tat ttg ege aat ttc etc gee gca ccg cca cct cag ege get 627 Gin Ser Tyr Leu Arg Asn Phe Leu Ala Ala Pro Pro Pro Gin Arg Ala 195 200 205 gee atg gee geg caa ttg caa get gtg ccg ggg geg gca cag tac ate 675 Ala Met Ala Ala Gin Leu Gin Ala Val Pro Gly Ala Ala Gin Tyr lie 210 215 220 ggc ett gtc gag teg gtt gee ggc tee tgc aac aac tat gag etc atg 723 Gly Leu Val Glu Ser Val Ala Gly Ser Cys Asn Asn Tyr Glu Leu Met
225 230 235 aeg att aat tac cag ttc ggg gac gtc gac get cat ggc gee atg ate 771 Thr lie Asn Tyr Gin Phe Gly Asp Val Asp Ala His Gly Ala Met lie 240 245 250 ege get cag geg geg teg ett gag geg gag cat cag gee ate gtt cgt 819 Arg Ala Gin Ala Ala Ser Leu Glu Ala Glu His Gin Ala 工le Val Arg 255 260 265 270 gat gtg ttg gee geg ggt gac ttt tgg ggc ggc gee ggt teg gtg get 867 Asp Val Leu Ala Ala Gly Asp Phe Trp Gly Gly Ala Gly Ser Val Ala 275 280 285 tgc cag gag ttc att acc cag ttg ggc cgt aac ttc cag gtg ate tac 915 Cys Gin Giu Phe 工le Thr Gin Leu Gly Arg Asn Phe Gin Val lie Tyr 290 295 300 gag cag gee aac gee cac ggg cag aag gtg cag get gee ggc aac aac 963 Glu Gin Ala Asn Ala His Gly Gin Lys Val Gin Ala Ala Gly Asn Asn 305 310 315 8 1223001 atg gcg caa acc gac age gee gtc ggc tee age tgg gee actagtaacg 1012 Met Ala Gin Thr Asp Ser Ala Val Gly Ser Ser Trp Ala 320 325 330 gccgccagtg tgctggaatt ctgcagatat ccatcacact ggcggccgct egageagate 1072 eggetgeta 1081 <210> 4 <211> 331 <212> PRT <213 >人工序列 <223>人工序列之說明··三—融合蛋白質 Erdl4 - DPV — ΜΉ (命名為 Mtb39A) <400> 4 Met His His His His His His Met Ala Thr Thr Leu Pro Val Gin Arg 1 5 10 15 His Pro Arg Ser Leu Phe Pro Glu Phe Ser Glu Leu Phe Ala Ala Phe 20 25 30 Pro Ser Phe Ala Gly Leu Arg Pro Thr Phe Asp Thr Arg Leu Met Arg 35 40 45 Leu Glu Asp Glu Met Lys Glu Gly Arg Tyr Glu Val Arg Ala Glu Leu 50 55 60 Pro Gly Val Asp Pro Asp Lys Asp Val Asp lie Met Val Arg Asp Gly 65 70 75 80 Gin Leu Thr lie Lys Ala Glu Arg Thr Glu Gin Lys Asp Phe Asp Gly 85 90 95 Arg Ser Glu Phe Ala Tyr Gly Ser Phe Val Arg Thr Val Ser Leu Pro 100 105 110 Val Gly Ala Asp Glu Asp Asp lie Lys Ala Thr Tyr Asp Lys Gly lie 115 120 125 Leu Thr Val Ser Val Ala Val Ser Glu Gly Lys Pro Thr Glu Lys His 130 135 140 工le Gin lie Arg Ser Thr Asn Lys Leu Asp Pro Val Asp Ala Val lie 145 150 155 160 Asn Thr Thr Cys Asn Tyr Gly Gin Val Val Ala Ala Leu Asn Ala Thr 165 170 175 Asp Pro Gly Ala Ala Ala Gin Phe Asn Ala Ser Pro Val Ala Gin Ser 180 185 190 Tyr Leu Arg Asn Phe Leu Ala Ala Pro Pro Pro Gin Arg Ala Ala Met 195 200 205 Ala Ala Gin Leu Gin Ala Val Pro Gly Ala Ala Gin Tyr 工le Gly Leu 210 215 220 Val Glu Ser Val Ala Gly Ser Cys Asn Asn Tyr Glu Leu Met Thr lie 225 230 235 240
9 1223001 Asn Tyr Gin Phe Gly Asp Val Asp Ala His Gly Ala Met lie Arg Ala 245 250 255 Gin Ala Ala Ser Leu Glu Ala Glu His Gin Ala lie Val Arg Asp Val 260 265 270 Leu Ala Ala Gly Asp Phe Trp Gly Gly Ala Gly Ser Val Ala Cys Gin 275 280 285 Glu Phe 工le Thr Gin Leu Gly Arg Asn Phe Gin Val lie Tyr Glu Gin 290 295 300 Ala Asn Ala His Gly Gin Lys Val Gin Ala Ala Gly Asn Asn Met Ala 305 310 315 320 Gin Thr Asp Ser Ala Val Gly Ser Ser Trp Ala 325 330
<210> 5 <211> 1993 <212〉 DNA <213 >人工序列 <220> <223>人工序列之說明:三-融合蛋白質 TbRa3-38kD-Tb38-l <220> <221> CDS <222> (152) . . (1276) <400> 5 tgttcttcga cggcaggctg gtggaggaag ggcccaccga acagctgttc tcctcgccga 60 agcatgcgga aaccgcccga tacgtcgccg gactgtcggg ggacgtcaag gacgccaagc 120 gcggaaattg aagagcacag aaaggtatgg c gtg aaa att cgt ttg cat acg 172
Val Lys 工le Arg Leu His Thr 1 5 ctg ttg gcc gtg ttg acc get geg ccg ctg ctg eta gca geg geg ggc 220 Leu Leu Ala Val Leu Thr Ala Ala Pro Leu Leu Leu Ala Ala Ala Gly 10 15 20 tgt ggc teg aaa cca ccg age ggt teg cct gaa acg ggc gcc ggc gcc 268 Cys Gly Ser Lys Pro Pro Ser Gly Ser Pro Glu Thr Gly Ala Gly Ala 25 30 35 ggt act gtc geg act acc ccc geg teg teg ccg gtg acg ttg geg gag 316 Gly Thr Val Ala Thr Thr Pro Ala Ser Ser Pro Val Thr Leu Ala Glu 40 45 50 55 acc ggt age acg ctg etc tac ccg ctg ttc aac ctg tgg ggt ccg gcc 364 Thr Gly Ser Thr Leu Leu Tyr Pro Leu Phe Asn Leu Trp Gly Pro Ala 60 65 70 ttt cac gag agg tat ccg aac gtc acg ate acc get cag ggc acc ggt 412 Phe His Glu Arg Tyr Pro Asn Val Thr 工le Thr Ala Gin Gly Thr Gly 75 80 85 10 1223001 tct ggt gcc ggg ate geg cag Ser Gly Ala Gly lie Ala Gin 90 gee tee gac gcc tat ctg teg Ala Ser Asp Ala Tyr Leu Ser 105 110 ctg atg aac ate geg eta gcc Leu Met Asn lie Ala Leu Ala 120 125 ctg ccc gga gtg age gag cac Leu Pro Gly Val Ser Glu His 140 gee atg tac cag ggc acc ate Ala Met Tyr Gin Gly Thr lie 155 geg etc aac ccc ggc gtg aac Ala Leu Asn Pro Gly Val Asn 170 ' cac ege tee gac ggg tee ggt His Arg Ser Asp Gly Ser Gly 185 190 tee aag caa gat ccc gag ggc Ser Lys Gin Asp Pro Glu Gly 200 205 acc gtc gac ttc ccg geg gtg Thr Val Asp Phe Pro Ala Val 220 ggc ggc atg gtg acc ggt tgc Gly Gly Met Val Thr Gly Cys 235 ate ggc ate age ttc etc gac lie Gly lie Ser Phe Leu Asp 250 gcc caa eta ggc aat age tct Ala Gin Leu Gly Asn Ser Ser 265 270 age att cag gcc geg geg get Ser lie Gin Ala Ala Ala Ala 280 285 cag geg att teg atg ate gac Gin Ala lie Ser Met 工le Asp 300 ate aac tac gag tac gcc ate 工le Asn Tyr Glu Tyr Ala lie 315 gcc gcc gcc ggg aeg gtc aac Ala Ala Ala Gly Thr Val Asn 95 100 gaa ggt gat atg gcc geg cac Glu Gly Asp Met Ala Ala His 115 ate tee get cag cag gtc aac lie Ser Ala Gin Gin Val Asn 130 etc aag ctg aac gga aaa gtc Leu Lys Leu Asn Gly Lys Val 145 aaa acc tgg gac gac ccg cag Lys Thr Trp Asp Asp Pro Gin 160 165 ctg ccc ggc acc geg gta gtt Leu Pro Gly Thr Ala Val Val 175 180 gac acc ttc ttg ttc acc cag Asp Thr Phe Leu Phe Thr Gin 195 tgg 99c aag teg ccc ggc ttc Trp Gly Lys Ser Pro Gly Phe 210 ccg ggt geg ctg ggt gag aac Pro Gly Ala Leu Gly Glu Asn 225 gee gag aca ccg ggc tgc gtg Ala Glu Thr Pro Gly Cys Val 240 245 cag gcc agt caa egg gga etc Gin Ala Ser Gin Arg Gly Leu 255 260 ggc aat ttc ttg ttg ccc gac Gly Asn Phe Leu Leu Pro Asp 275 ggc ttc gca teg aaa acc ccg Gly Phe Ala Ser Lys Thr Pro 290 ggg ccc gcc ccg gac ggc tac Gly Pro Ala Pro Asp Gly Tyr 305 gtc aac aac egg caa aag gac Val Asn Asn Arg Gin Lys Asp 320 325 att ggg 460 He Gly aag ggg 508 Lys Gly tac aac 556 Tyr Asn 135 ctg geg 604 Leu Ala 150 ate get 652 工le Ala ccg ctg 700 Pro Leu tac ctg 748 Tyr Leu ggc acc 796 Gly Thr 215 ggc aac 844 Gly Asn 230 gcc tat 892 Ala Tyr ggc gag 940 Gly Glu geg caa 988 Ala Gin geg aac 1036 Ala Asn 295 ccg ate 1084 Pro lie 310 gcc gcc 1132 Ala Ala
11 1223001 acc gcg cag acc ttg cag gca ttt ctg cac tgg gcg ate acc gac ggc 1180 Thr Ala Gin Thr Leu Gin Ala Phe Leu His Trp Ala 工le Thr Asp Gly 330 335 340 aac aag gcc teg ttc etc gac cag gtt cat ttc cag ccg ctg ccg ccc 1228 Asn Lys Ala Ser Phe Leu Asp Gin Val His Phe Gin Pro Leu Pro Pro 345 350 355 gcg gtg gtg aag ttg tet gac gcg ttg ate gcg aeg att tee age 1273 Ala Val Val Lys Leu Ser Asp Ala Leu lie Ala Thr lie Ser Ser 360 365 370 tagcctcgtt gaccaccacg cgacagcaac ctccgtcggg ccatcgggct gctttgcgga 1333 gcatgctggc ccgtgccggt gaagteggee gcgctggccc ggccatccgg tggttgggtg 1393 ggataggtgc ggtgatcccg ctgcttgcgc tggtcttggt gctggtggtg ctggtcatcg 1453
aggcgatggg tgcgatcagg ctcaacgggt tgcatttctt caccgccacc gaatggaatc 1513 caggcaacac etaeggegaa accgttgtca ccgacgcgtc gcccatccgg tcggcgccta 1573 ctacggggcg ttgccgctga tegtegggae gctggcgacc tcggcaatcg ccctgatcat 1633 cgcggtgccg gtctctgtag gageggeget ggtgatcgtg gaacggctgc cgaaacggtt 1693 ggeegagget gtgggaatag tcctggaatt gctcgccgga atccccagcg tggtcgtcgg 1753 tttgtggggg gcaatgacgt tcgggccgtt catcgctcat cacatcgctc cggtgatcgc 1813 tcacaacgct cccgatgtgc cggtgctgaa ctacttgcgc ggcgacccgg gcaacgggga 1873 gggcatgttg gtgtccggtc tggtgttggc ggtgatggtc gttcccatta tcgccaccac 1933 cactcatgac ctgttccggc aggtgccggt gttgccccgg gagggegega tegggaatte 1993
<210> 6 <211> 374 <212> PRT <213〉人工序列 <223>人工序列之說明:三—融合蛋白質 TbRa3 - 38kD - Tb38-1 <400> 6 Val Lys lie Arg Leu His Thr Leu Leu Ala Val Leu Thr Ala Ala Pro 15 10 15 Leu Leu Leu Ala Ala Ala Gly Cys Gly Ser Lys Pro Pro Ser Gly Ser 20 25 30 Pro Glu Thr Gly Ala Gly Ala Gly Thr Val Ala Thr Thr Pro Ala Ser 35 40 45 Ser Pro Val Thr Leu Ala Glu Thr Gly Ser Thr Leu Leu Tyr Pro Leu 50 55 60 Phe Asn Leu Trp Gly Pro Ala Phe His Glu Arg Tyr Pro Asn Val Thr 65 70 75 80 12 1223001 lie Thr Ala Gin Gly Thr Gly Ser Gly Ala Gly 工le Ala Gin Ala Ala 85 90 95 Ala Gly Thr Val Asn lie Gly Ala Ser Asp Ala Tyr Leu Ser Glu Gly 100 105 110 Asp Met Ala Ala His Lys Gly Leu Met Asn lie Ala Leu Ala lie Ser 115 120 125 Ala Gin Gin Val Asn Tyr Asn Leu Pro Gly Val Ser Glu His Leu Lys 130 135 140 Leu Asn Gly Lys Val Leu Ala Ala Met Tyr Gin Gly Thr lie Lys Thr 145 150 155 160 Trp Asp Asp Pro Gin 工le Ala Ala Leu Asn Pro Gly Val Asn Leu Pro 165 170 175 Gly Thr Ala Val Val Pro Leu His Arg Ser Asp Gly Ser Gly Asp Thr 180 185 190 Phe Leu Phe Thr Gin Tyr Leu Ser Lys Gin Asp Pro Glu Gly Trp Gly 195 ' 200 205 Lys Ser Pro Gly Phe Gly Thr Thr Val Asp Phe Pro Ala Val Pro Gly 210 215 220 Ala Leu Gly Glu Asn Gly Asn Gly Gly Met Val Thr Gly Cys Ala Glu 225 230 235 240 Thr Pro Gly Cys Val Ala Tyr 工le Gly lie Ser Phe Leu Asp Gin Ala 245 250 255 Ser Gin Arg Gly Leu Gly Glu Ala Gin Leu Gly Asn Ser Ser Gly Asn 260 265 270 Phe Leu Leu Pro Asp Ala Gin Ser lie Gin Ala Ala Ala Ala Gly Phe 275 280 285 Ala Ser Lys Thr Pro Ala Asn Gin Ala lie Ser Met lie Asp Gly Pro 290 295 300 Ala Pro Asp Gly Tyr Pro lie 工le Asn Tyr Glu Tyr Ala lie Val Asn 305 310 315 320 Asn Arg Gin Lys Asp Ala Ala Thr Ala Gin Thr Leu Gin Ala Phe Leu 325 330 335 His Trp Ala lie Thr Asp Gly Asn Lys Ala Ser Phe Leu Asp Gin Val 340 345 350 His Phe Gin Pro Leu Pro Pro Ala Val Val Lys Leu Ser Asp Ala Leu 355 360 365 lie Ala Thr lie Ser Ser 370
13 1223001 <210> 7 <211> 1777 <212> DNA <213 >人工序列 <220> <223>人工序列之說明:二-融合蛋白質 TbH9-Tb38- 1 <400> 7 ggtcttgacc accacctggg tgtcgaagtc ggtgcccgga ttgaagtcca ggtactcgtg 60 ggtggggcgg gcgaaacaat agcgacaagc atgcgagcag ccgcggtagc cgttgacggt 120 gtagcgaaac ggcaacgcgg ccgcgttggg caccttgttc agcgctgatt tgcacaacac 180 ctcgtggaag gtgatgccgt cgaattgtgg cgcgcgaacg ctgcggacca ggccgatccg 240 ctgcaacccg gcagcgcccg tcgtcaacgg gcatcccgtt caccgcgacg gcttgccggg 300 cccaacgcat accattattc gaacaaccgt tctatacttt gtcaacgctg gccgctaccg 360 agcgccgcac aggatgtgat atgccatctc tgcccgcaca gacaggagcc aggccttatg 420
acagcattcg gcgtcgagcc ctacgggcag ccgaagtacc tagaaatcgc cgggaagcgc 480 atggcgtata tcgacgaagg caagggtgac gccatcgtct ttcagcacgg caaccccacg 540 tcgtcttact tgtggcgcaa catcatgccg cacttggaag ggctgggccg gctggtggcc 600 tgcgatctga tcgggatggg cgcgtcggac aagctcagcc catcgggacc cgaccgctat 660 agctatggcg agcaacgaga ctttttgttc gcgctctggg atgcgctcga cctcggcgac 720 cacgtggtac tggtgctgca cgactggggc tcggcgctcg gcttcgactg ggctaaccag 780 catcgcgacc gagtgcaggg gatcgcgttc atggaagcga tcgtcacccc gatgacgtgg 840 gcggactggc cgccggccgt gcggggtgtg ttccagggtt tccgatcgcc tcaaggcgag 900 ccaatggcgt tggagcacaa catctttgtc gaacgggtgc tgcccggggc gatcctgcga 960 cagctcagcg acgaggaaat gaaccactat cggcggccat tcgtgaacgg cggcgaggac 1020 cgtcgcccca cgttgtcgtg gccacgaaac cttccaatcg acggtgagcc cgccgaggtc 1080 gtcgcgttgg tcaacgagta ccggagctgg ctcgaggaaa ccgacatgcc gaaactgttc 1140 atcaacgccg agcccggcgc gatcatcacc ggccgcatcc gtgactatgt caggagctgg 1200 cccaaccaga ccgaaatcac agtgcccggc gtgcatttcg ttcaggagga cagcgatggc 1260 gtcgtatcgt gggcgggcgc tcggcagcat cggcgacctg ggagcgctct catttcacga 1320 gaccaagaat gtgatttccg gcgaaggcgg cgccctgctt gtcaactcat aagacttcct 1380 gctccgggca gagattctca gggaaaaggg caccaatcgc agccgcttcc ttcgcaacga 1440 ggtcgacaaa tatacgtggc aggacaaagg tcttcctatt tgcccagcga attagtcgct 1500 gcctttctat gggctcagtt cgaggaagcc gagcggatca cgcgtatccg attggaccta 1560 tggaaccggt atcatgaaag cttcgaatca ttggaacagc gggggctcct gcgccgtccg 1620 atcatcccac agggctgctc tcacaacgcc cacatgtact acgtgttact agcgcccagc 1680
gccgatcggg aggaggtgct ggcgcgtctg acgagcgaag gtataggcgc ggtctttcat 1740 tacgtgccgc ttcacgattc gccggccggg cgtcgct 1777 <210> 8 <211> 358 <212> PRT <213〉人工序列 <220> <223>人工序列之說明:二-融合蛋白質 TbH9-Tb38- 1 <220> <221> MOD一RES <222> (254) <223> Xaa = any amino acid <400> 8 Val Ala Trp Met Ser Val Thr Ala Gly Gin Ala Glu Leu Thr Ala Ala 1 5 10 15 14 1223001 Gin Val Arg Val Ala Ala Ala Ala Tyr Glu Thr Ala Tyr Gly Leu Thr 20 25 30 Val Pro Pro Pro Val 工le Ala Glu Asn Arg Ala Glu Leu Met lie Leu 35 40 45 工le Ala Thr Asn Leu Leu Gly Gin Asn Thr Pro Ala 工le Ala Val Asn 50 55 60 Glu Ala Glu Tyr Gly Glu Met Trp Ala Gin Asp Ala Ala Ala Met Phe 65 70 75 80 Gly Tyr Ala Ala Ala Thr Ala Thr Ala Thr Ala Thr Leu Leu Pro Phe 85 90 95 Glu Glu Ala Pro Glu Met Thr Ser Ala Gly Gly Leu Leu Glu Gin Ala 100 105 110 Ala Ala Val Glu Glu Ala Ser Asp Thr Ala Ala Ala Asn Gin Leu Met 115 120 125 Asn Asn Val Pro Gin Ala Leu Lys Gin Leu Ala Gin Pro Thr Gin Gly 130 ' 135 140 Thr Thr Pro Ser Ser Lys Leu Gly Gly Leu Trp Lys Thr Val Ser Pro 145 150 155 160 His Arg Ser Pro lie Ser Asn Met Val Ser Met Ala Asn Asn His Met 165 170 175 Ser Met Thr Asn Ser Gly Val Ser Met Thr Asn Thr Leu Ser Ser Met 180 185 190 Leu Lys Gly Phe Ala Pro Ala Ala Ala Ala Gin Ala Val Gin Thr Ala 195 200 205 Ala Gin Asn Gly Val Arg Ala Met Ser Ser Leu Gly Ser Ser Leu Gly 210 215 220 Ser Ser Gly Leu Gly Gly Gly Val Ala Ala Asn Leu Gly Arg Ala Ala 225 230 235 240 Ser Val Arg Tyr Gly His Arg Asp Gly Gly Lys Tyr Ala Xaa Ser Gly 245 250 255 Arg Arg Asn Gly Gly Pro Ala Thr Asp Ala Ala Thr Leu Ala Gin Glu 260 265 270 Ala Gly Asn Phe Glu Arg lie Ser Gly Asp Leu Lys Thr Gin 工le Asp 275 280 285 Gin Val Glu Ser Thr Ala Gly Ser Leu Gin Gly Gin Trp Arg Gly Ala 290 295 300 Ala Gly Thr Ala Ala Gin Ala Ala Val Val Arg Phe Gin Glu Ala Ala 305 310 315 320 Asn Lys Gin Lys Gin Glu Leu Asp Glu lie Ser Thr Asn lie Arg Gin 325 330 335
15 1223001 Ala Gly Val Gin Tyr Ser Arg Ala Asp Glu Glu Gin Gin Gin Ala Leu 340 345 350 Ser Ser Gin Met Gly Phe 355 <210> 9 <211> 7676 <212〉 DNA <213>人工序列 <220> <223>人工序列之說明:四-融合蛋白質 TbRa3 - 38kD - Tb38 - 1 - DPEP (命名為 TbF - 2 ) <220> <221> CDS
<222> (5072) . . (7480) <400> 9 tggcgaatgg gacgcgccct gtagcggcgc attaagcgcg gcgggtgtgg tggttacgcg 60 cagcgtgacc gctacacttg ccagcgccct agcgcccgct cctttcgctt tcttcccttc 120 ctttctcgcc acgttcgccg gctttccccg tcaagctcta aatcgggggc tccctttagg 180 gttccgattt agtgctttac ggcacctcga ccccaaaaaa cttgattagg gtgatggttc 240 acgtagtggg ccatcgccct gatagacggt ttttcgccct ttgacgttgg agtccacgtt 300 ctttaatagt ggactcttgt tccaaactgg aacaacactc aaccctatct cggtctattc 360 ttttgattta taagggattt tgccgatttc ggcctattgg ttaaaaaatg agctgattta 420 acaaaaattt aacgcgaatt ttaacaaaat attaacgttt acaatttcag gtggcacttt 480 tcggggaaat gtgcgcggaa cccctatttg tttatttttc taaatacatt caaatatgta 540
tccgctcatg aattaattct tagaaaaact catcgagcat caaatgaaac tgcaatttat 600 tcatatcagg attatcaata ccatattttt gaaaaagccg tttctgtaat gaaggagaaa 660 actcaccgag gcagttccat aggatggcaa gatcctggta tcggtctgcg attccgactc 720 gtccaacatc aatacaacct attaatttcc cctcgtcaaa aataaggtta tcaagtgaga 780 aatcaccatg agtgacgact gaatccggtg agaatggcaa aagtttatgc atttctttcc 840 agacttgttc aacaggccag ccattacgct cgtcatcaaa atcactcgca tcaaccaaac 900 cgttattcat tcgtgattgc gcctgagcga gacgaaatac gcgatcgctg ttaaaaggac 960 aattacaaac aggaatcgaa tgcaaccggc gcaggaacac tgccagcgca tcaacaatat 1020 tttcacctga atcaggatat tcttctaata cctggaatgc tgttttcccg gggatcgcag 1080 tggtgagtaa ccatgcatca tcaggagtac ggataaaatg cttgatggtc ggaagaggca 1140 taaattccgt cagccagttt agtctgacca tctcatctgt aacatcattg gcaacgctac 1200 16 1223001
ctttgccatg tttcagaaac aactctggcg catcgggctt cccatacaat cgatagattg 1260 tcgcacctga ttgcccgaca ttatcgcgag cccatttata cccatataaa tcagcatcca 1320 tgttggaatt taatcgcggc ctagagcaag acgtttcccg ttgaatatgg ctcataacac 1380 cccttgtatt actgtttatg taagcagaca gttttattgt tcatgaccaa aatcccttaa 1440 cgtgagtttt cgttccactg agcgtcagac cccgtagaaa agatcaaagg atcttcttga 1500 gatccttttt ttctgcgcgt aatctgctgc ttgcaaacaa aaaaaccacc gctaccagcg 1560 gtggtttgtt tgccggatca agagctacca actctttttc cgaaggtaac tggcttcagc 1620 agagcgcaga taccaaatac tgtccttcta gtgtagccgt agttaggcca ccacttcaag 1680 aactctgtag caccgcctac atacctcgct ctgctaatcc tgttaccagt ggctgctgcc 1740 agtggcgata agtcgtgtct taccgggttg gactcaagac gatagttacc ggataaggcg 1800 cagcggtcgg gctgaacggg gggttcgtgc acacagccca gcttggagcg aacgacctac 1860 accgaactga gatacc'taca gcgtgagcta tgagaaagcg ccacgcttcc cgaagggaga 1920 aaggcggaca ggtatccggt aagcggcagg gtcggaacag gagagcgcac gagggagctt 1980 ccagggggaa acgcctggta tctttatagt cctgtcgggt ttcgccacct ctgacttgag 2040 cgtcgatttt tgtgatgctc gtcagggggg cggagcctat ggaaaaacgc cagcaacgcg 2100 gcctttttac ggttcctggc cttttgctgg ccttttgctc acatgttctt tcctgcgtta 2160 tcccctgatt ctgtggataa ccgtattacc gcctttgagt gagctgatac cgctcgccgc 2220 agccgaacga ccgagcgcag cgagtcagtg agcgaggaag cggaagagcg cctgatgcgg 2280 tattttctcc ttacgcatct gtgcggtatt tcacaccgca tatatggtgc actctcagta 2340 caatctgctc tgatgccgca tagttaagcc agtatacact ccgctatcgc tacgtgactg 2400 ggtcatggct gcgccccgac acccgccaac acccgctgac gcgccctgac gggcttgtct 2460 gctcccggca tccgcttaca- gacaagctgt gaccgtctcc gggagctgca tgtgtcagag 2520 gttttcaccg tcatcaccga aacgcgcgag gcagctgcgg taaagctcat cagcgtggtc 2580 gtgaagcgat tcacagatgt ctgcctgttc atccgcgtcc agctcgttga gtttctccag 2640 aagcgttaat gtctggcttc tgataaagcg ggccatgtta agggcggttt tttcctgttt 2700 ggtcactgat gcctccgtgt aagggggatt tctgttcatg ggggtaatga taccgatgaa 2760 acgagagagg atgctcacga tacgggttac tgatgatgaa catgcccggt tactggaacg 2820 ttgtgagggt aaacaactgg cggtatggat gcggcgggac cagagaaaaa tcactcaggg 2880 tcaatgccag cgcttcgtta atacagatgt aggtgttcca cagggtagcc agcagcatcc 2940 tgcgatgcag atccggaaca taatggtgca gggcgctgac ttccgcgttt ccagacttta 3000 cgaaacacgg aaaccgaaga ccattcatgt tgttgctcag gtcgcagacg ttttgcagca 3060 17 1223001 gcagtcgctt cacgttcgct cgcgtatcgg tgattcattc tgctaaccag taaggcaacc 3120 ccgccagcct agccgggtcc tcaacgacag gagcacgatc atgcgcaccc gtggggccgc 3180 catgccggcg ataatggcct gcttctcgcc gaaacgtttg gtggcgggac cagtgacgaa 3240 ggcttgagcg agggcgtgca agattccgaa taccgcaagc gacaggccga tcatcgtcgc 3300 gctccagcga aagcggtcct cgccgaaaat gacccagagc gctgccggca cctgtcctac 3360 gagttgcatg ataaagaaga cagtcataag tgcggcgacg atagtcatgc cccgcgccca 3420 ccggaaggag ctgactgggt tgaaggctct caagggcatc ggtcgagatc ccggtgccta 3480 atgagtgagc taacttacat taattgcgtt gcgctcactg cccgctttcc agtcgggaaa 3540 cctgtcgtgc cagctgcatt aatgaatcgg ccaacgcgcg gggagaggcg gtttgcgtat 3600 tgggcgccag ggtggttttt cttttcacca gtgagacggg caacagctga ttgcccttca 3660 ccgcctggcc ctgagagagt tgcagcaagc ggtccacgct ggtttgcccc agcaggcgaa 3720 aatcctgttt gatggtggtt aacggcggga tataacatga gctgtcttcg gtatcgtcgt 3780 atcccactac cgagatatcc gcaccaacgc gcagcccgga ctcggtaatg gcgcgcattg 3840 cgcccagcgc catctgatcg ttggcaacca gcatcgcagt gggaacgatg ccctcattca 3900 gcatttgcat ggtttgttga aaaccggaca tggcactcca gtcgccttcc cgttccgcta 3960 tcggctgaat ttgattgcga gtgagatatt tatgccagcc agccagacgc agacgcgccg 4020 agacagaact taatgggccc gctaacagcg cgatttgctg gtgacccaat gcgaccagat 4080 gctccacgcc cagtcgcgta ccgtcttcat gggagaaaat aatactgttg atgggtgtct 4140 ggtcagagac atcaagaaat aacgccggaa cattagtgca ggcagcttcc acagcaatgg 4200 catcctggtc atccagcgga tagttaatga tcagcccact gacgcgttgc gcgagaagat 4260 tgtgcaccgc cgctttacag gcttcgacgc cgcttcgttc taccatcgac accaccacgc 4320 tggcacccag ttgatcggcg- cgagatttaa tcgccgcgac aatttgcgac ggcgcgtgca 4380 gggccagact ggaggtggca acgccaatca gcaacgactg tttgcccgcc agttgttgtg 4440 ccacgcggtt gggaatgtaa ttcagctccg ccatcgccgc ttccactttt tcccgcgttt 4500 tcgcagaaac gtggctggcc tggttcacca cgcgggaaac ggtctgataa gagacaccgg 4560 catactctgc gacatcgtat aacgttactg gtttcacatt caccaccctg aattgactct 4620 cttccgggcg ctatcatgcc ataccgcgaa aggttttgcg ccattcgatg gtgtccggga 4680 tctcgacgct ctcccttatg cgactcctgc attaggaagc agcccagtag taggttgagg 4740 ccgttgagca ccgccgccgc aaggaatggt gcatgcaagg agatggcgcc caacagtccc 4800 ccggccacgg ggcctgccac catacccacg ccgaaacaag cgctcatgag cccgaagtgg 4860 cgagcccgat cttccccatc ggtgatgtcg gcgatatagg cgccagcaac cgcacctgtg 4920 18 1223001 gcgccggtga tgccggccac gatgcgtccg gcgtagagga tcgagatctc gatcccgcga 4980 aattaatacg actcactata ggggaattgt gagcggataa caattcccct ctagaaataa 5040 ttttgtttaa ctttaagaag gagatataca t atg ggc cat cat cat cat cat 5092 Met Gly His His His His His 1 5 cac gtg ate gac ate ate ggg acc age ccc aca tee tgg gaa cag geg 5140 His Val 工le Asp lie 工le Gly Thr Ser Pro Thr Ser Trp Glu Gin Ala 10 15 20 geg geg gag geg gtc cag egg geg egg gat age gtc gat gac ate ege 5188 Ala Ala Glu Ala Val Gin Arg Ala Arg Asp Ser Val Asp Asp lie Arg 25 30 35 gtc get egg gtc att gag cag gac atg gee gtg gac age gee ggc aag 5236 Val Ala Arg Val 工le Glu Gin Asp Met Ala Val Asp Ser Ala Gly Lys
40 45 50 55 ate acc tac ege ate aag etc gaa gtg teg ttc aag atg agg ccg geg 5284 工le Thr Tyr Arg lie Lys Leu Glu Val Ser Phe Lys Met Arg Pro Ala 60 65 70 caa ccg agg ggc teg aaa cca ccg age ggt teg cct gaa aeg ggc gee 5332 Gin Pro Arg Gly Ser Lys Pro Pro Ser Gly Ser Pro Glu Thr Gly Ala 75 80 85 ggc gee ggt act gtc geg act acc ccc geg teg teg ccg gtg aeg ttg 5380 Gly Ala Gly Thr Val Ala Thr Thr Pro Ala Ser Ser Pro Val Thr Leu 90 95 100 geg gag acc ggt age aeg ctg etc tac ccg ctg ttc aac ctg tgg ggt 5428 Ala Glu Thr Gly Ser Thr Leu Leu Tyr Pro Leu Phe Asn Leu Trp Gly 105 110 115 ccg gee ttt cac gag agg tat ccg aac gtc aeg ate acc get cag ggc 5476 Pro Ala Phe His Glu Arg Tyr Pro Asn Val Thr 工le Thr Ala Gin Gly
120 125 130 135 acc ggt tet ggt gee ggg ate geg cag gee gee gee ggg aeg gtc aac 5524 Thr Gly Ser Gly Ala Gly lie Ala Gin Ala Ala Ala Gly Thr Val Asn 140 145 150 att ggg gee tee gac gee tat ctg teg gaa ggt gat atg gee geg cac 5572 工le Gly Ala Ser Asp Ala Tyr Leu Ser Glu Gly Asp Met Ala Ala His 155 160 165 aa9 999 Ctg atg aac ate geg eta gee ate tee get cag cag gtc aac 5620 Lys Gly Leu Met Asn lie Ala Leu Ala lie Ser Ala Gin Gin Val Asn 170 175 180 tac aac ctg ccc gga gtg age gag cac etc aag ctg aac gga aaa gtc 5668 Tyr Asn Leu Pro Gly Val Ser Glu His Leu Lys Leu Asn Gly Lys Val 185 190 195 ctg geg gee atg tac cag ggc acc ate aaa acc tgg gac gac ccg cag 5716 Leu Ala Ala Met Tyr Gin Gly Thr lie Lys Thr Trp Asp Asp Pro Gin 200 205 210 215 19 1223001 ate get geg etc aac ccc ggc gtg aac ctg ccc ggc acc geg gta gtt 5764 lie Ala Ala Leu Asn Pro Gly Val Asn Leu Pro Gly Thr Ala Val Val 220 225 230 ccg ctg cac ege tee gac ggg tee ggt gac acc ttc ttg ttc acc cag 5812 Pro Leu His Arg Ser Asp Gly Ser Gly Asp Thr Phe Leu Phe Thr Gin 235 240 245 tac ctg tee aag caa gat ccc gag ggc tgg ggc aag teg ccc ggc ttc 5860 Tyr Leu Ser Lys Gin Asp Pro Glu Gly Trp Gly Lys Ser Pro Gly Phe 250 255 260 ggc acc acc gtc gac ttc ccg geg gtg ccg ggt geg ctg ggt gag aac 5908 Gly Thr Thr Val Asp Phe Pro Ala Val Pro Gly Ala Leu Gly Glu Asn 265 270 275 ggc aac ggc ggc atg gtg acc ggt tgc gee gag aca ccg ggc tgc gtg 5956 Gly Asn Gly Gly Met Val Thr Gly Cys Ala Glu Thr Pro Gly Cys Val 280 285 290 295 c e o t 1 -o a I 3 c y 91 gG c e t 1 a I t r ay t T c a cl gA age ttc etc gac cag gee agt caa egg gga etc 6004 Ser Phe Leu Asp Gin Ala Ser Gin Arg Gly Leu 305 310 ggc gag gee caa eta ggc aat age tet ggc aat ttc ttg ttg ccc gac 6052 Gly Glu Ala Gin Leu Gly Asn Ser Ser Gly Asn Phe Leu Leu Pro Asp 315 320 325 geg caa age att cag gee geg geg get ggc ttc gca teg aaa acc ccg 6100 Ala Gin Ser lie Gin Ala Ala Ala Ala Gly Phe Ala Ser Lys Thr Pro 330 335 340 geg aac cag geg att teg atg ate gac ggg ccc gee ccg gac ggc tac 6148 Ala Asn Gin Ala lie Ser Met lie Asp Gly Pro Ala Pro Asp Gly Tyr 345 350 355 ccg ate ate aac tac gag tac gee ate gtc aac aac egg caa aag gac 6196 Pro lie lie Asn Tyr Glu Tyr Ala lie Val Asn Asn Arg Gin Lys Asp 360 365 370 375 gee gee acc geg cag acc ttg cag gca ttt ctg cac tgg geg ate acc 6244 Ala Ala Thr Ala Gin Thr Leu Gin Ala Phe Leu His Trp Ala 工le Thr 380 - 385 390 gac ggc aac aag gee teg ttc etc gac cag gtt cat ttc cag ccg ctg 6292 Asp Gly Asn Lys Ala Ser Phe Leu Asp Gin Val His Phe Gin Pro Leu 395 400 405 ccg ccc geg gtg gtg aag ttg tet gac geg ttg ate geg aeg att tee 6340 Pro Pro Ala Val Val Lys Leu Ser Asp Ala Leu 工le Ala Thr lie Ser 410 415 420 age get gag atg aag acc gat gee get acc etc geg cag gag gca ggt 6388 Ser Ala Glu Met Lys Thr Asp Ala Ala Thr Leu Ala Gin Glu Ala Gly 425 430 435 aat ttc gag egg ate tee ggc gac ctg aaa acc cag ate gac cag gtg 6436 Asn Phe Glu Arg lie Ser Gly Asp Leu Lys Thr Gin lie Asp Gin Val 440 445 450 455 1223001 gag teg aeg gca ggt teg ttg cag ggc cag tgg ege ggc geg geg ggg Glu Ser Thr Ala Gly Ser Leu Gin Gly Gin Trp Arg Gly Ala Ala Gly 460 465 470 aeg gee gee cag gee geg gtg gtg ege ttc caa gaa gca gee aat aag Thr Ala Ala Gin Ala Ala Val Val Arg Phe Gin Glu Ala Ala Asn Lys 475 480 485 cag aag cag gaa etc gac gag ate teg aeg aat att cgt cag gee ggc Gin Lys Gin Glu Leu Asp Glu lie Ser Thr Asn lie Arg Gin Ala Gly 490 495 500 gtc caa tac teg agg gee gac gag gag cag cag cag geg ctg tee teg Val Gin Tyr Ser Arg Ala Asp Glu Glu Gin Gin Gin Ala Leu Ser Ser 505 510 515 caa atg ggc ttt gtg ccc aca aeg gee gee teg ccg ccg teg acc get Gin Met Gly Phe Val Pro Thr Thr Ala Ala Ser Pro Pro Ser Thr Ala 520 525 530 535 gca geg cca ccc gca ccg geg aca cct gtt gee ccc cca cca ccg gee Ala Ala Pro Pro Ala Pro Ala Thr Pro Val Ala Pro Pro Pro Pro Ala 540 545 550 gee gee aac aeg ccg aat gee cag ccg ggc gat ccc aac gca gca cct Ala Ala Asn Thr Pro Asn Ala Gin Pro Gly Asp Pro Asn Ala Ala Pro 555 560 565 ccg ccg gee gac ccg aac gca ccg ccg cca cct gtc att gee cca aac Pro Pro Ala Asp Pro Asn Ala Pro Pro Pro Pro Val lie Ala Pro Asn 570 575 580 gca ccc caa cct gtc egg ate gac aac ccg gtt gga gga ttc age ttc Ala Pro Gin Pro Val Arg 工le Asp Asn Pro Val Gly Gly Phe Ser Phe 585 590 595 geg ctg cct get ggc tgg gtg gag tet gac gee gee cac ttc gac tac Ala Leu Pro Ala Gly Trp Val Glu Ser Asp Ala Ala His Phe Asp Tyr 600 605 610 615 ggt tea gca etc etc age aaa acc acc ggg gac ccg cca ttt ccc gga Gly Ser Ala Leu Leu Ser Lys Thr Thr Gly Asp Pro Pro Phe Pro Gly 620 625 630 cag ccg ccg ccg gtg gee aat gac acc cgt ate gtg etc ggc egg eta Gin Pro Pro Pro Val Ala Asn Asp Thr Arg 工le Val Leu Gly Arg Leu 635 640 645 gac caa aag ett tac gee age gee gaa gee acc gac tee aag gee geg Asp Gin Lys Leu Tyr Ala Ser Ala Glu Ala Thr Asp Ser Lys Ala Ala 650 655 660 gee egg ttg ggc teg gac atg ggt gag ttc tat atg ccc tac ccg ggc Ala Arg Leu Gly Ser Asp Met Gly Glu Phe Tyr Met Pro Tyr Pro Gly 665 670 675 acc egg ate aac cag gaa acc gtc teg ett gac gee aac ggg gtg tet Thr Arg 工le Asn Gin Glu Thr Val Ser Leu Asp Ala Asn Gly Val Ser 680 685 690 695 6484 6532 6580 6628 6676 6724 6772 6820 6868 6916 6964 7 012 7060 7108 7156 21 1223001 gga age geg teg tat tac gaa gtc aag ttc age gat ccg agt aag ccg 7204 Gly Ser Ala Ser Tyr Tyr Glu Val Lys Phe Ser Asp Pro Ser Lys Pro 700 705 710 aac ggc cag ate tgg aeg ggc gta ate ggc teg ccc geg geg aac gca 7252 Asn Gly Gin lie Trp Thr Gly Val 工le Gly Ser Pro Ala Ala Asn Ala 715 720 725 ccg gac gee ggg ccc cct cag ege tgg ttt gtg gta tgg etc ggg acc 7300 Pro Asp Ala Gly Pro Pro Gin Arg Trp Phe Val Val Trp Leu Gly Thr 730 735 740 gee aac aac ccg gtg gac aag ggc geg gee aag geg ctg gee gaa teg 7348 Ala Asn Asn Pro Val Asp Lys Gly Ala Ala Lys Ala Leu Ala Glu Ser 745 750 755 ate egg cct ttg gtc gee ccg ccg ccg geg ccg gca ccg get cct gca 7396 工le Arg Pro Leu Val Ala Pro Pro Pro Ala Pro Ala Pro Ala Pro Ala
760 765 770 775 gag ccc get ccg geg ccg geg ccg gee ggg gaa gtc get cct acc ccg 7444 Glu Pro Ala Pro Ala Pro Ala Pro Ala Gly Glu Val Ala Pro Thr Pro 780 785 790 aeg aca ccg aca ccg cag egg acc tta ccg gee tgagaattet gcagatatcc 7497 Thr Thr Pro Thr Pro Gin Arg Thr Leu Pro Ala 795 800 atcacactgg cggccgctcg agcaccacca ccaccaccac tgagatccgg ctgctaacaa 7557 agcccgaaag gaagctgagt tggctgctgc caccgctgag caataactag cataacccct 7617 tggggcctct aaacgggtct tgaggggttt tttgctgaaa ggaggaacta tatccggat 7676
<210> 10 <211> 802 <212> PRT <213 >人工序列 <223>人工序列之說明:四-融合蛋白質 TbRa3 - 38kD - Tb38 - 1 - DPEP (命名為 TbF - 2 ) <400〉 10 Met Gly His His His His His His Val 工le Asp lie 工le Gly Thr Ser 15 10 15 Pro Thr Ser Trp Glu Gin Ala Ala Ala Glu Ala Val Gin Arg Ala Arg 20 25 30 Asp Ser Val Asp Asp lie Arg Val Ala Arg Val lie Glu Gin Asp Met 35 40 45 Ala Val Asp Ser Ala Gly Lys lie Thr Tyr Arg 工le Lys Leu Glu Val 50 55 60 Ser Phe Lys Met Arg Pro Ala Gin Pro Arg Gly Ser Lys Pro Pro Ser 65 70 75 80 Gly Ser Pro Glu Thr Gly Ala Gly Ala Gly Thr Val Ala Thr Thr Pro 85 90 95 22 1223001 Ala Ser Ser Pro Val Thr Leu Ala Glu Thr Gly Ser Thr Leu Leu Tyr 100 105 110 Pro Leu Phe Asn Leu Trp Gly Pro Ala Phe His Glu Arg Tyr Pro Asn 115 120 125 Val Thr lie Thr Ala Gin Gly Thr Gly Ser Gly Ala Gly lie Ala Gin 130 135 140 Ala Ala Ala Gly Thr Val Asn lie Gly Ala Ser Asp Ala Tyr Leu Ser 145 150 155 160 Glu Gly Asp Met Ala Ala His Lys Gly Leu Met Asn lie Ala Leu Ala 165 170 175 lie Ser Ala Gin Gin Val Asn Tyr Asn Leu Pro Gly Val Ser Glu His 180 185 190 Leu Lys Leu Asn Gly Lys Val Leu Ala Ala Met Tyr Gin Gly Thr lie 195 200 205 Lys Thr Trp Asp Asp Pro Gin lie Ala Ala Leu Asn Pro Gly Val Asn 210 " 215 220 Leu Pro Gly Thr Ala Val Val Pro Leu His Arg Ser Asp Gly Ser Gly 225 230 235 240 Asp Thr Phe Leu Phe Thr Gin Tyr Leu Ser Lys Gin Asp Pro Glu Gly 245 250 255 Trp Gly Lys Ser Pro Gly Phe Gly Thr Thr Val Asp Phe Pro Ala Val 260 265 270 Pro Gly Ala Leu Gly Glu Asn Gly Asn Gly Gly Met Val Thr Gly Cys 275 280 285 Ala Glu Thr Pro Gly Cys Val Ala Tyr lie Gly lie Ser Phe Leu Asp 290 295 300 Gin Ala Ser Gin Arg Gly Leu Gly Glu Ala Gin Leu Gly Asn Ser Ser 305 310 315 320 Gly Asn Phe Leu Leu Pro Asp Ala Gin Ser lie Gin Ala Ala Ala Ala 325 330 335 Gly Phe Ala Ser Lys Thr Pro Ala Asn Gin Ala lie Ser Met 工le Asp 340 345 350 Gly Pro Ala Pro Asp Gly Tyr Pro lie lie Asn Tyr Glu Tyr Ala lie 355 360 365 Val Asn Asn Arg Gin Lys Asp Ala Ala Thr Ala Gin Thr Leu Gin Ala 370 375 380 Phe Leu His Trp Ala 工le Thr Asp Gly Asn Lys Ala Ser Phe Leu Asp 385 390 395 400 Gin Val His Phe Gin Pro Leu Pro Pro Ala Val Val Lys Leu Ser Asp 405 410 415 23 1223001 Ala Leu 工le Ala Thr lie Ser Ser Ala Glu Met Lys Thr Asp Ala Ala ' 420 425 430 Thr Leu Ala Gin Glu Ala Gly Asn Phe Glu Arg lie Ser Gly Asp Leu 435 440 445 Lys Thr Gin 工le Asp Gin Val Glu Ser Thr Ala Gly Ser Leu Gin Gly 450 455 460 Gin Trp Arg Gly Ala Ala Gly Thr Ala Ala Gin Ala Ala Val Val Arg 465 470 475 480 Phe Gin Glu Ala Ala Asn Lys Gin Lys Gin Glu Leu Asp Glu lie Ser 485 490 495 Thr Asn lie Arg Gin Ala Gly Val Gin Tyr Ser Arg Ala Asp Glu Glu 500 505 510
Gin Gin Gin Ala Leu Ser Ser Gin Met Gly Phe Val Pro Thr Thr Ala 515 520 525 Ala Ser Pro Pro Ser Thr Ala Ala Ala Pro Pro Ala Pro Ala Thr Pro 530 ' 535 540 Val Ala Pro Pro Pro Pro Ala Ala Ala Asn Thr Pro Asn Ala Gin Pro 545 550 555 560 Gly Asp Pro Asn Ala Ala Pro Pro Pro Ala Asp Pro Asn Ala Pro Pro 565 570 575 Pro Pro Val lie Ala Pro Asn Ala Pro Gin Pro Val Arg lie Asp Asn 580 585 590 Pro Val Gly Gly Phe Ser Phe Ala Leu Pro Ala Gly Trp Val Glu Ser 595 600 605 Asp Ala Ala His Phe Asp Tyr Gly Ser Ala Leu Leu Ser Lys Thr Thr 610 615 620
Gly Asp Pro Pro Phe Pro Gly Gin Pro Pro Pro Val Ala Asn Asp Thr 625 630 635 640 Arg lie Val Leu Gly Arg Leu Asp Gin Lys Leu Tyr Ala Ser Ala Glu 645 650 655 Ala Thr Asp Ser Lys Ala Ala Ala Arg Leu Gly Ser Asp Met Gly Glu 660 665 670 Phe Tyr Met Pro Tyr Pro Gly Thr Arg 工le Asn Gin Glu Thr Val Ser 675 680 685 Leu Asp Ala Asn Gly Val Ser Gly Ser Ala Ser Tyr Tyr Glu Val Lys 690 695 700 Phe Ser Asp Pro Ser Lys Pro Asn Gly Gin lie Trp Thr Gly Val lie 705 710 715 720 Gly Ser Pro Ala Ala Asn Ala Pro Asp Ala Gly Pro Pro Gin Arg Trp 725 730 735 24 1223001 Phe Val Val Trp Leu Gly Thr Ala Asn Asn Pro Val Asp Lys Gly Ala 740 745 750 Ala Lys Ala Leu Ala Glu Ser 工le Arg Pro Leu Val Ala Pro Pro Pro 755 760 765 Ala Pro Ala Pro Ala Pro Ala Glu Pro Ala Pro Ala Pro Ala Pro Ala 770 775 780 Gly Glu Val Ala Pro Thr Pro Thr Thr Pro Thr Pro Gin Arg Thr Leu 785 790 795 800 Pro Ala
<210> 11 <211> 2577 <212> DNA <213 >人工序列 <220> <223>人工序列之說明:五-融合蛋白質 Erdl4 - DPV - TTI - MSL - MTCC2 (命名為 Mtb88f) <220> <221> CDS <222〉(1) · · (2571) <400> 11 cat atg cat cac cat cac cat cac atg gcc acc acc ctt ccc gtt cag 48 His Met His His His His His His Met Ala Thr Thr Leu Pro Val Gin 15 10 15 cgc cac ccg egg tcc etc ttc ccc gag ttt tet gag ctg ttc geg gcc 96 Arg His Pro Arg Ser Leu Phe Pro Glu Phe Ser Glu Leu Phe Ala Ala 20 25 30
ttc ccg tea ttc gcc gga etc egg ccc acc ttc gac acc egg ttg atg 144 Phe Pro Ser Phe Ala Gly Leu Arg Pro Thr Phe Asp Thr Arg Leu Met 35 40 45 egg ctg gaa gac gag atg aaa gag ggg cgc tac gag gta cgc geg gag 192 Arg Leu Glu Asp Glu Met Lys Glu Gly Arg Tyr Glu Val Arg Ala Glu 50 55 60 ctt ccc ggg gtc gac ccc gac aag gac gtc gac att atg gtc cgc gat 240 Leu Pro Gly Val Asp Pro Asp Lys Asp Val Asp 工le Met Val Arg Asp 65 7 0 75 80 ggt cag ctg acc ate aag gcc gag cgc acc gag cag aag gac ttc gac 288 Gly Gin Leu Thr lie Lys Ala Glu Arg Thr Glu Gin Lys Asp Phe Asp 85 90 95 ggt cgc teg gaa ttc geg tac ggt tcc ttc gtt cgc aeg gtg teg ctg 336 Gly Arg Ser Glu Phe Ala Tyr Gly Ser Phe Val Arg Thr Val Ser Leu 100 105 110 ccg gta ggt get gac gag gac gac att aag gcc acc tac gac aag ggc 384 Pr〇 Val Gly Ala Asp Glu Asp Asp lie Lys Ala Thr Tyr Asp Lys Gly 115 120 125 25 1223001 att lie cac His 145 att lie acg Thr tcc Ser atg Met ctt Leu 225 att lie get Ala gtg Val cag Gin cag Gin 305 geg Ala ctt Leu gcc Ala ctt act gtg teg gtg geg Leu Thr Val Ser Val Ala 130 135 att cag ate egg tec acc 工le Gin lie Arg Ser Thr 150 aac acc acc tgc aat tac Asn Thr Thr Cys Asn Tyr 165 gat ccg ggg get gcc gca Asp Pro Gly Ala Ala Ala 180 tat ttg ege aat ttc etc Tyr Leu Arg Asn Phe Leu 195 gcc geg caa ttg caa get Ala Ala Gin Leu Gin Ala 210 ' 215 gtc gag teg gtt gcc ggc Val Glu Ser Val Ala Gly 230 aat tac cag ttc ggg gac Asn Tyr Gin Phe Gly Asp 245 cag geg geg teg ctt gag Gin Ala Ala Ser Leu Glu 260 ttg gcc geg ggt gac ttt Leu Ala Ala Gly Asp Phe 275 gag ttc att acc cag ttg Glu Phe 工le Thr Gin Leu 290 295 gcc aac gcc cac ggg cag Ala Asn Ala His Gly Gin 310 caa acc gac age gcc gtc Gin Thr Asp Ser Ala Val 325 ttg gat get cat ate cca Leu Asp Ala His lie Pro 340 gcc aag geg ggg ctg atg Ala Lys Ala Gly Leu Met 355 gtt teg gaa ggg aag cca acc Val Ser Glu Gly Lys Pro Thr 140 aac aag ctt gat ccc gtg gac Asn Lys Leu Asp Pro Val Asp 155 ggg cag gta gta get geg etc Gly Gin Val Val Ala Ala Leu 170 cag ttc aac gcc tea ccg gtg Gin Phe Asn Ala Ser Pro Val 185 190 gcc gca ccg cca cct cag ege Ala Ala Pro Pro Pro Gin Arg 200 205 gtg ccg ggg geg gca cag tac Val Pro Gly Ala Ala Gin Tyr 220 tec tgc aac aac tat gag etc Ser Cys Asn Asn Tyr Glu Leu 235 gtc gac get cat ggc gcc atg Val Asp Ala His Gly Ala Met 250 geg gag cat cag gcc ate gtt Ala Glu His Gin Ala 工le Val 265 270 tgg ggc ggc gcc ggt teg gtg Trp Gly Gly Ala Gly Ser Val 280 285 ggc cgt aac ttc cag gtg ate Gly Arg Asn Phe Gin Val lie 300 aag gtg cag get gcc ggc aac Lys Val Gin Ala Ala Gly Asn 315 ggc tec age tgg gcc act agt Gly Ser Ser Trp Ala Thr Ser 330 cag ttg gtg gcc tec cag teg Gin Leu Val Ala Ser Gin Ser 345 350 egg cac acg ate ggt cag gcc Arg His Thr lie Gly Gin Ala 360 365 gaa aag 432 Glu Lys geg gtc 480 Ala Val 160 aac geg 528 Asn Ala 175 geg cag 576 Ala Gin get gcc 624 Ala Ala ate ggc 672 He Gly atg acg 720 Met Thr 240 ate ege 768 工le Arg 255 cgt gat 816 Arg Asp get tgc 864 Ala Cys tac gag 912 Tyr Glu aac atg 960 Asn Met 320 atg age 1008 Met Ser 335 geg ttt 1056 Ala Phe gag cag 1104 Glu Gin
26 11521223001 gcg gcg atg teg get cag geg ttt cac cag ggg gag teg teg geg geg Ala Ala Met Ser Ala Gin Ala Phe His Gin Gly Glu Ser Ser Ala Ala 370 375 380 ttt cag gee gee cat gee egg ttt gtg gcg gcg gee gee aaa gtc aac Phe Gin Ala Ala His Ala Arg Phe Val Ala Ala Ala Ala Lys Val Asn 385 390 395 400 acc ttg ttg gat gtc gcg cag gcg aat ctg ggt gag gee gee ggt acc Thr Leu Leu Asp Val Ala Gin Ala Asn Leu Gly Glu Ala Ala Gly Thr 405 410 415 tat gtg gee gee gat get gcg gee gcg teg acc tat acc ggg ttc gat Tyr Val Ala Ala Asp Ala Ala Ala Ala Ser Thr Tyr Thr Gly Phe Asp 420 425 430 ate atg gat ttc ggg ett tta cct ccg gaa gtg aat tea age ega atg 工le Met Asp Phe Gly Leu Leu Pro Pro Glu Val Asn Ser Ser Arg Met 435 440 445 tat tee ggt ccg ggg ccg gag teg atg eta gee gee gcg gee gee tgg Tyr Ser Gly Pro Gly Pro Glu Ser Met Leu Ala Ala Ala Ala Ala Trp 450 " 455 460 gac ggt gtg gee gcg gag ttg act tee gee gcg gtc teg tat gga teg Asp Gly Val Ala Ala Glu Leu Thr Ser Ala Ala Val Ser Tyr Gly Ser 465 470 475 480 gtg gtg teg aeg ctg ate gtt gag ccg tgg atg ggg ccg gcg gcg gee Val Val Ser Thr Leu 工le Val Glu Pro Trp Met Gly Pro Ala Ala Ala 485 490 495 gcg atg gcg gee gcg gca aeg ccg tat gtg ggg tgg ctg gee gee aeg Ala Met Ala Ala Ala Ala Thr Pro Tyr Val Gly Trp Leu Ala Ala Thr 500 505 510 gcg gcg ctg gcg aag gag aeg gee aca cag gcg agg gca gcg gcg gaa Ala Ala Leu Ala Lys Glu Thr Ala Thr Gin Ala Arg Ala Ala Ala Glu 515 520 525 gcg ttt ggg aeg gcg ttc gcg atg aeg gtg cca cca tee etc gtc gcg Ala Phe Gly Thr Ala Phe Ala Met Thr Val Pro Pro Ser Leu Val Ala 530 535 540 gee aac ege age egg ttg atg teg ctg gtc gcg gcg aac att ctg ggg Ala Asn Arg Ser Arg Leu Met Ser Leu Val Ala Ala Asn lie Leu Gly 545 550 555 560 caa aac agt gcg gcg ate gcg get acc cag gee gag tat gee gaa atg Gin Asn Ser Ala Ala lie Ala Ala Thr Gin Ala Glu Tyr Ala Glu Met 565 570 575 tgg gee caa gac get gee gtg atg tac age tat gag ggg gca tet gcg Trp Ala Gin Asp Ala Ala Val Met Tyr Ser Tyr Glu Gly Ala Ser Ala 580 585 590 gee gcg teg gcg ttg ccg ccg ttc act cca ccc gtg caa ggc acc ggc Ala Ala Ser Ala Leu Pro Pro Phe Thr Pro Pro Val Gin Gly Thr Gly 595 600 605 1200 1248 1296 1344 1392 1440 1488 1536 1584 1632 1680 1728 1776 1824
27 1223001 ccg gee ggg ccc geg gee gca gee geg geg acc caa gee gee ggt geg 1872 Pro Ala Gly Pro Ala Ala Ala Ala Ala Ala Thr Gin Ala Ala Gly Ala 610 615 620 ggc gee gtt geg gat gca cag geg aca ctg gee cag ctg ccc ccg ggg 1920 Gly Ala Val Ala Asp Ala Gin Ala Thr Leu Ala Gin Leu Pro Pro Gly 625 630 635 640 ate ctg age gac att ctg tee gca ttg gee gee aac get gat ccg ctg 1968 lie Leu Ser Asp lie Leu Ser Ala Leu Ala Ala Asn Ala Asp Pro Leu 645 650 655 aca teg gga ctg ttg ggg ate geg teg acc etc aac ccg caa gtc gga 2016 Thr Ser Gly Leu Leu Gly lie Ala Ser Thr Leu Asn Pro Gin Val Gly 660 665 670 tee get cag ccg ata gtg ate ccc acc ccg ata ggg gaa ttg gac gtg 2064 Ser Ala Gin Pro lie Val lie Pro Thr Pro lie Gly Glu Leu Asp Val 675 680 685 ate geg etc tac att gca tee ate geg acc ggc age att geg etc geg 2112 lie Ala Leu Tyr He Ala Ser lie Ala Thr Gly Ser lie Ala Leu Ala 690 695 700 ate aeg aac aeg gee aga ccc tgg cac ate ggc eta tac ggg aac gee 2160 lie Thr Asn Thr Ala Arg Pro Trp His lie Gly Leu Tyr Gly Asn Ala 705 710 715 720 ggc ggg ctg gga ccg aeg cag ggc cat cca ctg agt teg geg acc gac 2208 Giy Gly Leu Gly Pro Thr Gin Gly His Pro Leu Ser Ser Ala Thr Asp 725 730 735 gag ccg gag ccg cac tgg ggc ccc ttc ggg ggc geg geg ccg gtg tee 2256 Glu Pro Glu Pro His Trp Gly Pro Phe Gly Gly Ala Ala Pro Val Ser 740 745 750 geg ggc gtc ggc cac gca gca tta gtc gga geg ttg teg gtg ccg cac 2304 Ala Gly Val Gly His Ala Ala Leu Val Gly Ala Leu Ser Val Pro His 755 760 765 age tgg acc aeg gee gee ccg gag ate cag etc gee gtt cag gca aca 2352 Ser Trp Thr Thr Ala Ala Pro Glu lie Gin Leu Ala Val Gin Ala Thr 770 775 780 ccc acc ttc age tee age gee ggc gee gac ccg aeg gee eta aac ggg 2400 Pro Thr Phe Ser Ser Ser Ala Gly Ala Asp Pro Thr Ala Leu Asn Gly 785 790 795 800 atg ccg gca ggc ctg etc age ggg atg get ttg geg age ctg gee gca 2448 Met Pro Ala Gly Leu Leu Ser Gly Met Ala Leu Ala Ser Leu Ala Ala 805 810 815 ege ggc aeg aeg ggc ggt ggc ggc acc cgt age ggc acc age act gac 2496 Arg Gly Thr Thr Gly Gly Gly Gly Thr Arg Ser Gly Thr Ser Thr Asp 820 825 830 ggc caa gag gac ggc ege aaa ccc ccg gta gtt gtg att aga gag cag 2544 Gly Gin Glu Asp Gly Arg Lys Pro Pro Val Val Val lie Arg Glu Gin 835 840 845 28 1223001 ccg ccg ccc gga aac ccc ccg egg taagatatc 2577 Pro Pro Pro Gly Asn Pro Pro Arg 850 855 <210> 12 <211> 856 <212> PRT <213〉人工序列 <223>人工序列之說明··五—融合蛋白質 Erdl4 - DPV - TTI — MSL — MTCC2 (命名為 Mtb88f ) <400> 12 His Met His His His His His His Met Ala Thr Thr Leu Pro Val Gin 15 10 15
Arg His Pro Arg Ser Leu Phe Pro Glu Phe Ser Glu Leu Phe Ala Ala 20 25 30 Phe Pro Ser Phe Ala Gly Leu Arg Pro Thr Phe Asp Thr Arg Leu Met 35 40 45 Arg Leu Glu Asp Glu Met Lys Glu Gly Arg Tyr Glu Val Arg Ala Glu 50 55 60 Leu Pro Gly Val Asp Pro Asp Lys Asp Val Asp 工le Met Val Arg Asp 65 70 75 80 Gly Gin Leu Thr lie Lys Ala Glu Arg Thr Glu Gin Lys Asp Phe Asp 85 90 95 Gly Arg Ser Glu Phe Ala Tyr Gly Ser Phe Val Arg Thr Val Ser Leu 100 105 110 Pr〇 Val Gly Ala Asp Glu Asp Asp lie Lys Ala Thr Tyr Asp Lys Gly 115 120 125
工le Leu Thr Val Ser Val Ala Val Ser Glu Gly Lys Pro Thr Glu Lys 130 135 140 His lie Gin lie Arg Ser Thr Asn Lys Leu Asp Pro Val Asp Ala Val 145 150 155 160 lie Asn Thr Thr Cys Asn Tyr Gly Gin Val Val Ala Ala Leu Asn Ala 165 170 175 Thr Asp Pro Gly Ala Ala Ala Gin Phe Asn Ala Ser Pro Val Ala Gin 180 185 190 Ser Tyr Leu Arg Asn Phe Leu Ala Ala Pro Pro Pro Gin Arg Ala Ala 195 200 205 Met Ala Ala Gin Leu Gin Ala Val Pro Gly Ala Ala Gin Tyr lie Gly 210 215 220 Leu Val Glu Ser Val Ala Gly Ser Cys Asn Asn Tyr Glu Leu Met Thr 225 230 235 240 工le Asn Tyr Gin Phe Gly Asp Val Asp Ala His Gly Ala Met 工le Arg 245 250 255 29 1223001 Ala Gin Ala Ala Ser Leu Glu Ala Glu His Gin Ala lie Val Arg Asp 260 265 270 Val Leu Ala Ala Gly Asp Phe Trp Gly Gly Ala Gly Ser Val Ala Cys 275 280 285 Gin Glu Phe lie Thr Gin Leu Gly Arg Asn Phe Gin Val lie Tyr Glu 290 295 300 Gin Ala Asn Ala His Gly Gin Lys Val Gin Ala Ala Gly Asn Asn Met 305 310 315 320 Ala Gin Thr Asp Ser Ala Val Gly Ser Ser Trp Ala Thr Ser Met Ser 325 330 335 Leu Leu Asp Ala His lie Pro Gin Leu Val Ala Ser Gin Ser Ala Phe 340 345 350 Ala Ala Lys Ala Gly Leu Met Arg His Thr lie Gly Gin Ala Glu Gin 355 360 365 Ala Ala Met Ser Ala Gin Ala Phe His Gin Gly Glu Ser Ser Ala Ala 370 " 375 380 Phe Gin Ala Ala His Ala Arg Phe Val Ala Ala Ala Ala Lys Val Asn 385 390 395 400 Thr Leu Leu Asp Val Ala Gin Ala Asn Leu Gly Glu Ala Ala Gly Thr 405 410 415 Tyr Val Ala Ala Asp Ala Ala Ala Ala Ser Thr Tyr Thr Gly Phe Asp 420 425 430 lie Met Asp Phe Gly Leu Leu Pro Pro Glu Val Asn Ser Ser Arg Met 435 440 445 Tyr Ser Gly Pro Gly Pro Glu Ser Met Leu Ala Ala Ala Ala Ala Trp 450 455 460 Asp Gly Val Ala Ala Glu Leu Thr Ser Ala Ala Val Ser Tyr Gly Ser 465 470 475 480 Val Val Ser Thr Leu lie Val Glu Pro Trp Met Gly Pro Ala Ala Ala 485 490 495 Ala Met Ala Ala Ala Ala Thr Pro Tyr Val Gly Trp Leu Ala Ala Thr 500 505 510 Ala Ala Leu Ala Lys Glu Thr Ala Thr Gin Ala Arg Ala Ala Ala Glu 515 520 525 Ala Phe Gly Thr Ala Phe Ala Met Thr Val Pro Pro Ser Leu Val Ala 530 535 540 Ala Asn Arg Ser Arg Leu Met Ser Leu Val Ala Ala Asn 工le Leu Gly 545 550 555 560 Gin Asn Ser Ala Ala lie Ala Ala Thr Gin Ala Glu Tyr Ala Glu Met 565 570 575 30 Trp Ala Gin Asp Ala Ala Val Met Tyr Ser Tyr Glu Gly Ala Ser Ala 580 585 590 Ala Ala Ser Ala Leu Pro Pro Phe Thr Pro Pro Val Gin Gly Thr Gly 595 600 605 Pro Ala Gly Pro Ala Ala Ala Ala Ala Ala Thr Gin Ala Ala Gly Ala 610 615 620 Gly Ala Val Ala Asp Ala Gin Ala Thr Leu Ala Gin Leu Pro Pro Gly 625 630 635 640 工le Leu Ser Asp 工le Leu Ser Ala Leu Ala Ala Asn Ala Asp Pro Leu 645 650 655 Thr Ser Gly Leu Leu Gly lie Ala Ser Thr Leu Asn Pro Gin Val Gly 660 665 670 Ser Ala Gin Pro 工le Val lie Pro Thr Pro 工le Gly Glu Leu Asp Val 675 680 685 工le Ala Leu Tyr 工le Ala Ser lie Ala Thr Gly Ser 工le Ala Leu Ala 690 ' 695 700 lie Thr Asn Thr Ala Arg Pro Trp His 工le Gly Leu Tyr Gly Asn Ala 705 710 715 720 Gly Gly Leu Gly Pro Thr Gin Gly His Pro Leu Ser Ser Ala Thr Asp 725 730 735 Glu Pro Glu Pro His Trp Gly Pro Phe Gly Gly Ala Ala Pro Val Ser 740 745 750 Ala Gly Val Gly His Ala Ala Leu Val Gly Ala Leu Ser Val Pro His 755 760 765 Ser Trp Thr Thr Ala Ala Pro Glu lie Gin Leu Ala Val Gin Ala Thr 770 775 780 Pro Thr Phe Ser Ser Ser Ala Gly Ala Asp Pro Thr Ala Leu Asn Gly 785 790 795 800 Met Pro Ala Gly Leu Leu Ser Gly Met Ala Leu Ala Ser Leu Ala Ala 805 810 815 Arg Gly Thr Thr Gly Gly Gly Gly Thr Arg Ser Gly Thr Ser Thr Asp 820 825 830 Gly Gin Glu Asp Gly Arg Lys Pro Pro Val Val Val 工le Arg Glu Gin 835 840 845 Pro Pro Pro Gly Asn Pro Pro Arg 850 855 <210> 13 <211> 1299 <212> DNA <213>人工序列 31 1223001 <220> <223>人工序列之說明··四-融合蛋白質 Erdl4-DPV —MTI-MSL(命名為 Mtb46f) <22〇> <221> CDS <222> (1) . . (1299) <400> 13 cat atg cat cac cat cac cat cac atg gee acc acc ett ccc gtt cag 48 His Met His His His His His His Met Ala Thr Thr Leu Pro Val Gin 1 5 10 15 cgc cac ccg egg tee etc ttc ccc gag ttt tet gag ctg ttc geg gee 96 Arg His Pro Arg Ser Leu Phe Pro Glu Phe Ser Glu Leu Phe Ala Ala 20 25 30 ttc ccg tea ttc gee gga etc egg ccc acc ttc gac acc egg ttg atg 144 Phe Pro Ser Phe Ala Gly Leu Arg Pro Thr Phe Asp Thr Arg Leu Met 35 40 45 egg ctg gaa gac gag atg aaa gag ggg cgc tac gag gta cgc geg gag 192 Arg Leu Glu Asp Glu Met Lys Glu Gly Arg Tyr Glu Val Arg Ala Glu 50 55 60 ett ccc ggg gtc gac ccc gac aag gac gtc gac att atg gtc cgc gat 240 Leu Pro Gly Val Asp Pro Asp Lys Asp Val Asp lie Met Val Arg Asp 65 70 7 5 80 ggt cag ctg acc ate aag gee gag cgc acc gag cag aag gac ttc gac 288 Gly Gin Leu Thr lie Lys Ala Glu Arg Thr Glu Gin Lys Asp Phe Asp 85 90 95 ggt cgc teg gaa ttc geg tac ggt tee ttc gtt cgc aeg gtg teg ctg 336 Gly Arg Ser Glu Phe Ala Tyr Gly Ser Phe Val Arg Thr Val Ser Leu 100 105 110 ccg gta ggt get gac gag gac gac att aag gee acc tac gac aag ggc 384 Pro Val Gly Ala Asp Glu Asp Asp lie Lys Ala Thr Tyr Asp Lys Gly 115 120 125 att ett act gtg teg gtg geg gtt teg gaa ggg aag cca acc gaa aag 432 lie Leu Thr Val Ser Val Ala Val Ser Glu Gly Lys Pro Thr Glu Lys 130 135 140 cac att cag ate egg tee acc aac aag ett gat ccc gtg gac geg gtc 480 His lie Gin lie Arg Ser Thr Asn Lys Leu Asp Pro Val Asp Ala Val 145 150 155 160 att aac acc acc tgc aat tac ggg cag gta gta get geg etc aac geg 528 lie Asn Thr Thr Cys Asn Tyr Gly Gin Val Val Ala Ala Leu Asn Ala 165 170 175 aeg gat ccg ggg get gee gca cag ttc aac gee tea ccg gtg geg cag 576 Thr Asp Pro Gly Ala Ala Ala Gin Phe Asn Ala Ser Pro Val Ala Gin 180 185 190 tee tat ttg cgc aat ttc etc gee gca ccg cca cct cag cgc get gee 624 Ser Tyr Leu Arg Asn Phe Leu Ala Ala Pro Pro Pro Gin Arg Ala Ala 195 200 205
32 6721223001 at9 gcc gcg caa ttg caa get gtg ccg ggg geg gca cag tac ate ggc Met Ala Ala Gin Leu Gin Ala Val Pro Gly Ala Ala Gin Tyr lie Gly 210 215 220 ett gtc gag teg gtt gee ggc tee tgc aac aac tat gag etc atg aeg Leu Val Glu Ser Val Ala Gly Ser Cys Asn Asn Tyr Glu Leu Met Thr 225 230 235 240 att aat tac cag ttc ggg gac gtc gac get cat ggc gee atg ate ege lie Asn Tyr Gin Phe Gly Asp Val Asp Ala His Gly Ala Met lie Arg 245 250 255 get cag gcg gcg teg ett gag gcg gag cat cag gee ate gtt cgt gat Ala Gin Ala Ala Ser Leu Glu Ala Glu His Gin Ala lie Val Arg Asp 260 265 270 gtg ttg gee gcg ggt gac ttt tgg ggc ggc gee ggt teg gtg get tgc Val Leu Ala Ala Gly Asp Phe Trp Gly Gly Ala Gly Ser Val Ala Cys 275 280 285 cag gag ttc att acc cag ttg ggc cgt aac ttc cag gtg ate tac gag Gin Glu Phe lie Thr Qln Leu Gly Arg Asn Phe Gin Val lie Tyr Glu 290 ' 295 300 cag gee aac gee cac ggg cag aag gtg cag get gee ggc aac aac atg Gin Ala Asn Ala His Gly Gin Lys Val Gin Ala Ala Gly Asn Asn Met 305 310 315 320 gcg caa acc gac age gee gtc ggc tee age tgg gee act agt atg age Ala Gin Thr Asp Ser Ala Val Gly Ser Ser Trp Ala Thr Ser Met Ser 325 330 335 ett ttg gat get cat ate cca cag ttg gtg gee tee cag teg gcg ttt Leu Leu Asp Ala His lie Pro Gin Leu Val Ala Ser Gin Ser Ala Phe 340 345 350 gee gee aag gcg ggg ctg atg egg cac aeg ate ggt cag gee gag cag Ala Ala Lys Ala Gly Leu Met Arg His Thr lie Gly Gin Ala Glu Gin 355 360 365 gcg gcg atg teg get cag gcg ttt cac cag ggg gag teg teg gcg gcg Ala Ala Met Ser Ala Gin Ala Phe His Gin Gly Glu Ser Ser Ala Ala 370 375 380 ttt cag gee gee cat gee egg ttt gtg gcg gcg gee gee aaa gtc aac Phe Gin Ala Ala His Ala Arg Phe Val Ala Ala Ala Ala Lys Val Asn 385 390 395 400 acc ttg ttg gat gtc gcg cag gcg aat ctg ggt gag gee gee ggt acc Thr Leu Leu Asp Val Ala Gin Ala Asn Leu Gly Glu Ala Ala Gly Thr 405 410 415 tat gtg gee gee gat get gcg gee gcg teg acc tat acc ggg ttc gat Tyr Val Ala Ala Asp Ala Ala Ala Ala Ser Thr Tyr Thr Gly Phe Asp 420 425 430 ate lie 720 768 816 864
912 960 1008 1056 1104 1152 1200 1248 1296
33 1299 1223001 <210> 14 <211> 433 <212> PRT <213> 人工序列 <223>人工序列之說明··四—融合蛋白質 一 Erdl4-DPV-MTI —MSL(命名為 Mtb46f) <400> 14 His Met His His His His His His Met Ala Thr Thr Leu Pro Val Gin 15 10 15 Arg His Pro Arg Ser Leu Phe Pro Glu Phe Ser Glu Leu Phe Ala Ala 20 25 30 Phe Pro Ser Phe Ala Gly Leu Arg Pro Thr Phe Asp Thr Arg Leu Met 35 40 45 Arg Leu Glu Asp Glu Met Lys Glu Gly Arg Tyr Glu Val Arg Ala Glu 50 55 60 Leu Pro Gly Val Asp Pro Asp Lys Asp Val Asp 工le Met Val Arg Asp 65 70 75 80 Gly Gin Leu Thq: lie Lys Ala Glu Arg Thr Glu Gin Lys Asp Phe Asp 85 90 95 Gly Arg Ser Glu Phe Ala Tyr Gly Ser Phe Val Arg Thr Val Ser Leu 100 105 110 Pro Val Gly Ala Asp Glu Asp Asp lie Lys Ala Thr Tyr Asp Lys Gly 115 120 125 工le Leu Thr Val Ser Val Ala Val Ser Glu Gly Lys Pro Thr Glu Lys 130 135 140 His 工le Gin lie Arg Ser Thr Asn Lys Leu Asp Pro Val Asp Ala Val 145 150 155 160 工le Asn Thr Thr Cys Asn Tyr Gly Gin Val Val Ala Ala Leu Asn Ala 165 170 175 Thr Asp Pro Gly Ala Ala Ala Gin Phe Asn Ala Ser Pro Val Ala Gin 180 185 190 Ser Tyr Leu Arg Asn Phe Leu Ala Ala Pro Pro Pro Gin Arg Ala Ala 195 200 205 Met Ala Ala Gin Leu Gin Ala Val Pro Gly Ala Ala Gin Tyr 工le Gly 210 215 220 Leu Val Glu Ser Val Ala Gly Ser Cys Asn Asn Tyr Glu Leu Met Thr 225 230 235 240 lie Asn Tyr Gin Phe Gly Asp Val Asp Ala His Gly Ala Met lie Arg 245 250 255 Ala Gin Ala Ala Ser Leu Glu Ala Glu His Gin Ala 工le Val Arg Asp 260 265 270 Val Leu Ala Ala Gly Asp Phe Trp Gly Gly Ala Gly Ser Val Ala Cys 275 280 285
34 1223001 Gin Glu Phe 工le Thr Gin Leu Gly Arg Asn Phe Gin Val lie Tyr Glu 290 295 300 Gin Ala Asn Ala His Gly Gin Lys Val Gin Ala Ala Gly Asn Asn Met 305 310 315 320 Ala Gin Thr Asp Ser Ala Val Gly Ser Ser Trp Ala Thr Ser Met Ser 325 330 335 Leu Leu Asp Ala His 工le Pro Gin Leu Val Ala Ser Gin Ser Ala Phe 340 345 350 Ala Ala Lys Ala Gly Leu Met Arg His Thr lie Gly Gin Ala Glu Gin 355 360 365 Ala Ala Met Ser Ala Gin Ala Phe His Gin Gly Glu Ser Ser Ala Ala 370 375 380
Phe Gin Ala Ala His Ala Arg Phe Val Ala Ala Ala Ala Lys Val Asn 385 390 395 400 Thr Leu Leu Asp Val Ala Gin Ala Asn Leu Gly Glu Ala Ala Gly Thr 405 410 415 Tyr Val Ala Ala Asp Ala Ala Ala Ala Ser Thr Tyr Thr Gly Phe Asp 420 425 430 lie <210> 15 <211> 2168 <212> DNA <213>人工序列 <220> <223>人工序列之說明:四-融合蛋白質 DPV — MTI — MSL - MTCC2 (命名為 Mtb71 f)
<220> <221> CDS <222> (1) . . (2133) <400> 15 cat atg cat cac cat cac cat cac gat ccc gtg gac gcg gtc att aac 48 His Met His His His His His His Asp Pro Val Asp Ala Val 工le Asn 15 10 15 acc acc tgc aat tac ggg cag gta gta get gcg etc aac gcg aeg gat 96 Thr Thr Cys Asn Tyr Gly Gin Val Val Ala Ala Leu Asn Ala Thr Asp 20 25 30 ccg ggg get gcc gca cag ttc aac gcc tea ccg gtg gcg cag tcc tat 144 Pro Gly Ala Ala Ala Gin Phe Asn Ala Ser Pro Val Ala Gin Ser Tyr 35 40 45 ttg ege aat ttc etc gcc gca ccg cca cct cag ege get gcc atg gcc 192 Leu Arg Asn Phe Leu Ala Ala Pro Pro Pro Gin Arg Ala Ala Met Ala 50 55 60 35 1223001 gcg caa ttg caa get gtg ccg ggg geg gca cag tac ate ggc ett gtc 24〇 Ala Gin Leu Gin Ala Val Pro Gly Ala Ala Gin Tyr lie Gly Leu Val 65 70 75 80 gag teg gtt gee ggc tee tgc aac aac tat gag etc atg aeg att aat 288 Glu Ser Val Ala Gly Ser Cys Asn Asn Tyr Glu Leu Met Thr 工le Asn 85 90 95 tac cag ttc ggg gac gtc gac get cat ggc gee atg ate ege get cag 336 Tyr Gin Phe Gly Asp Val Asp Ala His Gly Ala Met lie Arg Ala Gin 100 105 110 gcg gcg teg ett gag gcg gag cat cag gee ate gtt cgt gat gtg ttg 384 Ala Ala Ser Leu Glu Ala Glu His Gin Ala 工le Val Arg Asp Val Leu 115 120 125 gee gcg ggt gac ttt tgg ggc ggc gee ggt teg gtg get tgc cag gag 432
Ala Ala Gly Asp Phe Trp Gly Gly Ala Gly Ser Val Ala Cys Gin Glu 130 135 140 ttc att acc cag ttg ggc cgt aac ttc cag gtg ate tac gag cag gee 480 Phe 工le Thr Gin Leu Gly Arg Asn Phe Gin Val 工le Tyr Glu Gin Ala 145 " 150 155 160 aac gee cac ggg cag aag gtg cag get gee ggc aac aac atg gcg caa 528 Asn Ala His Gly Gin Lys Val Gin Ala Ala Gly Asn Asn Met Ala Gin 165 170 175 acc gac age gee gtc ggc tee age tgg gee act agt atg age ett ttg 576 Thr Asp Ser Ala Val Gly Ser Ser Trp Ala Thr Ser Met Ser Leu Leu 180 185 190 gat get cat ate cca cag ttg gtg gee tee cag teg gcg ttt gee gee 624 Asp Ala His lie Pro Gin Leu Val Ala Ser Gin Ser Ala Phe Ala Ala 195 200 205 aag gcg ggg ctg atg egg cac aeg ate ggt cag gee gag cag gcg gcg 672 Lys Ala Gly Leu Met Arg His Thr lie Gly Gin Ala Glu Gin Ala Ala
210 215 220 atg teg get cag gcg ttt cac cag ggg gag teg teg gcg gcg ttt cag 720 Met Ser Ala Gin Ala Phe His Gin Gly Glu Ser Ser Ala Ala Phe Gin 225 230 235 240 gee gee cat gee egg ttt gtg gcg gcg gee gee aaa gtc aac acc ttg 768 Ala Ala His Ala Arg Phe Val Ala Ala Ala Ala Lys Val Asn Thr Leu 245 250 255 ttg gat gtc gcg cag gcg aat ctg ggt gag gee gee ggt acc tat gtg 816 Leu Asp Val Ala Gin Ala Asn Leu Gly Glu Ala Ala Gly Thr Tyr Val 260 265 270 gee gee gat get gcg gee gcg teg acc tat acc ggg ttc gat ate atg 864 Ala Ala Asp Ala Ala Ala Ala Ser Thr Tyr Thr Gly Phe Asp 工le Met 275 280 285 gat ttc ggg ett tta cct ccg gaa gtg aat tea age ega atg tat tee 912 Asp Phe Gly Leu Leu Pro Pro Glu Val Asn Ser Ser Arg Met Tyr Ser 290 295 300 36 9601223001 ggt ccg ggg ccg gag teg atg eta gee gee geg gee gee tgg gac ggt Gly Pro Gly Pro Glu Ser Met Leu Ala Ala Ala Ala Ala Trp Asp Gly 3〇5 310 315 320 gtg gee geg gag ttg act tee gee geg gtc teg tat gga teg gtg gtg Val Ala Ala Glu Leu Thr Ser Ala Ala Val Ser Tyr Gly Ser Val Val 325 330 335 teg aeg ctg ate gtt gag ccg tgg atg ggg ccg geg geg gee geg atg Ser Thr Leu lie Val Glu Pro Trp Met Gly Pro Ala Ala Ala Ala Met 340 345 350 geg gee geg gca aeg ccg tat gtg ggg tgg ctg gee gee aeg geg geg Ala Ala Ala Ala Thr Pro Tyr Val Gly Trp Leu Ala Ala Thr Ala Ala 355 360 365 1008 1056 1104 ctg geg aag gag aeg gee aca cag geg agg gca geg geg gaa geg ttt Leu Ala Lys Glu Thr Ala Thr Gin Ala Arg Ala Ala Ala Glu Ala Phe 370 375 380 ggg aeg geg ttc geg atg aeg gtg cca cca tee etc gtc geg gee aac Gly Thr Ala Phe Ala Met Thr Val Pro Pro Ser Leu Val Ala Ala Asn 385 ' 390 395 400 ege age egg ttg atg teg ctg gtc geg geg aac att ctg ggg caa aac J Arg Ser Arg Leu Met Ser Leu Val Ala Ala Asn lie Leu Gly Gin Asn 405 410 415 agt geg geg ate geg get acc cag gee gag tat gee gaa atg tgg gee Ser Ala Ala lie Ala Ala Thr Gin Ala Glu Tyr Ala Glu Met Trp Ala 420 425 430 caa gac get gee gtg atg tac age tat gag ggg gca tet geg gee geg Gin Asp Ala Ala Val Met Tyr Ser Tyr Glu Gly Ala Ser Ala Ala Ala 435 440 445 teg geg ttg ccg ccg ttc act cca ccc gtg caa ggc acc ggc ccg gee Ser Ala Leu Pro Pro Phe Thr Pro Pro Val Gin Gly Thr Gly Pro Ala 450 455 460 ggg ccc geg gee gca gee geg geg acc caa gee gee ggt geg ggc gee Gly Pro Ala Ala Ala Ala Ala Ala Thr Gin Ala Ala Gly Ala Gly Ala 465 470 475 480 gtt geg gat gca cag geg aca ctg gee cag ctg ccc ccg ggg ate ctg Val Ala Asp Ala Gin Ala Thr Leu Ala Gin Leu Pro Pro Gly lie Leu 485 490 495 age gac att ctg tee gca ttg gee gee aac get gat ccg ctg aca teg Ser Asp lie Leu Ser Ala Leu Ala Ala Asn Ala Asp Pro Leu Thr Ser 500 505 510 gga ctg ttg ggg ate geg teg acc etc aac ccg caa gtc gga tee get Giy Leu Leu Gly 工le Ala Ser Thr Leu Asn Pro Gin Val Gly Ser Ala 515 520 525 ~ cag ccg ata gtg ate ccc acc ccg ata ggg gaa ttg gac gtg ate geg Gin Pro lie Val lie Pro Thr Pro 工le Gly Glu Leu Asp Val lie Ala 530 535 540 1152 1200 1248 1296 1344 1392 1440 1488 1536 1584 1632 37 1223001 etc tac att gca tee ate geg acc ggc age att geg etc geg ate aeg Leu Tyr 工le Ala Ser 工le Ala Thr Gly Ser 工le Ala Leu Ala lie Thr 545 550 555 560 aac aeg gee aga ccc tgg cac ate ggc eta tac ggg aac gee ggc ggg Asn Thr Ala Arg Pro Trp His 工le Gly Leu Tyr Gly Asn Ala Gly Gly 565 570 575 ctg gga ccg aeg cag ggc cat cca ctg agt teg geg acc gac gag ccg Leu Gly Pro Thr Gin Gly His Pro Leu Ser Ser Ala Thr Asp Glu Pro 580 585 590 gag ccg cac tgg ggc ccc ttc ggg ggc geg geg ccg gtg tee geg ggc Glu Pro His Trp Gly Pro Phe Gly Gly Ala Ala Pro Val Ser Ala Gly 595 600 605 gtc ggc cac gca gca tta gtc gga geg ttg teg gtg ccg cac age tgg Val Gly His Ala Ala Leu Val Gly Ala Leu Ser Val Pro His Ser Trp 610 615 620 acc aeg gee gee ccg gag ate cag etc gee gtt cag gca aca ccc acc Thr Thr Ala Ala Pro Glu lie Gin Leu Ala Val Gin Ala Thr Pro Thr 625 ' 630 635 640 ttc age tee age gee ggc gee gac ccg aeg gee eta aac ggg atg ccg Phe Ser Ser Ser Ala Gly Ala Asp Pro Thr Ala Leu Asn Gly Met Pro 645 650 655 gca ggc ctg etc age ggg atg get ttg geg age ctg gee gca ege ggc Ala Gly Leu Leu Ser Gly Met Ala Leu Ala Ser Leu Ala Ala Arg Gly 660 665 670 aeg aeg ggc ggt ggc ggc acc cgt age ggc acc age act gac ggc caa Thr Thr Gly Gly Gly Gly Thr Arg Ser Gly Thr Ser Thr Asp Gly Gin 675 680 685 gag gac ggc ege aaa ccc ccg gta gtt gtg att aga gag cag ccg ccg Glu Asp Gly Arg Lys Pro Pro Val Val Val 工le Arg Glu Gin Pro Pro 690 695 700 ccc gga aac ccc ccg egg taagatttct aaatccatca cactggcggc egetegag Pro Gly Asn Pro Pro Arg 705 710 1680 1728 1776 1824 1872
1920 1968 2016 2064 2112 2168
<210> 16 <211> 710 - <212> PRT <213>人工序列 <223〉人工序列之說明.四—融合蛋白質 DPV-MTI-MSL-MTCC2(4^&gMtb71f) <400> 16 His Met His His His His His His Asp Pro Val Asp Ala Val 工le Asn 1 5 10 15 Thr Thr Cys Asn Tyr Gly Gin Val Val Ala Ala Leu Asn Ala Thr Asp 20 25 30 Pro Gly Ala Ala Ala Gin Phe Asn Ala Ser Pro Val Ala Gin Ser Tyr 35 40 45 38 1223001 Leu Arg Asn Phe Leu Ala Ala Pro Pro Pro Gin Arg Ala Ala Met Ala 50 55 60 Ala Gin Leu Gin Ala Val Pro Gly Ala Ala Gin Tyr lie Gly Leu Val 65 70 75 80 Glu Ser Val Ala Gly Ser Cys Asn Asn Tyr Glu Leu Met Thr 工le Asn 85 90 95 Tyr Gin Phe Gly Asp Val Asp Ala His Gly Ala Met lie Arg Ala Gin 100 105 110 Ala Ala Ser Leu Glu Ala Glu His Gin Ala lie Val Arg Asp Val Leu 115 120 125 Ala Ala Gly Asp Phe Trp Gly Gly Ala Gly Ser Val Ala Cys Gin Glu 130 135 140
Phe 工le Thr Gin Leu Gly Arg Asn Phe Gin Val 工le Tyr Glu Gin Ala 145 150 155 160 Asn Ala His Gly Gin Lys Val Gin Ala Ala Gly Asn Asn Met Ala Gin 165 170 175 Thr Asp Ser Ala Val Gly Ser Ser Trp Ala Thr Ser Met Ser Leu Leu 180 185 190 Asp Ala His lie Pro Gin Leu Val Ala Ser Gin Ser Ala Phe Ala Ala 195 200 205 Lys Ala Gly Leu Met Arg His Thr lie Gly Gin Ala Glu Gin Ala Ala 210 215 220 Met Ser Ala Gin Ala Phe His Gin Gly Glu Ser Ser Ala Ala Phe Gin 225 230 235 240 Ala Ala His Ala Arg Phe Val Ala Ala Ala Ala Lys Val Asn Thr Leu 245 250 255 Leu Asp Val Ala Gin Ala Asn Leu Gly Glu Ala Ala Gly Thr Tyr Val 260 265 270 Ala Ala Asp Ala Ala Ala Ala Ser Thr Tyr Thr Gly Phe Asp lie Met 275 280 285 Asp Phe Gly Leu Leu Pro Pro Glu Val Asn Ser Ser Arg Met Tyr Ser 290 295 300 Gly Pro Gly Pro Glu Ser Met Leu Ala Ala Ala Ala Ala Trp Asp Gly 305 310 315 320 Val Ala Ala Glu Leu Thr Ser Ala Ala Val Ser Tyr Gly Ser Val Val 325 330 335 Ser Thr Leu 工le Val Glu Pro Trp Met Gly Pro Ala Ala Ala Ala Met 340 345 350 Ala Ala Ala Ala Thr Pro Tyr Val Gly Trp Leu Ala Ala Thr Ala Ala 355 360 365 39 1223001 Leu Ala Lys Glu Thr Ala Thr Gin Ala Arg Ala Ala Ala Glu Ala Phe 370 375 380 Gly Thr Ala Phe Ala Met Thr Val Pro Pro Ser Leu Val Ala Ala Asn 385 390 395 400 Arg Ser Arg Leu Met Ser Leu Val Ala Ala Asn lie Leu Gly Gin Asn 405 410 415 Ser Ala Ala lie Ala Ala Thr Gin Ala Glu Tyr Ala Glu Met Trp Ala 420 425 430 Gin Asp Ala Ala Val Met Tyr Ser Tyr Glu Gly Ala Ser Ala Ala Ala 435 440 445 Ser Ala Leu Pro Pro Phe Thr Pro Pro Val Gin Gly Thr Gly Pro Ala 450 455 460
Gly Pro Ala Ala Ala Ala Ala Ala Thr Gin Ala Ala Gly Ala Gly Ala 465 470 475 480 Val Ala Asp Ala Gin Thr Leu Ala Gin Leu Pro Pro Gly lie Leu 485 490 495 Ser Asp 工le Leu Ser Ala Leu Ala Ala Asn Ala Asp Pro Leu Thr Ser 500 505 510 Gly Leu Leu Gly lie Ala Ser Thr Leu Asn Pro Gin Val Gly Ser Ala 515 520 525 Gin Pro 工le Val 工le Pro Thr Pro 工le Gly Glu Leu Asp Val 工le Ala 530 535 540 Leu Tyr lie Ala Ser lie Ala Thr Gly Ser 工le Ala Leu Ala lie Thr 545 550 555 560 Asn Thr Ala Arg Pro Trp His lie Gly Leu Tyr Gly Asn Ala Gly Gly 565 570 575
Leu Gly Pro Thr Gin Gly His Pro Leu Ser Ser Ala Thr Asp Glu Pro 580 585 590 Glu Pro His Trp Gly Pro Phe Gly Gly Ala Ala Pro Val Ser Ala Gly 595 600 605 Val Gly His Ala Ala Leu Val Gly Ala Leu Ser Val Pro His Ser Trp 610 615 620 Thr Thr Ala Ala Pro Glu lie Gin Leu Ala Val Gin Ala Thr Pro Thr 625 630 635 640 Phe Ser Ser Ser Ala Gly Ala Asp Pro Thr Ala Leu Asn Gly Met Pro 645 650 655 Ala Gly Leu Leu Ser Gly Met Ala Leu Ala Ser Leu Ala Ala Arg Gly 660 665 670 Thr Thr Gly Gly Gly Gly Thr Arg Ser Gly Thr Ser Thr Asp Gly Gin 675 680 685 40 1223001 Glu Asp Gly Arg Lys Pro Pro Val Val Val 工le Arg Glu Gin Pro Pr〇 690 695 700 Pro Gly Asn Pro Pro Arg 705 710 <210> 17 <211> 921 <212> DNA <213>人工序列 <220> <223>人工序列之說明:三-融合蛋白質_ DPV-MTI —MSL (命名為 Mtb31f) <220>
<221> CDS <222> (1).·(900) <400> 17 cat atg cat cac cat cac cat cac gat ccc gtg gac gcg gtc att aac 48 His Met His His His His His His Asp Pro Val Asp Ala Val 工le Asn 15 10 15 acc acc tgc aat tac ggg cag gta gta get gcg etc aac gcg aeg gat 96 Thr Thr Cys Asn Tyr Gly Gin Val Val Ala Ala Leu Asn Ala Thr Asp 20 25 30 ccg ggg get gee gca cag ttc aac gee tea ccg gtg gcg cag tee tat 144 Pro Gly Ala Ala Ala Gin Phe Asn Ala Ser Pro Val Ala Gin Ser Tyr 35 40 45 ttg ege aat ttc etc gee gca ccg cca cct cag ege get gee atg gee 192 Leu Arg Asn Phe Leu Ala Ala Pro Pro Pro Gin Arg Ala Ala Met Ala 50 55 60 gcg caa ttg caa get gtg ccg ggg gcg gca cag tac ate ggc ett gtc 240
Ala Gin Leu Gin Ala Val Pro Gly Ala Ala Gin Tyr lie Gly Leu Val 65 70 75 80 gag teg gtt gee ggc tee tgc aac aac tat gag etc atg aeg att aat 288 Glu Ser Val Ala Gly Ser Cys Asn Asn Tyr Glu Leu Met Thr 工le Asn 85 90 95 tac cag ttc ggg gac gtc gac get cat ggc gee atg ate ege get cag 336 Tyr Gin Phe Gly Asp Val Asp Ala His Gly Ala Met 工le Arg Ala Gin 100 105 110 gcg gcg teg ett gag gcg gag cat cag gee ate gtt cgt gat gtg ttg 384 Ala Ala Ser Leu Glu Ala Glu His Gin Ala lie Val Arg Asp Val Leu 115 120 125 gee gcg ggt gac ttt tgg ggc ggc gee ggt teg gtg get tgc cag gag 432 Ala Ala Gly Asp Phe Trp Gly Gly Ala Gly Ser Val Ala Cys Gin Glu 130 135 140 ttc att acc cag ttg ggc cgt aac ttc cag gtg ate tac gag cag gee 480 Phe lie Thr Gin Leu Gly Arg Asn Phe Gin Val 工le Tyr Glu Gin Ala 145 150 155 160 41 1223001 aac gcc cac ggg cag aag gtg cag get gee ggc aac aac atg geg caa 528 Asn Ala His Gly Gin Lys Val Gin Ala Ala Gly Asn Asn Met Ala Gin 165 170 175 acc gac age gcc gtc ggc tee age tgg gcc act agt atg age ett ttg 576 Thr Asp Ser Ala Val Gly Ser Ser Trp Ala Thr Ser Met Ser Leu Leu 180 185 190 gat get cat ate cca cag ttg gtg gcc tee cag teg geg ttt gcc gcc 624 Asp Ala His lie Pro Gin Leu Val Ala Ser Gin Ser Ala Phe Ala Ala 195 200 205 aag geg ggg ctg atg egg cac aeg ate ggt cag gcc gag cag geg geg 672 Lys Ala Gly Leu Met Arg His Thr lie Gly Gin Ala Glu Gin Ala Ala 210 215 220 atg teg get cag geg ttt cac cag ggg gag teg teg geg geg ttt cag 720 Met Ser Ala Gin Ala Phe His Gin Gly Glu Ser Ser Ala Ala Phe Gin
225 230 235 240 gcc gcc cat gcc egg ttt gtg geg geg gcc gcc aaa gtc aac acc ttg 768 Ala Ala His Ala Arg Phe Val Ala Ala Ala Ala Lys Val Asn Thr Leu 245 250 255 ttg gat gtc geg cag geg aat ctg ggt gag gcc gcc ggt acc tat gtg 816 Leu Asp Val Ala Gin Ala Asn Leu Gly Glu Ala Ala Gly Thr Tyr Val 260 265 270 gee gcc gat get geg gcc geg teg acc tat acc ggg ttc gat ate cat 864 Ala Ala Asp Ala Ala Ala Ala Ser Thr Tyr Thr Gly Phe Asp lie His 275 280 285 cac act ggc ggc ege teg age aga tee ggc tgc taacaaagcc egaaaggaag 917 His Thr Gly Gly Arg Ser Ser Arg Ser Gly Cys 290 295 ctga 921
<210> 18 <211> 299 <212> PRT <213>人工序列 <223〉人工序列之說明:三—融合蛋白質 0卩乂-]\41[1-1^[(命名為]^出31〇 <400> 18 His Met His His His His His His Asp Pro Val Asp Ala Val 工le Asn 15 10 15 Thr Thr Cys Asn Tyr Gly Gin Val Val Ala Ala Leu Asn Ala Thr Asp 20 25 30 Pro Gly Ala Ala Ala Gin Phe Asn Ala Ser Pro Val Ala Gin Ser Tyr 35 40 45 Leu Arg Asn Phe Leu Ala Ala Pro Pro Pro Gin Arg Ala Ala Met Ala 50 55 60 Ala Gin Leu Gin Ala Val Pro Gly Ala Ala Gin Tyr lie Gly Leu Val 65 70 75 80 42 1223001 Glu Ser Val Ala Gly Ser Cys Asn Asn Tyr Glu Leu Met Thr lie Asn 85 90 95 Tyr Gin Phe Gly Asp Val Asp Ala His Gly Ala Met lie Arg Ala Gin 100 105 110 Ala Ala Ser Leu Glu Ala Glu His Gin Ala 工le Val Arg Asp Val Leu 115 120 125 Ala Ala Gly Asp Phe Trp Gly Gly Ala Gly Ser Val Ala Cys Gin Glu 130 135 140 Phe lie Thr Gin Leu Gly Arg Asn Phe Gin Val lie Tyr Glu Gin Ala 145 150 155 160 Asn Ala His Gly Gin Lys Val Gin Ala Ala Gly Asn Asn Met Ala Gin 165 170 175
Thr Asp Ser Ala Val Gly Ser Ser Trp Ala Thr Ser Met Ser Leu Leu 180 185 190 Asp Ala His lie Pro Gin Leu Val Ala Ser Gin Ser Ala Phe Ala Ala 195 " 200 205 Lys Ala Gly Leu Met Arg His Thr lie Gly Gin Ala Glu Gin Ala Ala 210 215 220 Met Ser Ala Gin Ala Phe His Gin Gly Glu Ser Ser Ala Ala Phe Gin 225 230 235 240 Ala Ala His Ala Arg Phe Val Ala Ala Ala Ala Lys Val Asn Thr Leu 245 250 255 Leu Asp Val Ala Gin Ala Asn Leu Gly Glu Ala Ala Gly Thr Tyr Val 260 265 270 Ala Ala Asp Ala Ala Ala Ala Ser Thr Tyr Thr Gly Phe Asp lie His 275 280 285
His Thr Gly Gly Arg Ser Ser Arg Ser Gly Cys 290 295 <21〇> 19 <211> 1801 <212> DNA <213>人工序列 <220> <223>人工序列之說明··三—融合蛋白質 TbH9-DPV-MTI(命名為 Mtb61f) <220> <221> CDS <222> ⑴,,(1800) <400> 19 cat atg cat cac cat cac cat cac atg gtg gat ttc ggg gcg tta cca 48 His Met His His His His His His Met Val Asp Phe Gly Ala Leu Pro 15 10 15 43 961223001 ccg gag ate aac tee geg agg atg tac gee ggc ccg ggt teg gee teg Pro Glu 工le Asn Ser Ala Arg Met Tyr Ala Gly Pro Gly Ser Ala Ser 20 25 30 ctg gtg gee geg get cag atg tgg gac age gtg geg agt gac ctg ttt Leu Val Ala Ala Ala Gin Met Trp Asp Ser Val Ala Ser Asp Leu Phe 35 40 45 teg gee geg teg geg ttt cag teg gtg gtc tgg ggt ctg aeg gtg ggg Ser Ala Ala Ser Ala Phe Gin Ser Val Val Trp Gly Leu Thr Val Gly 50 55 60 teg tgg ata ggt teg teg geg ggt ctg atg gtg geg geg gee teg ccg Ser Trp 工le Gly Ser Ser Ala Gly Leu Met Val Ala Ala Ala Ser Pro 65 70 75 80 tat gtg geg tgg atg age gtc acc geg ggg cag gee gag ctg acc gee Tyr Val Ala Trp Met Ser Val Thr Ala Gly Gin Ala Glu Leu Thr Ala 85 90 95 gee cag gtc egg gtt get geg geg gee tac gag aeg geg tat ggg ctg Ala Gin Val Arg Val Ala Ala Ala Ala Tyr Glu Thr Ala Tyr Gly Leu 100 ' 105 110 aeg gtg ccc ccg ccg gtg ate gee gag aac cgt get gaa ctg atg att Thr Val Pro Pro Pro Val 工le Ala Glu Asn Arg Ala Glu Leu Met lie 115 120 125 ctg ata geg acc aac etc ttg ggg caa aac acc ccg geg ate geg gtc Leu lie Ala Thr Asn Leu Leu Gly Gin Asn Thr Pro Ala lie Ala Val 130 135 140 aac gag gee gaa tac ggc gag atg tgg gee caa gac gee gee geg atg Asn Glu Ala Glu Tyr Gly Glu Met Trp Ala Gin Asp Ala Ala Ala Met 145 150 155 160 ttt ggc tac gee geg geg aeg geg aeg geg aeg geg aeg ttg ctg ccg Phe Gly Tyr Ala Ala Ala Thr Ala Thr Ala Thr Ala Thr Leu Leu Pro 165 170 175 ttc gag gag geg ccg gag atg acc age geg ggt ggg etc etc gag cag Phe Glu Glu Ala Pro Glu Met Thr Ser Ala Gly Gly Leu Leu Glu Gin 180 185 190 gee gee geg gtc gag gag gee tee gac acc gee geg geg aac cag ttg Ala Ala Ala Val Glu Glu Ala Ser Asp Thr Ala Ala Ala Asn Gin Leu 195 200 205 atg aac aat gtg ccc cag geg ctg caa cag ctg gee cag ccc aeg cag Met Asn Asn Val Pro Gin Ala Leu Gin Gin Leu Ala Gin Pro Thr Gin 210 215 220 ggc acc aeg cct tet tee aag ctg ggt ggc ctg tgg aag aeg gtc teg Gly Thr Thr Pro Ser Ser Lys Leu Gly Gly Leu Trp Lys Thr Val Ser 225 230 235 240 ccg cat egg teg ccg ate age aac atg gtg teg atg gee aac aac cac Pro His Arg Ser Pro lie Ser Asn Met Val Ser Met Ala Asn Asn His 245 250 255 144 192 240 288 336 384 432 480 528 5Ί6 624 672 720 44 768 8161223001 atg teg atg acc aac teg ggt gtg teg atg acc aac acc ttg age teg Met Ser Met Thr Asn Ser Gly Val Ser Met Thr Asn Thr Leu Ser Ser 260 265 270 atg ttg aag ggc ttt get ccg geg geg gee gee cag gee gtg caa acc Met Leu Lys Gly Phe Ala Pro Ala Ala Ala Ala Gin Ala Val Gin Thr 275 280 285 geg geg caa aac ggg gtc egg geg atg age teg ctg ggc age teg ctg Ala Ala Gin Asn Gly Val Arg Ala Met Ser Ser Leu Gly Ser Ser Leu 290 295 300 ggt tet teg ggt ctg ggc ggt ggg gtg gee gee aac ttg ggt egg geg Gly Ser Ser Gly Leu Gly Gly Gly Val Ala Ala Asn Leu Gly Arg Ala 305 310 315 320 gee teg gtc ggt teg ttg teg gtg ccg cag gee tgg gee geg gee aac Ala Ser Val Gly Ser Leu Ser Val Pro Gin Ala Trp Ala Ala Ala Asn 325 330 335 cag gca gtc acc ccg geg geg egg geg ctg ccg ctg acc age ctg acc Gin Ala Val Thr Pro Ala Ala Arg Ala Leu Pro Leu Thr Ser Leu Thr 340 ' 345 350 age gee geg gaa aga ggg ccc ggg cag atg ctg ggc ggg ctg ccg gtg Ser Ala Ala Glu Arg Gly Pro Gly Gin Met Leu Gly Gly Leu Pro Val 355 360 365 ggg cag atg ggc gee agg gee ggt ggt ggg etc agt ggt gtg ctg cgt Gly Gin Met Gly Ala Arg Ala Gly Gly Gly Leu Ser Gly Val Leu Arg 370 375 380 gtt ccg ccg ega ccc tat gtg atg ccg cat tet ccg gca gee ggc aag Val Pro Pro Arg Pro Tyr Val Met Pro His Ser Pro Ala Ala Gly Lys 385 390 395 400 ett gat ccc gtg gac geg gtc att aac acc acc tgc aat tac ggg cag Leu Asp Pro Val Asp Ala Val lie Asn Thr Thr Cys Asn Tyr Gly Gin 405 410 415 gta gta get geg etc aac geg aeg gat ccg ggg get gee gca cag ttc Val Val Ala Ala Leu Asn Ala Thr Asp Pro Gly Ala Ala Ala Gin Phe 420 425 430 aac gee tea ccg gtg geg cag tee tat ttg ege aat ttc etc gee gca Asn Ala Ser Pro Val Ala Gin Ser Tyr Leu Arg Asn Phe Leu Ala Ala 435 440 445 ccg cca cct cag ege get gee atg gee geg caa ttg caa get gtg ccg Pro Pro Pro Gin Arg Ala Ala Met Ala Ala Gin Leu Gin Ala Val Pro 450 455 460 ggg geg gca cag tac ate ggc ett gtc gag teg gtt gee ggc tee tgc Gly Ala Ala Gin Tyr lie Gly Leu Val Glu Ser Val _Ala Gly Ser Cys 465 470 475 480 aac aac tat gag etc atg aeg att aat tac cag ttc ggg gac gtc gac Asn Asn Tyr Glu Leu Met Thr lie Asn Tyr Gin Phe Gly Asp Val Asp 485 490 495 864 912 960 1008 1056 1104 1152 1200 1248 1296 1344 1392 1440
45 1488 1223001 get cat ggc gee atg ate ege get cag geg geg teg ett gag geg gag 1536 Ala His Gly Ala Met lie Arg Ala Gin Ala Ala Ser Leu Glu Ala Glu 500 505 510 cat cag gee ate gtt cgt gat gtg ttg gee geg ggt gac ttt tgg ggc 1584 His Gin Ala lie Val Arg Asp Val Leu Ala Ala Gly Asp Phe Trp Gly 515 520 525 ggc gee ggt teg gtg get tgc cag gag ttc att acc cag ttg ggc cgt 1632 Gly Ala Gly Ser Val Ala Cys Gin Glu Phe lie Thr Gin Leu Gly Arg 530 535 540 aac ttc cag gtg ate tac gag cag gee aac gee cac ggg cag aag gtg 1680 Asn Phe Gin Val 工le Tyr Glu Gin Ala Asn Ala His Gly Gin Lys Val 545 550 555 560 cag get gee ggc aac aac atg geg caa acc gac age gee gtc ggc tee 1728 Gin Ala Ala Gly Asn Asn Met Ala Gin Thr Asp Ser Ala Val Gly Ser 565 570 575
age tgg gee act agt aac ggc ege cag tgt get gga att ctg cag ata 1776 Ser Trp Ala Thr Ser Asn Gly Arg Gin Cys Ala Gly lie Leu Gin lie 580 585 590 tee ate aca ctg geg gee get ega g 1801 Ser lie Thr Leu Ala Ala Ala Arg 595 600 <210> 20 <211> 600 <212> PRT <213>人工序列 <223>人工序列之說明:三-融合蛋白質 TbH9-DPV-MTI(命名為 Mtb61f) <400> 20 His Met His His His His His His Met Val Asp Phe Gly Ala Leu Pro 15 10 15
Pro Glu lie Asn Ser Ala Arg Met Tyr Ala Gly Pro Gly Ser Ala Ser 20 25 30 Leu Val Ala Ala Ala ain Met Trp Asp Ser Val Ala Ser Asp Leu Phe 35 40 45 Ser Ala Ala Ser Ala Phe Gin Ser Val Val Trp Gly Leu Thr Val Gly 50 55 60 Ser Trp 工le Gly Ser Ser Ala Gly Leu Met Val Ala Ala Ala Ser Pro 65 70 75 80 Tyr Val Ala Trp Met Ser Val Thr Ala Gly Gin Ala Glu Leu Thr Ala 85 90 95 Ala Gin Val Arg Val Ala Ala Ala Ala Tyr Glu Thr Ala Tyr Gly Leu 100 105 110 Thr Val Pro Pro Pro Val 工le Ala Glu Asn Arg Ala Glu Leu Met lie 115 120 125 46 Leu 工le Ala Thr Asn Leu Leu Gly Gin Asn Thr Pro Ala 工le Ala Val 130 135 140 Asn Glu Ala Glu Tyr Gly Glu Met Trp Ala Gin Asp Ala Ala Ala Met 145 150 155 160 Phe Gly Tyr Ala Ala Ala Thr Ala Thr Ala Thr Ala Thr Leu Leu Pro 165 170 175 Phe Glu Glu Ala Pro Glu Met Thr Ser Ala Gly Gly Leu Leu Glu Gin 180 185 190 Ala Ala Ala Val Glu Glu Ala Ser Asp Thr Ala Ala Ala Asn Gin Leu 195 200 205 Met Asn Asn Val Pro Gin Ala Leu Gin Gin Leu Ala Gin Pro Thr Gin 210 215 220 Gly Thr Thr Pro Ser Ser Lys Leu Gly Gly Leu Trp Lys Thr Val Ser 225 230 235 240 Pro His Arg Ser Pro lie Ser Asn Met Val Ser Met Ala Asn Asn His 245 250 255 Met Ser Met Thr Asn Ser Gly Val Ser Met Thr Asn Thr Leu Ser Ser 260 265 270 Met Leu Lys Gly Phe Ala Pro Ala Ala Ala Ala Gin Ala Val Gin Thr 275 280 285 Ala Ala Gin Asn Gly Val Arg Ala Met Ser Ser Leu Gly Ser Ser Leu 290 295 300 Gly Ser Ser Gly Leu Gly Gly Gly Val Ala Ala Asn Leu Gly Arg Ala 305 310 315 320 Ala Ser Val Gly Ser Leu Ser Val Pro Gin Ala Trp Ala Ala Ala Asn 325 330 335 Gin Ala Val Thr Pro Ala Ala Arg Ala Leu Pro Leu Thr Ser Leu Thr 340 345 350 Ser Ala Ala Glu Arg Gly Pro Gly Gin Met Leu Gly Gly Leu Pro Val 355 360 365 Gly Gin Met Gly Ala Arg Ala Gly Gly Gly Leu Ser Gly Val Leu Arg 370 375 380 Val Pro Pro Arg Pro Tyr Val Met Pro His Ser Pro Ala Ala Gly Lys 385 390 395 400 Leu Asp Pro Val Asp Ala Val 工le Asn Thr Thr Cys Asn Tyr Gly Gin 405 410 415 Val Val Ala Ala Leu Asn Ala Thr Asp Pro Gly Ala Ala Ala Gin Phe 420 425 430 Asn Ala Ser Pro Val Ala Gin Ser Tyr Leu Arg Asn Phe Leu Ala Ala 435 440 445 1223001 Pro Pro Pro Gin Arg Ala Ala Met Ala Ala Gin Leu Gin Ala Val Pro 450 455 460 Gly Ala Ala Gin Tyr lie Gly Leu Val Glu Ser Val Ala Gly Ser Cys 465 470 475 480 Asn Asn Tyr Glu Leu Met Thr lie Asn Tyr Gin Phe Gly Asp Val Asp 485 490 495 Ala His Gly Ala Met lie Arg Ala Gin Ala Ala Ser Leu Glu Ala Glu 500 505 510 His Gin Ala 工le Val Arg Asp Val Leu Ala Ala Gly Asp Phe Trp Gly 515 520 525 Gly Ala Gly Ser Val Ala Cys Gin Glu Phe lie Thr Gin Leu Gly Arg 530 535 540
Asn Phe Gin Val lie Tyr Glu Gin Ala Asn Ala His Gly Gin Lys Val 545 550 555 560 Gin Ala Ala Gly Asn Asn Met Ala Gin Thr Asp Ser Ala Val Gly Ser 565 570 575 Ser Trp Ala Thr Ser Asn Gly Arg Gin Cys Ala Gly lie Leu Gin lie 580 585 590 Ser lie Thr Leu Ala Ala Ala Arg 595 600 <210> 21 <211> 1104 <212> DNA <213>人工序列 <220>
<223>人工序列之說明··三—融合蛋白質 Erdl4-DPV-MTI(命名為 Mtb36f) <220> <221> CDS <222> (1) . . (1104) <400> 21 cat atg cat cac cat cac cat cac atg gcc acc acc ctt ccc gtt cag 48 His Met His His His His His His Met Ala Thr Thr Leu Pro Val Gin 1 5 10 15 cgc cac ccg egg tcc etc ttc ccc gag ttt tet gag ctg ttc geg gcc 96 Arg His Pro Arg Ser Leu Phe Pro Glu Phe Ser Glu Leu Phe Ala Ala 20 25 30 ttc ccg tea ttc gcc gga etc egg ccc acc ttc gac acc egg ttg atg 144 Phe Pro Ser Phe Ala Gly Leu Arg Pro Thr Phe Asp Thr Arg Leu Met 35 40 45 egg ctg gaa gac gag atg aaa gag ggg cgc tac gag gta cgc geg gag 192 Arg Leu Glu Asp Glu Met Lys Glu Gly Arg Tyr Glu Val Arg Ala Glu 50 55 60 48 1223001 ctt ccc ggg gtc gac ccc gac Leu Pro Gly Val Asp Pro Asp 65 70 ggt cag ctg acc ate aag gee Gly Gin Leu Thr lie Lys Ala 85 ggt ege teg gaa ttc geg tac Gly Arg Ser Glu Phe Ala Tyr 100 ccg gta ggt get gac gag gac Pro Val Gly Ala Asp Glu Asp 115 att ctt act gtg teg gtg geg lie Leu Thr Val Ser Val Ala 130 135 cac att cag ate egg tee acc His 工le Gin lie Arg Ser Thr 145 · 150 att aac acc acc tgc aat tac 工le Asn Thr Thr Cys Asn Tyr 165 aeg gat ccg ggg get gee gca Thr Asp Pro Gly Ala Ala Ala 180 tee tat ttg ege aat ttc etc Ser Tyr Leu Arg Asn Phe Leu 195 atg gee geg caa ttg caa get Met Ala Ala Gin Leu Gin Ala 210 215 ctt gtc gag teg gtt gee ggc Leu Val Glu Ser Val Ala Gly 225 230 att aat tac cag ttc ggg gac 工le Asn Tyr Gin Phe Gly Asp 245 get cag geg geg teg ctt gag Ala Gin Ala Ala Ser Leu Glu 260 gtg ttg gee geg ggt gac ttt Val Leu Ala Ala Gly Asp Phe 275 cag gag ttc att acc cag ttg Gin Glu Phe 工le Thr Gin Leu 290 295 aag gac gtc gac att atg gtc Lys Asp Val Asp lie Met Val 75 gag ege acc gag cag aag gac Glu Arg Thr Glu Gin Lys Asp 90 ggt tee ttc gtt ege aeg gtg Gly Ser Phe Val Arg Thr Val 105 110 gac att aag gee acc tac gac Asp lie Lys Ala Thr Tyr Asp 120 125 gtt teg gaa ggg aag cca acc Val Ser Glu Gly Lys Pro Thr 140 aac aag ctt gat ccc gtg gac Asn Lys Leu Asp Pro Val Asp 155 ggg cag gta gta get geg etc Gly Gin Val Val Ala Ala Leu 170 cag ttc aac gee tea ccg gtg Gin Phe Asn Ala Ser Pro Val 185 190 gee gca ccg cca cct cag ege Ala Ala Pro Pro Pro Gin Arg 200 205 gtg ccg ggg geg gca cag tac Val Pro Gly Ala Ala Gin Tyr 220 tee tgc aac aac tat gag etc Ser Cys Asn Asn Tyr Glu Leu 235 gtc gac get cat ggc gee atg Val Asp Ala His Gly Ala Met 250 geg gag cat cag gee ate gtt Ala Glu His Gin Ala 工le Val 265 270 tgg ggc ggc gee ggt teg gtg Trp Gly Gly Ala Gly Ser Val 280 285 ggc cgt aac ttc cag gtg ate Gly Arg Asn Phe Gin Val lie 300 ege gat 240 Arg Asp 80 ttc gac 288 Phe Asp 95 teg ctg 336 Ser Leu aag ggc 384 Lys Gly gaa aag 432 Glu Lys geg gtc 480 Ala Val 160 aac geg 528 Asn Ala 175 geg cag 576 Ala Gin get gee 624 Ala Ala ate ggc 672 lie Gly atg aeg 720 Met Thr 240 ate ege 768 工le Arg 255 cgt gat 816 Arg Asp get tgc 864 Ala Cys tac gag 912 Tyr Glu
49 960 1223001 cag gcc aac gcc cac ggg cag aag gtg cag get gee ggc aac aac atg Gin Ala Asn Ala His Gly Gin Lys Val Gin Ala Ala Gly Asn Asn Met 305 310 315 320 geg caa acc gac age gcc gtc ggc tee age tgg gcc act agt aac ggc Ala Gin Thr Asp Ser Ala Val Gly Ser Ser Trp Ala Thr Ser Asn Gly 325 330 335 ege cag tgt get gga att ctg cag ata tee ate aca ctg geg gcc get Arg Gin Cys Ala Gly lie Leu Gin lie Ser 工le Thr Leu Ala Ala Ala 340 345 350 ega gca gat ccg get get aac aaa gcc ega aag gaa get gag ttg get Arg Ala Asp Pro Ala Ala Asn Lys Ala Arg Lys Glu Ala Glu Leu Ala 355 360 365 1008 1056 1104 <210> 22 <211> 368 <212> PRT <213 >人工序列 <223>人工序列之說明:三-融合蛋白質 Erdl4-DPV-MTI(命名為 Mtb36f) <400> 22 His Met His His His His His His Met Ala Thr Thr Leu Pro Val Gin 15 10 15 Arg His Pro Arg Ser Leu Phe Pro Glu Phe Ser Glu Leu Phe Ala Ala 20 25 30 Phe Pro Ser Phe Ala Gly Leu Arg Pro Thr Phe Asp Thr Arg Leu Met 35 40 45 Arg Leu Glu Asp Glu Met Lys Glu Gly Arg Tyr Glu Val Arg Ala Glu 50 55 60 Leu Pro Gly Val Asp Pro Asp Lys Asp Val Asp lie Met Val Arg Asp 65 70 75 80 Gly Gin Leu Thr lie Lys Ala Glu Arg Thr Glu Gin Lys Asp Phe Asp 85 90 95 Gly Arg Ser Glu Phe Ala Tyr Gly Ser Phe Val Arg Thr Val Ser Leu 100 105 110 Pro Val Gly Ala Asp Glu Asp Asp lie Lys Ala Thr Tyr Asp Lys Gly 115 120 125 工le Leu Thr Val Ser Val Ala Val S^r Glu Gly Lys Pro Thr Glu Lys 130 135 140 His lie Gin lie Arg Ser Thr Asn Lys Leu Asp Pro Val Asp Ala Val 145 150 155 160 工le Asn Thr Thr Cys Asn Tyr Gly Gin Val Val Ala Ala Leu Asn Ala 165 170 175 Thr Asp Pro Gly Ala Ala Ala Gin Phe Asn Ala Ser Pro Val Ala Gin 180 185 190
50 1223001 Ser Tyr Leu Arg Asn Phe Leu Ala Ala Pro Pro Pro Gin Arg Ala Ala 195 200 205 Met Ala Ala Gin Leu Gin Ala Val Pro Gly Ala Ala Gin Tyr 工le Gly 210 215 220 Leu Val Glu Ser Val Ala Gly Ser Cys Asn Asn Tyr Glu Leu Met Thr 225 230 235 240 lie Asn Tyr Gin Phe Gly Asp Val Asp Ala His Gly Ala Met lie Arg 245 250 255 Ala Gin Ala Ala Ser Leu Glu Ala Glu His Gin Ala 工le Val Arg Asp 260 265 270 Val Leu Ala Ala Gly Asp Phe Trp Gly Gly Ala Gly Ser Val Ala Cys 275 280 285
Gin Glu Phe lie Thr Gin Leu Gly Arg Asn Phe Gin Val lie Tyr Glu 290 295 300 Gin Ala Asn Ala His Gly Gin Lys Val Gin Ala Ala Gly Asn Asn Met 305 ' 310 315 320 Ala Gin Thr Asp Ser Ala Val Gly Ser Ser Trp Ala Thr Ser Asn Gly 325 330 335 Arg Gin Cys Ala Gly lie Leu Gin lie Ser lie Thr Leu Ala Ala Ala 340 345 350 Arg Ala Asp Pro Ala Ala Asn Lys Ala Arg Lys Glu Ala Glu Leu Ala 355 360 365 <210> 23 <211> 1797 <212> DNA <213 >人工序列
<220> . <223>人工序列之說明:二-融合蛋白皙 TbH9-Ra35(命名為 Mtb59f) ^ <220> <221> CDS <222> (1)…(1791) <400> 23 cat atg cat cac cat cac cat cac atg gtg gat ttc ggg gcg tta cca 48 His Met His His His His His His Met Val Asp Phe Gly Ala Leu Pro 1 5 10 15 ccg gag ate aac tcc gcg agg atg tac gcc ggc ccg ggt teg gcc teg 96 Pro Glu 工le Asn Ser Ala Arg Met Tyr Ala Gly Pro Gly Ser Ala Ser 20 25 30 ctg gtg gcc gcg get cag atg tgg gac age gtg gcg agt gac ctg ttt 144 Leu Val Ala Ala Ala Gin Met Trp Asp Ser Val Ala Ser Asp Leu Phe 35 40 45 51 1223001 teg gee geg teg geg ttt cag teg gtg gtc tgg ggt ctg aeg gtg ggg 192 Ser Ala Ala Ser Ala Phe Gin Ser Val Val Trp Gly Leu Thr Val Gly 50 55 60 teg tgg ata ggt teg teg geg ggt ctg atg gtg geg geg gee teg ccg 240 Ser Trp lie Gly Ser Ser Ala Gly Leu Met Val Ala Ala Ala Ser Pro 65 70 75 80 tat gtg geg tgg atg age gtc acc geg ggg cag gee gag ctg acc gee 288 Tyr Val Ala Trp Met Ser Val Thr Ala Gly Gin Ala Glu Leu Thr Ala 85 90 95 gee cag gtc egg gtt get geg geg gee tac gag aeg geg tat ggg ctg 336 Ala Gin Val Arg Val Ala Ala Ala Ala Tyr Glu Thr Ala Tyr Gly Leu 100 105 110 ac9 gtg ccc ccg ccg gtg ate gee gag aac cgt get gaa ctg atg att 384 Thr Val Pro Pro Pro Val lie Ala Glu Asn Arg Ala Glu Leu Met lie
115 120 125 ctg ata geg acc aac etc ttg ggg caa aac acc ccg geg ate geg gtc 432 Leu 工le Ala Thr Asn Leu Leu Gly Gin Asn Thr Pro Ala lie Ala Val 130 ' 135 140 aac gag gee gaa tac ggc gag atg tgg gee caa gac gee gee geg atg 480 Asn Glu Ala Glu Tyr Gly Glu Met Trp Ala Gin Asp Ala Ala Ala Met 145 150 155 160 ttt ggc tac gee geg geg aeg geg aeg geg aeg geg aeg ttg ctg ccg 528 Phe Gly Tyr Ala Ala Ala Thr Ala Thr Ala Thr Ala Thr Leu Leu Pro 165 170 175 ttc gag gag geg ccg gag atg acc age geg ggt ggg etc etc gag cag 576 Phe Glu Glu Ala Pro Glu Met Thr Ser Ala Gly Gly Leu Leu Glu Gin 180 185 190 gee gee geg gtc gag gag gee tee gac acc gee geg geg aac cag ttg 624 Ala Ala Ala Val Glu Glu Ala Ser Asp Thr Ala Ala Ala Asn Gin Leu
195 200 205 atg aac aat gtg ccc cag geg ctg caa cag ctg gee cag ccc aeg cag 672 Met Asn Asn Val Pro Gin Ala Leu Gin Gin Leu Ala Gin Pro Thr Gin 210 215 220 ggc acc aeg cct tet tee aag ctg ggt ggc ctg tgg aag aeg gtc teg 720 Gly Thr Thr Pro Ser Ser Lys Leu Gly Gly Leu Trp Lys Thr Val Ser 225 230 235 240 ccg cat egg teg ccg ate age aac atg gtg teg atg gee aac aac cac 768 Pro His Arg Ser Pro lie Ser Asn Met Val Ser Met Ala Asn Asn His 245 250 255 atg teg atg acc aac teg ggt gtg teg atg acc aac acc ttg age teg 816 Met Ser Met Thr Asn Ser Gly Val Ser Met Thr Asn Thr Leu Ser Ser 260 265 270 atg ttg aag ggc ttt get ccg geg geg gee gee cag gee gtg caa acc 864 Met Leu Lys Gly Phe Ala Pro Ala Ala Ala Ala Gin Ala Val Gin Thr 275 280 285 52 9121223001 gcg gcg caa aac ggg gtc egg geg atg age teg ctg ggc age teg ctg Ala Ala Gin Asn Gly Val Arg Ala Met Ser Ser Leu Gly Ser Ser Leu 290 295 300 ggt tet teg ggt ctg ggc ggt ggg gtg gee gee aac ttg ggt egg gcg Gly Ser Ser Gly Leu Gly Gly Gly Val Ala Ala Asn Leu Gly Arg Ala 305 310 315 320 gee teg gtc ggt teg ttg teg gtg ccg cag gee tgg gee gcg gee aac Ala Ser Val Gly Ser Leu Ser Val Pro Gin Ala Trp Ala Ala Ala Asn 325 330 335 cag gca gtc acc ccg gcg gcg egg gcg ctg ccg ctg acc age ctg acc Gin Ala Val Thr Pro Ala Ala Arg Ala Leu Pro Leu Thr Ser Leu Thr 340 345 350 age gee gcg gaa aga ggg ccc ggg cag atg ctg ggc ggg ctg ccg gtg Ser Ala Ala Glu Arg Gly Pro Gly Gin Met Leu Gly Gly Leu Pro Val 355 360 365 ggg cag atg ggc gee agg gee ggt ggt ggg etc agt ggt gtg ctg cgt Gly Gin Met Gly Ala Arg Ala Gly Gly Gly Leu Ser Gly Val Leu Arg 370 " 375 380 gtt ccg ccg ega ccc tat gtg atg ccg cat tet ccg gca gee ggc gat Val Pro Pro Arg Pro Tyr Val Met Pro His Ser Pro Ala Ala Gly Asp 385 390 395 400 ate gee ccg ccg gee ttg teg cag gac egg ttc gee gac ttc ccc gcg lie Ala Pro Pro Ala Leu Ser Gin Asp Arg Phe Ala Asp Phe Pro Ala 405 410 415 ctg ccc etc gac ccg tee gcg atg gtc gee caa gtg ggg cca cag gtg Leu Pro Leu Asp Pro Ser Ala Met Val Ala Gin Val Gly Pro Gin Val 420 425 430 gtc aac ate aac acc aaa ctg ggc tac aac aac gee gtg ggc gee ggg Val Asn lie Asn Thr Lys Leu Gly Tyr Asn Asn Ala Val Gly Ala Gly 435 440 445 acc ggc ate gtc ate gat ccc aac ggt gtc gtg ctg acc aac aac cac Thr Gly lie Val 工le Asp Pro Asn Gly Val Val Leu Thr Asn Asn His 450 455 460 gtg ate gcg ggc gee acc gac ate aat gcg ttc age gtc ggc tee ggc Val 工le Ala Gly Ala Thr Asp 工le Asn Ala Phe Ser Val Gly Ser Gly 465 470 475 480 caa acc tac ggc gtc gat gtg gtc ggg tat gac ege acc cag gat gtc Gin Thr Tyr Gly Val Asp Val Val Gly Tyr Asp Arg Thr Gin Asp Val 485 490 495 gcg gtg ctg cag ctg ege ggt gee ggt ggc ctg ccg teg gcg gcg ate Ala Val Leu Gin Leu Arg Gly Ala Gly Gly Leu Pro Ser Ala Ala lie 500 505 510 ggt ggc ggc gtc gcg gtt ggt gag ccc gtc gtc gcg atg ggc aac age Gly Gly Gly Val Ala Val Gly Glu Pro Val Val Ala Met Gly Asn Ser 515 520 525 960 1008 1056 1104
1152 1200 1248 1296 1344 1392 1440 1488 1536 1584
53 1223001 ggt 999- cag ggc gga acg ccc cgt gcg gtg cct ggc agg gtg gtc gcg Gly Gly Gin Gly Gly Thr Pro Arg Ala Val Pro Gly Arg Val Val Ala 530 535 540 etc ggc caa acc gtg cag gcg teg gat teg ctg acc ggt gee gaa gag Leu Gly Gin Thr Val Gin Ala Ser Asp Ser Leu Thr Gly Ala Glu Glu 545 550 555 560 aca ttg aac ggg ttg ate cag ttc gat gee gcg ate cag ccc ggt gat Thr Leu Asn Gly Leu lie Gin Phe Asp Ala Ala lie Gin Pro Gly Asp 565 570 575 teg ggc ggg ccc gtc gtc aac ggc eta gga cag gtg gtc ggt atg aac Ser Gly Gly Pro Val Val Asn Gly Leu Gly Gin Val Val Gly Met Asn 580 585 590 aeg gee gcg tee taggatatc Thr Ala Ala Ser 595 1632 1680 1728 1776 1797 <210> 24 <211> 596 ' <212> PRT <213>人工序列 <223>人工序列之說明:二—融合蛋白質 TbH9 —Ra35(命名為 Mtb59f) <400> 24 His Met His His His His His His Met Val Asp Phe Gly Ala Leu Pro 1 5 10 15 Pro Glu 工le Asn Ser Ala Arg Met Tyr Ala Gly Pro Gly Ser Ala Ser 20 25 30 Leu Val Ala Ala Ala Gin Met Trp Asp Ser Val Ala Ser Asp Leu Phe 35 40 45 Ser Ala Ala Ser Ala Phe Gin Ser Val Val Trp Gly Leu Thr Val Gly 50 55 60 Ser Trp 工l,e Gly Ser Ser Ala Gly Leu Met Val Ala Ala Ala Ser Pro 65 70 75 80 Tyr Val Ala Trp Met Ser Val Thr Ala Gly Gin Ala Glu Leu Thr Ala 85 90 95 Ala Gin Val Arg Val Ala Ala Ala Ala Tyr Glu Thr Ala Tyr Gly Leu 100 105 110 Thr Val Pro Pro Pro Val lie Ala Glu Asn Arg Ala Glu Leu Met lie 115 120 125 Leu lie Ala Thr Asn Leu Leu Gly Gin Asn Thr Pro Ala lie Ala Val 130 135 140 Asn Glu Ala Glu Tyr Gly Glu Met Trp Ala Gin Asp Ala Ala Ala Met 145 150 155 160 Phe Gly Tyr Ala Ala Ala Thr Ala Thr Ala Thr Ala Thr Leu Leu Pro 165 170 175
54 1223001 Phe Glu Glu Ala Pro Glu Met Thr Ser Ala Gly Gly Leu Leu Glu Gin 180 185 190 Ala Ala Ala Val Glu Glu Ala Ser Asp Thr Ala Ala Ala Asn Gin Leu 195 200 205 Met Asn Asn Val Pro Gin Ala Leu Gin Gin Leu Ala Gin Pro Thr Gin 210 215 220 Gly Thr Thr Pro Ser Ser Lys Leu Gly Gly Leu Trp Lys Thr Val Ser 225 230 235 240 Pro His Arg Ser Pro 工le Ser Asn Met Val Ser Met Ala Asn Asn His 245 250 255 Met Ser Met Thr Asn Ser Gly Val Ser Met Thr Asn Thr Leu Ser Ser 260 265 270
Met Leu Lys Gly Phe Ala Pro Ala Ala Ala Ala Gin Ala Val Gin Thr 275 280 285 Ala Ala Gin Asn Gly Val Arg Ala Met Ser Ser Leu Gly Ser Ser Leu 290 295 300 Gly Ser Ser Gly Leu Gly Gly Gly Val Ala Ala Asn Leu Gly Arg Ala 305 310 315 320 Ala Ser Val Gly Ser Leu Ser Val Pro Gin Ala Trp Ala Ala Ala Asn 325 330 335 Gin Ala Val Thr Pro Ala Ala Arg Ala Leu Pro Leu Thr Ser Leu Thr 340 345 350 Ser Ala Ala Glu Arg Gly Pro Gly Gin Met Leu Gly Gly Leu Pro Val 355 360 365 Gly Gin Met Gly Ala Arg Ala Gly Gly Gly Leu Ser Gly Val Leu Arg 370 375 380 Val Pro Pro Arg Pro Tyr Val Met Pro His Ser Pro Ala Ala Gly Asp 385 390 395 400 工le Ala Pro Pro Ala Leu Ser Gin Asp Arg Phe Ala Asp Phe Pro Ala 405 410 415 Leu Pro Leu Asp Pro Ser Ala Met Val Ala Gin Val Gly Pro Gin Val 420 425 430 Val Asn lie Asn Thr Lys Leu Gly Tyr Asn Asn Ala Val Gly Ala Gly 435 440 445 Thr Gly 工le Val 工le Asp Pro Asn Gly Val Val Leu Thr Asn Asn His 450 455 460 Val lie Ala Gly Ala Thr Asp lie Asn Ala Phe Ser Val Gly Ser Gly 465 470 475 480 Gin Thr Tyr Gly Val Asp Val Val Gly Tyr Asp Arg Thr Gin Asp Val 485 490 495 55 1223001 Ala Val Leu Gin Leu Arg Gly Ala Gly Gly Leu Pro Ser Ala Ala lie 500 505 510 Gly Gly Gly Val Ala Val Gly Glu Pro Val Val Ala Met Gly Asn Ser 515 520 525 Gly Gly Gin Gly Gly Thr Pro Arg Ala Val Pro Gly Arg Val Val Ala 530 535 540 Leu Gly Gin Thr Val Gin Ala Ser Asp Ser Leu Thr Gly Ala Glu Glu 545 550 555 560 Thr Leu Asn Gly Leu 工le Gin Phe Asp Ala Ala lie Gin Pro Gly Asp 565 570 575 Ser Gly Gly Pro Val Val Asn Gly Leu Gly Gin Val Val Gly Met Asn 580 585 590
Thr Ala Ala Ser 595 <210> 25 <211> 702 <212> DNA <213>人工序列 <220> <223>人工序列之說明:二-融合蛋白質 Ral2-DPPD (命名為Mtb24),開放譯讀架1 <220> <221〉 CDS <222> (1) . . (696) <223>二-融合蛋白質Ral2 —DPPD(命名為Mtb24), 開放譯讀架1
<220> <221> CDS <222> (2)..(700) 開放譯讀架2 <220> <221> CDS <222> (3)..(701) <223>開放譯讀架3 <400> 25 cat atg cat cac cat cac cat cac acg gcc gcg tcc gat aac ttc cag 48 His Met His His His His His His Thr Ala Ala Ser Asp Asn Phe Gin 1 5 10 15 ctg tcc cag ggt ggg cag gga ttc gcc att ccg ate ggg cag gcg atg 96 Leu Ser Gin Gly Gly Gin Gly Phe Ala lie Pro lie Gly Gin Ala Met 20 25 30 gcg ate gcg ggc cag ate ega teg ggt ggg ggg tea ccc acc gtt cat 144 Ala lie Ala Gly Gin lie Arg Ser Gly Gly Gly Ser Pro Thr Val His 35 40 45 56 1223001 ate ggg cct acc gee ttc etc ggc ttg ggt gtt gtc gac aac aac ggc 192 lie Gly Pro Thr Ala Phe Leu Gly Leu Gly Val Val Asp Asn Asn Gly 50 55 60 aac ggc gca ega gtc caa ege gtg gtc ggg age get ccg geg gca agt 240 Asn Gly Ala Arg Val Gin Arg Val Val Gly Ser Ala Pro Ala Ala Ser 65 70 75 80 etc ggc ate tec acc ggc gac gtg ate acc geg gtc gac ggc get ccg 288 Leu Gly lie Ser Thr Gly Asp Val lie Thr Ala Val Asp Gly Ala Pro 85 90 95 ate aac teg gee acc geg atg geg gac geg ett aac ggg cat cat ccc 336 lie Asn Ser Ala Thr Ala Met Ala Asp Ala Leu Asn Gly His His Pro 100 105 110 ggt gac gtc ate teg gtg acc tgg caa acc aag teg ggc ggc aeg cgt 384 Gly Asp Val lie Ser Val Thr Trp Gin Thr Lys Ser Gly Gly Thr Arg 115 120 125 aca ggg aac gtg aca ttg gee gag gga ccc ccg gee gaa ttc gac gac 432 Thr Gly Asn Val Thr Leu Ala Glu Gly Pro Pro Ala Glu Phe Asp Asp 130 135 140 gac gac aag gat cca cct gac ccg cat cag ccg gac atg aeg aaa ggc 480 Asp Asp Lys Asp Pro Pro Asp Pro His Gin Pro Asp Met Thr Lys Gly 145 150 155 160 tat tgc ccg ggt ggc ega tgg ggt ttt ggc gac ttg gee gtg tgc gac 528 Tyr Cys Pro Gly Gly Arg Trp Gly Phe Gly Asp Leu Ala Val Cys Asp 165 170 175 ggc gag aag tac ccc gac ggc teg ttt tgg cac cag tgg atg caa aeg 576 Gly Glu Lys Tyr Pro Asp Gly Ser Phe Trp His Gin Trp Met Gin Thr 180 185 190 tgg ttt acc ggc cca cag ttt tac ttc gat tgt gtc age ggc ggt gag 624 Trp Phe Thr Gly Pro Gin Phe Tyr Phe Asp Cys Val Ser Gly Gly Glu 195 200 205 ccc etc ccc ggc ccg ccg cca ccg ggt ggt tgc ggt ggg gca att ccg 672 Pro Leu Pro Gly Pro Pro Pro Pro Gly Gly Cys Gly Gly Ala lie Pro 210 215 220 tcc gag cag ccc aac get ccc tgagaattc 702 Ser Glu Gin Pro Asn Ala Pro 225 230
<210> 26 <211> 231 <212> PRT <213 >人工序列 <223>人工序列之說明:二-融合蛋白質 Ral2 -DPPD (命名為Mtb24) ’開放譯讀架1 <400> 26 His Met His His His His His His Thr Ala Ala Ser Asp Asn Phe Gin 1 5 10 is 57 1223001 Leu Ser Gin Gly Gly Gin Gly Phe Ala lie Pro lie Gly Gin Ala Met 20 25 30 Ala lie Ala Gly Gin lie Arg Ser Gly Gly Gly Ser Pro Thr Val His 35 40 45 工le Gly Pr〇 Thr Ala Phe Leu Gly Leu Gly Val Val Asp Asn Asn Gly 50 55 60 Asn Gly Ala Arg Val Gin Arg Val Val Gly Ser Ala Pro Ala Ala Ser 65 70 75 80 Leu Gly lie Ser Thr Gly Asp Val lie Thr Ala Val Asp Gly Ala Pro 85 90 95 工le Asn Ser Ala Thr Ala Met Ala Asp Ala Leu Asn Gly His His Pro 100 105 110
Gly Asp Val lie Ser Val Thr Trp Gin Thr Lys Ser Gly Gly Thr Arg 115 120 125 Thr Gly Asn Val Thr Leu Ala Glu Gly Pro Pro Ala Glu Phe Asp Asp 130 135 140 Asp Asp Lys Asp Pro Pro Asp Pro His Gin Pro Asp Met Thr Lys Gly 145 150 155 160 Tyr Cys Pro Gly Gly Arg Trp Gly Phe Gly Asp Leu Ala Val Cys Asp 165 170 175 Gly Glu Lys Tyr Pro Asp Gly Ser Phe Trp His Gin Trp Met Gin Thr 180 185 190 Trp Phe Thr Gly Pro Gin Phe Tyr Phe Asp Cys Val Ser Gly Gly Glu 195 200 205 Pro Leu Pro Gly Pro Pro Pro Pro Gly Gly Cys Gly Gly Ala lie Pro 210 215 220 Ser Glu Gin Pro Asn Ala Pro 225 230 <210> 2Ί <211> 87 <212> PRT <213〉人工序列 <223>人工序列之說明:開放譯讀架2之胜肽 <400> 27 lie Cys 工le Thr 工le Thr lie Thr Arg Pro Arg Pro lie Thr Ser Ser 1 5 10 15 Cys Pro Arg Val Gly Arg Asp Ser Pro Phe Arg Ser Gly Arg Arg Trp 20 25 30 Arg Ser Arg Ala Arg Ser Asp Arg Val Gly Gly His Pro Pro Phe lie 35 40 45 58 1223001 Ser Gly Leu Pro Pro Ser Ser Ala Trp Val Leu Ser Thr Thr Thr Ala 50 55 60 Thr Ala His Glu Ser Asn Ala Trp Ser Gly Ala Leu Arg Arg Gin Val 65 70 75 80 Ser Ala Ser Pro Pro Ala Thr 85 <210> 28 <211> 29 <212> PRT <213〉人工序列 <223>人工序列之說明:開放譯讀架2之胜肽 <400> 28 Ser Pro Arg Ser Thr Ala Leu Arg Ser Thr Arg Pro Pro Arg Trp Arg 15 10 15 Thr Arg Leu Thr Gly lie 工le Pro Val Thr Ser Ser Arg 20 25 <210> 29 <211> 13 <212> PRT <213 >人工序列 2之胜肽
<223:>人工序列之說明:開放譯讀架 <400> 29 Pro Gly Lys Pro Ser Arg Ala Ala Arg Val Gin Gly Thr 1 5 10
<210> 30 <211> 24 <212> PRT <213>人工序列 <2 2 3 >人工序列之說明.開放譯讀架2之胜月太 <400> 30 His Trp Pro Arg Asp Pro Arg Pro Asn Ser Thr Thr Thr Thr Arg lie 1 5 10 15 His Leu Thr Arg lie Ser Arg Thr 20 <210> 31 <211> 77 <212> PRT 人工序列 <223>人工序列之說明:開放譯讀架2之胜肽 59 1223001 <400> 31 Arg Lys Ala 工le Ala Arg Val Ala Asp Gly Val Leu Ala Thr Trp Pro 15 10 15 Cys Ala Thr Ala Arg Ser Thr Pro Thr Ala Arg Phe Gly Thr Ser Gly 20 25 30 Cys Lys Arg Gly Leu Pro Ala His Ser Phe Thr Ser 工le Val Ser Ala 35 40 45 Ala Val Ser Pro Ser Pro Ala Arg Arg His Arg Val Val Ala Val Gly 50 55 60 Gin Phe Arg Pro Ser Ser Pro Thr Leu Pro Glu Asn Ser 65 70 75 <21〇> 32 <211> 13 <212> PRT <213>人工序列 <223>人工序列之說明··開放譯讀架3之胜肽 <400> 32 Pro Tyr Ala Ser Pro Ser Pro Ser His Gly Arg Val Arg 15 10 <223:
<210> 33 <211> 93 <212> PRT <213>人工序列 人工序列之說明:開放譯讀架3之胜肽 <400> 33
Leu Pro Ala Val Pro Gly Trp Ala Gly lie Arg His Ser Asp Arg Ala 15 10 15 Gly Asp Gly Asp Arg Gly Pro Asp Pro 工le Gly Trp Gly Val Thr His 20 25 30 Arg Ser Tyr Arg Ala Tyr Arg Leu Pro Arg Leu Gly Cys Cys Arg Gin 35 40 45 Gin Arg Gin Arg Arg Thr Ser Pro Thr Arg Gly Arg Glu Arg Ser Gly 50 55 60 Gly Lys Ser Arg His Leu His Arg Arg Arg Asp His Arg Gly Arg Arg 65 70 75 80 Arg Ser Asp Gin Leu Gly His Arg Asp Gly Gly Arg Ala 85 90 60 1223001 <210> 34 <211> 5 <212> PRT <213>人工序列 <223>人工序列之說明:開放譯讀架3之胜肽 <400> 34 Arg Ala Ser Ser Arg 1 5 <210> 35 <211> 36 <212> PRT <213>人工序列 <223>人工序列之說明:開放譯讀架3之胜肽 <400> 35 Arg His Leu Gly Asp Leu Ala Asn Gin Val Gly Arg His Ala Tyr Arg 1 . 5 l〇 15 Glu Arg Asp lie Gly Arg Gly Thr Pro Gly Arg lie Arg Arg Arg Arg 20 25 30 Gin Gly Ser Thr 35
<210> 36 <211> 56 <212> PRT <213 >人工序列 人工序列之說明:開放譯讀架 <223; 之胜肽 <400> 36 Pro Ala Ser Ala Gly His Asp Glu Arg Leu Leu Pro Gly Trp Pro Met 15 10 is Gly Phe Trp Arg Leu Gly Arg Val Arg Arg Arg Glu Val Pro Arg Arg 20 25 3〇 Leu Val Leu Ala Pro Val Asp Ala Asn Val Val Tyr Arg Pro Thr Val 35 40 45 Leu Leu Arg Leu Cys Gin Arg Arg 50 55
<210> 37 <211> 26 <212> PRT <213>人工序列 <223>人工序列之說明:開放譯讀架3之胜肽 <400> 37 Ala Pro Pro Arg Pro Ala Ala Thr Gly Trp Leu Arg Trp Gly Asn Ser 15 10 15 61 1223001 Val Arg Ala Ala Gin Arg Ser Leu Arg lie 20 25 <210> 38 <211> 374 <212> PRT <213>結核分枝桿菌 <220> <223> 3 8 kD 抗原. <400> 38 Met Lys 工le Arg Leu His Thr Leu Leu Ala Val Leu Thr Ala Ala Pro 15 10 15 Leu Leu Leu Ala Ala Ala Gly Cys Gly Ser Lys Pro Pro Ser Gly Ser 20 25 30
Pro Glu Thr Gly Ala Gly Ala Gly Thr Val Ala Thr Thr Pro Ala Ser 35 40 45 Ser Pro Val Thr Leu Ala Glu Thr Gly Ser Thr Leu Leu Tyr Pro Leu 50 55 60 Phe Asn Leu Trp Gly Pro Ala Phe His Glu Arg Tyr Pro Asn Val Thr 65 70 75 80 工le Thr Ala Gin Gly Thr Gly Ser Gly Ala Gly lie Ala Gin Ala Ala 85 90 95 Ala Gly Thr Val Asn lie Gly Ala Ser Asp Ala Tyr Leu Ser Glu Gly 100 105 110 Asp Met Ala Ala His Lys Gly Leu Met Asn lie Ala Leu Ala lie Ser 115 120 125
Ala Gin Gin Val Asn Tyr Asn Leu Pro Gly Val Ser Glu His Leu Lys 130 135 140 Leu Asn Gly Lys Val Leu Ala Ala Met Tyr Gin Gly Thr lie Lys Thr 145 150 155 160 Trp Asp Asp Pro Gin lie Ala Ala Leu Asn Pro Gly Val Asn Leu Pro 165 170 175 Gly Thr Ala Val Val Pro Leu His Arg Ser Asp Gly Ser Gly Asp Thr 180 185 190 Phe Leu Phe Thr Gin Tyr Leu Ser Lys Gin Asp Pro Glu Gly Trp Gly 195 200 205 Lys Ser Pro Gly Phe Gly Thr Thr Val Asp Phe Pro Ala Val Pro Gly 210 215 220 Ala Leu Gly Glu Asn Gly Asn Gly Gly Met Val Thr Gly Cys Ala Glu 225 230 235 240 Thr Pro Gly Cys Val Ala Tyr lie Gly lie Ser Phe Leu Asp Gin Ala 245 250 255 62 1223001 Ser Gin Arg Gly Leu Gly Glu Ala Gin Leu Gly Asn Ser Ser Gly Asn 260 265 270 Phe Leu Leu Pro Asp Ala Gin Ser lie Gin Ala Ala Ala Ala Gly Phe 275 280 285 Ala Ser Lys Thr Pro Ala Asn Gin Ala lie Ser Met 工le Asp Gly Pro 290 295 300 Ala Pro Asp Gly Tyr Pro lie lie Asn Tyr Glu Tyr Ala lie Val Asn 305 310 315 320 Asn Arg Gin Lys Asp Ala Ala Thr Ala Gin Thr Leu Gin Ala Phe Leu 325 330 335 His Trp Ala lie Thr Asp Gly Asn Lys Ala Ser Phe Leu Asp Gin Val 340 345 350
His Phe Gin Pro Leu Pro Pro Ala Val Val Lys Leu Ser Asp Ala Leu 355 360 365 工le Ala Thr lie Ser Ser 370 ' <210> 39 <211> 5 <212> PRT <213>人工序列 <220> <223>人工序列之說明:彈性的聚連接子 <400> 39 Gly Gly Gly Gly Ser 1 5
<210> 40 <211> 9 <212> PRT <213 >人工序列 <220> <223>人工序列之說明:從pET聚連接子及SEQIDNO:15 之2143至2168位置之Xhol限制位置轉錄之胜肽 <400> 40 工le His His Thr Gly Gly Arg Ser Ser 1 5 " <210> 41 <211> 6 <212> PRT <213>人工序列 63 1223001 <220> <223>人工序列之說明:從901至918位置之SEQIDNO:17 轉錄之胜肽 <400> 41 Gin Ser Pro Lys Gly Ser 1 5
64
TW088105532A 1998-12-30 1999-04-26 Fusion proteins of mycobacterium tuberculosis antigens and their uses TWI223001B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/223,040 US6544522B1 (en) 1998-12-30 1998-12-30 Fusion proteins of mycobacterium tuberculosis antigens and their uses

Publications (1)

Publication Number Publication Date
TWI223001B true TWI223001B (en) 2004-11-01

Family

ID=22834762

Family Applications (1)

Application Number Title Priority Date Filing Date
TW088105532A TWI223001B (en) 1998-12-30 1999-04-26 Fusion proteins of mycobacterium tuberculosis antigens and their uses

Country Status (9)

Country Link
US (2) US6544522B1 (zh)
EP (2) EP2397555A1 (zh)
JP (1) JP4516616B2 (zh)
AR (2) AR020066A1 (zh)
CO (1) CO5070585A1 (zh)
CZ (1) CZ302852B6 (zh)
NO (1) NO20120234L (zh)
PL (1) PL209260B1 (zh)
TW (1) TWI223001B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US7087713B2 (en) 2000-02-25 2006-08-08 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
NZ507378A (en) * 1998-04-07 2002-12-20 Corixa Corp Fusion proteins of mycobacterium tuberculosis antigens and their uses
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
WO2001024820A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
DE60033583T2 (de) * 1999-10-07 2007-09-13 Corixa Corp. CSC, Wilmington Eine mycobacterium tuberculosis kodierende sequenz zur expression von heterologen proteinen
US7009042B1 (en) * 1999-10-07 2006-03-07 Corixa Corporation Methods of using a Mycobacterium tuberculosis coding sequence to facilitate stable and high yield expression of the heterologous proteins
EP2133100B1 (en) * 2000-06-20 2011-10-05 Corixa Corporation MTB32A Antigen of mycobacterium tuberculosis with inactivated active site and fusion proteins thereof
AU2003213118A1 (en) * 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US8475735B2 (en) * 2004-11-01 2013-07-02 Uma Mahesh Babu Disposable immunodiagnostic test system
WO2006053871A2 (en) 2004-11-16 2006-05-26 Crucell Holland B.V. Multivalent vaccines comprising recombinant viral vectors
US7608277B2 (en) * 2004-12-01 2009-10-27 Gene Therapy Systems, Inc. Tuberculosis nucleic acids, polypeptides and immunogenic compositions
US7968694B2 (en) * 2005-07-01 2011-06-28 Forsyth Dental Infirmary For Children Tuberculosis antigen detection assays and vaccines
WO2007041539A1 (en) * 2005-09-30 2007-04-12 Transcutaneous Technologies, Inc. Iontophoresis apparatus and method for the diagnosis of tuberculosis
US8708320B2 (en) 2006-12-15 2014-04-29 Air Products And Chemicals, Inc. Splashguard and inlet diffuser for high vacuum, high flow bubbler vessel
HUE031184T2 (en) 2010-01-27 2017-06-28 Glaxosmithkline Biologicals Sa Modified tuberculosis antigens

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5330754A (en) 1992-06-29 1994-07-19 Archana Kapoor Membrane-associated immunogens of mycobacteria
DK79893D0 (da) * 1993-07-02 1993-07-02 Statens Seruminstitut New vaccine
DK79793D0 (da) 1993-07-02 1993-07-02 Statens Seruminstitut Diagnostic test
EP0771322B9 (en) 1993-11-23 2009-08-12 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
DE69625802T2 (de) * 1995-03-13 2003-11-13 The Secretary Of State For Defence, Salisbury Impfstoffe gegen die pest
IL123506A (en) 1995-09-01 2004-12-15 Corixa Corp Polypeptide compounds and preparations for immunotherapy and diagnosis of tuberculosis
CA2230927A1 (en) 1995-09-01 1997-03-13 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6555653B2 (en) * 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use

Also Published As

Publication number Publication date
US7064195B2 (en) 2006-06-20
JP4516616B2 (ja) 2010-08-04
US6544522B1 (en) 2003-04-08
EP2383342A1 (en) 2011-11-02
CO5070585A1 (es) 2001-08-28
PL209260B1 (pl) 2011-08-31
JP2009000107A (ja) 2009-01-08
NO20120234L (no) 2000-11-30
CZ302852B6 (cs) 2011-12-14
EP2397555A1 (en) 2011-12-21
AR067658A2 (es) 2009-10-21
AR020066A1 (es) 2002-04-10
US20040013677A1 (en) 2004-01-22

Similar Documents

Publication Publication Date Title
US6627198B2 (en) Fusion proteins of Mycobacterium tuberculosis antigens and their uses
TWI223001B (en) Fusion proteins of mycobacterium tuberculosis antigens and their uses
JP4227302B2 (ja) Mycobacteriumtuberculosis抗原の融合タンパク質およびその使用
KR100970854B1 (ko) Wt1 특이적 면역요법용 조성물 및 방법
MXPA04003852A (es) Composiciones de vacuna estreptococica multivalente, y metodos para sus uso.
CN115702928A (zh) 非洲猪瘟病毒亚单位疫苗组合物、非洲猪瘟病毒蛋白抗原的组合及其应用
CZ126599A3 (cs) Polypeptid pro imunoterapii a diagnosu tuberkulosy
CN115814071A (zh) 非洲猪瘟病毒亚单位疫苗组合物及其制备方法和应用
KR20160102993A (ko) Ospa의 돌연변이 단편 및 이와 관련된 방법 및 용도
CN110499324A (zh) 一种用于鉴定肿瘤新抗原的细菌表达载体及筛选鉴定肿瘤新抗原的方法
US20090281168A1 (en) Fusion proteins of mycobacterium tuberculosis antigens and their uses
KR102700388B1 (ko) 박테리아에 의한 재조합 glp-1 펩타이드의 연속 생성 방법
MXPA01009383A (es) Antigenos de tuberculosis y metodos para utilizar los mismos.
CN116019905A (zh) 非洲猪瘟病毒亚单位疫苗组合物、非洲猪瘟病毒蛋白抗原的组合和应用
US20040151727A1 (en) Yersinia species compositions
CN111848758A (zh) 一种适用于低钙离子浓度的纤维小体对接蛋白突变体及应用
CN116327901A (zh) 一种预防棘球蚴病的疫苗组合物、及其制备方法和应用
KR102528947B1 (ko) Nlrx1 단백질의 lrr 도메인을 기반으로 하는 신경계 자가면역질환 예방 또는 치료용 조성물
CN116251179A (zh) 非洲猪瘟病毒亚单位疫苗组合物及其应用
CN114015711B (zh) 抑制维氏气单胞菌感染的重组蛋白质及其制备方法与应用
CN114736310B (zh) 产生圆环病毒2型病毒样颗粒的蛋白质及生物材料与应用
CN116693630A (zh) 非洲猪瘟病毒p34-p14亚单位蛋白及其应用和产品
KR102164282B1 (ko) 돼지 병원성대장균의 재조합 톡소이드 및 이 톡소이드를 항원으로 포함하는 돼지 대장균 설사증, 부종병 등 질환 예방 백신 조성물
CN113755513A (zh) 一种基于非洲猪瘟病毒p30、p72蛋白的病毒样颗粒的制备与应用
WO2009150419A1 (en) Fructose biphosphate aldolase (fba) in neisseria